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Prologue to thesis/Abstract 
Maintenance dialysis programmes for end-stage renal disease (ESRD) began in the United 
Kingdom in the 1960s.1-3 Until the 1980s, renal replacement therapy (RRT, i.e., dialysis or 
kidney transplantation) was restricted to ESRD patients who were considered the most 
economically active and those with diabetes or other comorbidities were often not referred or 
treated.4 This contrasts with the situation 50 years later when the median age of patients 
starting maintenance RRT is 65 years and diabetes is the leading cause of ESRD.5  
Examining long-term temporal mortality trends helps describe past and current serious 
health risks. Their interpretation is difficult in RRT populations as comparisons between 
treated ESRD and other populations need to take account of the substantial secular changes 
in the prevalence of comorbid illnesses which influence both mortality6-8 and the likelihood of 
receiving RRT. To date, no large study has standardized mortality rates in treated ESRD and 
general population cohorts to the same comorbidity as well as age/sex structure. Therefore, 
although data from ESRD registries in the United States 1977-2007,9 Europe 1998-2007,10 
Australasia 1992-2005,11 and UK 2002-20115 have all shown modest improvements in 
mortality for people with treated ESRD, it is unclear whether the magnitude of this change is 
comparable to those observed in the general population during the same period.12 
The Oxford Record Linkage Study (ORLS) was established in 1963 and recorded 
information about all hospital inpatient admissions in Oxfordshire and the surrounding 
counties.13 Hospital Episode Statistics (HES) succeeded ORLS and established nationwide 
coverage from 1998. Mortality trends among new maintenance RRT patients and a set of 
general population controls, extracted from these two datasets were performed. Novel 
approaches ensured that both cohorts could be corrected for changes in prior comorbidity 
over time and the effects of transplantation, and stratified analyses in patients with and 
without diabetes could be performed. 
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Key aims of thesis 
 
1) Derive and validate a cohort of end-stage renal disease (ESRD) patients 
exclusively from anonymised, individually-linked prospectively collected 
hospital inpatients datasets 
 
2) Analyse the temporal trends of age, sex and comorbidity adjusted mortality 
rates in the ESRD cohort 
 
3) Concurrently derive a comparative general population to provide an opportunity 
to compare trends between the ESRD and general populations 
 
4) Demonstrate other uses of routinely collected hospital inpatients datasets in 
renal epidemiology 
Table of contents  [Page VIII] 
 
Table of contents 
Intellectual Property and Publication Statements ...................................................... II 
Dedication ............................................................................................................. IV 
Acknowledgements/Contributions .......................................................................... V 
Prologue to thesis/Abstract .................................................................................... VI 
Key aims of thesis ................................................................................................. VII 
Table of contents ................................................................................................... VIII 
Lists of Tables and Illustrative Material .................................................................... X 
List of abbreviations ............................................................................................. XIII 
Chapter 1 Introduction ........................................................................................... 15 
1.1 Introduction to end-stage renal disease ............................................................ 16 
1.2 Early historical aspects: Haemodialysis ............................................................. 17 
1.3 Early historical aspects: Peritoneal dialysis ........................................................ 19 
1.4 Early historical aspects: Kidney transplantation ................................................. 20 
1.5 Developments of dialytic therapies in the United Kingdom ................................ 21 
1.6 Progress from the 1980s to date ....................................................................... 23 
1.7 Background literature ...................................................................................... 25 
1.8 Detailed thesis aims ......................................................................................... 29 
1.9 Bullet Points of Chapter 1................................................................................. 31 
Chapter 2 Cohort derivation ................................................................................... 32 
2.1 Abstract .......................................................................................................... 33 
2.2 Introduction .................................................................................................... 35 
2.3 Datasets ......................................................................................................... 36 
2.4 Nomenclature used in hospital inpatient datasets ............................................. 44 
2.5 Time periods covered by the cohorts ................................................................ 45 
2.6 Diagnostic and procedurals manuals ................................................................. 46 
2.7 Procedures performed to identify an ESRD cohort in HES, 2000-2008 .................. 49 
2.8 Procedures performed to identify an ESRD cohort in ORLS, 1970-1996 ................ 57 
2.9 Internal validation of the rules which defined maintenance RRT ......................... 66 
2.10 Procedures performed to identify general population hospital controls, 1970-2008
 ...................................................................................................................... 68 
2.11 Extraction of baseline characteristics for ESRD and general population ............. 70 
2.12 Extraction of outcomes; mortality data ........................................................... 76 
2.13 Discussion and conclusions ............................................................................. 79 
2.14 Bullet points of Chapter 2 ............................................................................... 82 
Chapter 3 Baseline characteristics ........................................................................... 83 
3.1 Abstract .......................................................................................................... 84 
3.2 Introduction .................................................................................................... 86 
3.3 Methods ......................................................................................................... 86 
3.4 Results ............................................................................................................ 89 
3.5 Discussion ..................................................................................................... 102 
3.6 Conclusions ................................................................................................... 110 
3.7 Bullet points of Chapter 3 .............................................................................. 111 
Chapter 4 Validation ............................................................................................ 112 
Table of contents  [Page IX] 
 
4.1 Abstract ........................................................................................................ 113 
4.2 Introduction .................................................................................................. 115 
4.3 Methods/Procedures ..................................................................................... 117 
4.4 Results .......................................................................................................... 121 
4.5 Discussion ..................................................................................................... 132 
4.6 Conclusions ................................................................................................... 136 
4.7 Bullet points of Chapter 4 .............................................................................. 137 
Chapter 5 Main results; mortality trends ............................................................... 138 
5.1 Abstract ........................................................................................................ 139 
5.2 Introduction .................................................................................................. 141 
5.3 Methods ....................................................................................................... 142 
5.4 Expanded statistical methods ......................................................................... 146 
5.5 Results .......................................................................................................... 153 
5.6 Discussion ..................................................................................................... 160 
5.7 Conclusion .................................................................................................... 164 
5.8 Main illustrative materials for results ............................................................. 165 
5.9 Supplementary material for results chapter, not in published manuscript ......... 177 
5.10 Bullet points of Chapter 5 ............................................................................. 180 
Chapter 6 Other uses of the dataset ...................................................................... 181 
6.1 Abstract ........................................................................................................ 182 
6.2 Introduction .................................................................................................. 184 
6.3 Methods ....................................................................................................... 185 
6.4 Results .......................................................................................................... 189 
6.5 Discussion ..................................................................................................... 194 
6.6 Illustrative materials/tables and figures for Chapter 6 ..................................... 198 
6.7 Bullet points of Chapter 6 .............................................................................. 206 
Chapter 7 Concluding remarks .............................................................................. 207 
Future uses ......................................................................................................... 212 
Summary ............................................................................................................ 213 
Chapter 8 Supplemental material ......................................................................... 214 
8.1 Information governance toolkit ...................................................................... 215 
8.2 Ethics approval documentation ...................................................................... 216 
8.3 Contributions; by chapter .............................................................................. 217 
Chapter 9 References ........................................................................................... 220 
  
Lists of Tables and Illustrative Material  [Page X] 
 
Lists of Tables and Illustrative Material 
Table 2-1: Diagnostic and procedural codes used to identify patients with renal disease in versions 
of A) International Statistical Classification of Diseases and Related Health Problems and B) 
Office of Population Censuses and Surveys Classification of Surgical Operations and 
Procedures .................................................................................................................... 51 
Table 2-2: Additional information extracted from hospital records used in place of missing 
variables in Oxford Record Linkage Study (1970-1998) ...................................................... 59 
Table 2-3: Internal validation of the rules which confirmed maintenance RRT ............................ 66 
Table 2-4: Diagnoses and procedures used to identify the index admission for control population, 
by coding manual .......................................................................................................... 69 
Table 2-5: Categories of ethnicity coding used in Hospital Episode Statistics .............................. 70 
Table 2-6: Coding of comorbidity by International Classification of Disease (ICD) diagnoses and 
Office of Population ....................................................................................................... 73 
Table 2-7: Diagnostic codes used to identify main groups of primary renal disease ..................... 75 
Table 2-8: Coding of death categories by International Classification of Disease (ICD) version ..... 78 
Table 3-1: Baseline characteristics of new treated end-stage renal disease patients, by region and 
year .............................................................................................................................. 93 
Table 3-2: Baseline characteristics of new treated end-stage renal disease patients with 
transplantation being the first recorded modality of renal replacement therapy ................. 97 
Table 3-3: Baseline characteristics of new treated end-stage renal disease patients in which dialysis 
was the first recorded modality of renal replacement therapy .......................................... 98 
Table 3-4: Baseline characteristics of general population hospital controls, by year .................. 101 
Table 3-5: Level of agreement of individual components of pre-dialysis CKD cohort between 
hospital inpatients records and clinical notes ................................................................. 103 
Table 3-6: Number of episodes available for retrospective follow-up prior to start of RRT to 
identify comorbidities (with number of diagnoses per episode), by year and by age at start of 
RRT ............................................................................................................................ 106 
Table 3-7: Baseline comorbidities by different durations of retrospective follow-up prior to start of 
RRT, by year ................................................................................................................ 107 
Table 4-1: Baseline characteristics of all-England adults being treated for end-stage renal disease, 
recorded in all-England Hospital Episode Statistics and the UK Renal Registry, by year ...... 123 
Table 4-2: Number of kidney transplant operations in England recorded in all-England Hospital 
Episode Statistics and the UK Transplant Registry, by month and year ............................. 125 
Table 4-3: Demographic of treated end-stage renal disease patients in Oxfordshire, by dataset 127 
Table 4-4: Baseline characteristics of adult incident maintenance renal replacement therapy 
patients in Oxfordshire and surrounding counties, by data source and year ..................... 128 
Table 4-5: Age and sex standardized three-year mortality rates in new treated end-stage renal 
disease patients, by dataset ......................................................................................... 128 
Table 4-6: Direct comparison of adjudication confirmed site-reported maintenance dialysis vs 
Hospital Episode Statistics in SHARP Study .................................................................... 129 
Lists of Tables and Illustrative Material  [Page XI] 
 
Table 4-8: Direct comparison of adjudicated-confirmed kidney transplant in randomised trial vs 
Hospital Episode Statistics identified kidney transplantation in SHARP participants .......... 130 
Table 4-9: 2 x 2 table of agreement of the recording of polycystic kidney disease. Comparison from 
3C database and all-England HES .................................................................................. 131 
Table 5-1: Baseline characteristics of new treated new treated end-stage renal disease patients, by 
year ............................................................................................................................ 165 
Table 5-2: Baseline characteristics of end-stage renal disease populations used for standardization
 .................................................................................................................................. 173 
Table 5-3: Crude and different levels of adjusted three−year mortality rates in new treated 
end−stage disease patients and renal general population controls, by year and reference 
population .................................................................................................................. 174 
Table 5-4: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls, stratified by cohort and prior diabetes status ... 177 
Table 5-5: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls, stratified by cohort and sex ............................. 178 
Table 5-6: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls, stratified by cohort and age group ................... 179 
Table 6-1: Baseline characteristics of patients with polycystic kidney disease versus control 
populations at date of entry (all England HES 1998–2012) ............................................... 198 
Table 6-2: Diagnostic and procedural codes used to define biliary tract disease, serious liver 
complications and extra-renal complications ................................................................. 201 
 
Figure 2-1: Expanding coverage of Oxford Record Linkage Study ............................................... 38 
Figure 2-2: Summary of datasets used to derive study populations ........................................... 45 
Figure 2-3: Time periods covered by clinical coding manuals used to record death, diagnoses and 
procedures .................................................................................................................... 48 
Figure 2-4: Treated end-stage renal disease cohort derivation (all-England HES 2000-2008) ........ 55 
Figure 2-5: Treated end-stage renal disease cohort derivation (ORLS 1970-1996) ....................... 65 
Figure 2-6: Coding of death categories by International Classification of Disease (ICD) version .... 77 
Figure 3-1: Datasets used to identify retrospective cohorts of end-stage renal disease patients ... 86 
Figure 3-2: Baseline characteristics of new treated end-stage renal disease patients, by year ...... 92 
Figure 4-1: Age and sex standardized three-year mortality rates in new treated end-stage renal 
disease patients, by dataset ......................................................................................... 127 
Figure 5-1: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls ...................................................................... 166 
Figure 5-2: Standardized three−year mortality rates in new treated end−stage renal disease 
patients, stratified by whether patient is transplanted within 3 years of starting renal 
replacement therapy ................................................................................................... 167 
Figure 5-3: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls, stratified by prior diabetes .............................. 168 
Lists of Tables and Illustrative Material  [Page XII] 
 
Figure 5-4: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls, stratified by sex ............................................. 169 
Figure 5-5: Standardized three−year mortality rates in new treated end−stage renal disease 
patients and general population controls, stratified by age ............................................. 170 
Figure 5-6: Standardized three−year vascular and non−vascular mortality rates in new treated 
end−stage renal disease patients and general population controls .................................. 171 
Figure 5-7: Crude and standardized three−year mortality rates in new treated end−stage renal 
disease patients .......................................................................................................... 172 
Figure 5-8: Standardized one− to five−year survival probabilities in new treated end−stage renal 
disease patients .......................................................................................................... 175 
Figure 5-9: Three−year cause specific deaths as a proportion of all deaths ............................... 176 
Figure 6-1: Association between polycystic kidney disease and risk of hospitalisation for different 
diseases in all−England Hospital Episode Statistics 1998−2012 ......................................... 199 
Figure 6-2: Association between polycystic kidney disease and risk of hospitalisation for biliary 
tract and serious liver complications by age and sex in all−England Hospital Episode Statistics 
1998−2012 .................................................................................................................. 200 
Figure 6-3: Association between polycystic kidney disease and risk of hospitalisation for different 
disease by diagnostic position in all−England Hospital Episode Statistics 1998−2012 
(sensitivity analysis) ..................................................................................................... 202 
Figure 6-4: Association between polycystic kidney disease and risk of hospitalisation for different 
diseases by diagnostic position in all−England Hospital Episode Statistics 1998−2012 
(sensitivity analysis)  .................................................................................................... 203 
Figure 6-5: Underlying causes of death in all people with polycystic kidney disease by; prior biliary 
tract or serious liver complication (panel A), or without such complications ..................... 204 
Figure 6-6: Underlying causes of death in all people with polycystic kidney disease and prior biliary 
tract or serious liver complications in; females (panel A), or males (panel B) .................... 205 
Figure 8-1: Information Governance Toolkit from NHS Digital ................................................. 215 
Figure 8-2: Ethics letter of approval ...................................................................................... 216 
List of abbreviations  [Page XIII] 
 
List of abbreviations 
AKI  Acute kidney injury 
ANZDATA Australia and New Zealand Dialysis and Transplant 
Registry 
AVF Arterio-venous fistula 
AVG Arterio-venous graft 
CI Confidence interval 
CKD Chronic kidney disease 
COPD Chronic obstructive airways disease 
CV Cardiovascular 
eGFR Estimated glomerular filtration rate 
ERA/EDTA European Renal Association/European Dialysis and 
Transplant Association 
ESRD  End stage renal disease 
HD Haemodialysis 
HES Hospital Episode Statistics 
HSCIC Health and Social Care Information Centre, now called 
NHS Digital 
ICD International Statistical Classification of Diseases and 
Related Health Problems 
K/DOQI Kidney Disease Outcomes Quality Initiative 
KDIGO Kidney Disease Improving Global Outcomes 
NHS National Health Service 
NHSBT National Health Service Blood and Transplant 
OKU Oxford Kidney Unit 
ONS Office of National Statistics 
OPCS Office of Population Censuses and Surveys Classification 
List of abbreviations  [Page XIV] 
 
of Surgical Operations and Procedures 
ORLS Oxford Record Linkage Study 
PD Peritoneal dialysis 
PRD Primary renal disease 
RR Relative risk 
RRT Renal replacement therapy 
UHCE Unit of Healthcare Epidemiology 
UK United Kingdom 
UK-RR United Kingdom Renal Registry 
UK-TR United Kingdom Transplant Registry 
USRDS United States Renal Data System 
Introduction  [Page 15] 
 
Chapter 1  Introduction 
Introduction to end-stage renal disease and 
the historical context of its treatment by renal 
replacement therapy 
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1.1 Introduction to end-stage renal disease 
End-stage renal disease (ESRD) is the culmination of injurious processes which renders the 
kidneys unable to perform at a level which keeps patients from developing a heterogeneous 
constellation of signs and symptoms, caused principally by the accumulation of ‘uraemic’ 
toxins which are not able to be excreted in the urine. 
 
Renal replacement therapy (which includes dialysis and kidney transplantation) are two 
treatments that have transformed the life prospects of patients suffering from ESRD. Before 
their introduction, death from irreversible renal disease was inevitable and unpleasant. 
Dialysis is a medical treatment, based on physical, chemical and engineering principles and 
is applicable in severe acute (often reversible) kidney injury and irreversible ESRD. It 
requires a semi-permeable membrane and there are two types of dialysis; haemodialysis 
which uses extracorporeal blood and dialyses this against a dialysate solution across the 
(semi-permeable) dialyser. Alternatively, peritoneal dialysis harnesses the semi-permeable 
properties of the peritoneal lining and cavity into which dialysate fluid is inserted via a 
specialized catheter into the abdominal cavity, left to allow convective and diffusive 
processes to occur, before being drained and replaced with fresh dialysate fluid. Kidney 
transplantation emerged from a surgical and immunological background and involves 
implanting another human’s kidney into a recipient with ESRD, reconnecting the vasculature 
and its outflow tube, the ureter, into the bladder. It is only ever used to treat ESRD and has 
no role in the management of acute kidney injury (AKI). 
 
Transplantation and dialytic therapies (RRT) are the only life-prolonging treatments for 
ESRD and both have only emerged as viable options over the last half century and their 
historical perspective merits discussion to contextualise some of the inherent challenges 
there are when attempting to study long term mortality trends in this population.  
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1.2 Early historical aspects: Haemodialysis 
The term “dialysis” was coined by a Glaswegian chemist called Thomas Graham (1805-
1869). He observed the sieving properties of vegetable parchment which when floated on 
water permitted the passage of small crystalloid molecules but prevented larger colloid 
molecules to pass through.14 Graham pursued other interests and it was another 50 years 
before John J. Abel (1857-1938) and his team at John Hopkins University investigated this 
principle on nephrectomized animals. Their research on “vividiffusion” using an “artificial 
kidney” came to a halt with World War One as they could no longer source hirudin, an 
anticoagulant needed to stop blood clotting on the dialysis membrane.15,16 After the Great 
War the first experiments of haemodialysis on human patients emerged, performed by 
George Haas (1886-1971). His fractionated method involved repeatedly withdrawing venous 
blood and then dialysing it against a physiological solution and then returning it through the 
same channel. He was unsuccessful though, writing in 1925, that severe uraemia was “a 
condition against which the doctors stands otherwise powerless.”17 This disheartening reality 
remained so until the first successful haemodialysis was performed in the context of the 
Second World War by Wilheim Johan (Pim) Kolff (1911-2009) in Kampen, Netherlands. 
Sourcing his raw materials for a dialysis drum from a local enamel factory, buying sausage 
skins to use as a dialysis membrane, and deceiving German authorities to employ skilled 
staff was a remarkable and enduring feat.18-20 From early 1943 onwards Kolff and his 
dedicated small team performed a series of unsuccessful attempts on a variety of acute and 
chronic renal failure patients but his first ‘success’ came in September 1945, with “patient 
number 17”. Sophie Schafstadt was a 67 year old suffering from septicaemia caused by 
cholecystitis (acute severe inflammation of the gallbladder), and sulphonamide crystal 
anuria. Ironically, she was being imprisoned in the military barracks outside Kampen for 
being a Nazi collaborator yet the barrack’s commander-in-chief was an acquaintance of Kolff 
and so he allowed her to be treated. In Kolff’s infamous doctorate he wrote: 
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“I am convinced that she would have died if the treatment with the artificial kidney had not 
taken place. If others agree with me this would have made it likely that it is possible to save 
the life of patients suffering from acute uraemia with the help of vividialysis. An incitement to 
continue along this course” 
 
His efforts have forever changed the treatment of acute and chronic renal failure. His 
achievements though would not have been possible without the prior discovery of two other 
key materials: heparin and cellophane. The credit for the discovery of heparin has been 
disputed but Jay Maclean (1890-1957) and William Howell (1860-1945) both clearly 
contributed.21 Cellulose, was first regenerated into its sheet form by Jacques Brandenburger 
(1872-1954) yet it was William Thalhimer (1884-1961) who saw its potential applications as 
a dialysis material.22  
Two other pioneers, working on different sides of the Atlantic deserve mention for their 
contributions. Kolff was insulated to other contemporary work as he was isolated in war-torn 
mainland Europe. In Canada, D.W.G. “Gordon” Murray, (1894-1976), was a talented cardiac 
surgeon who brought heparin into the routine clinical use,23,24 inserted the first homologous 
aortic valve replacement,25 and was first to use haemodialysis on human subjects in North 
America in 1946. Nils Alwall’s (1906-1986), based in Lund, Sweden research was not 
interrupted by events of the Second World War as Sweden had remained neutral. His 
methodical nature and understated demeanour has meant his legacy to the history has 
perhaps been undervalued. He not only developed an early dialysis machine which had a 
more controlled mechanism of ultrafiltration (the process by which excess salt and water is 
removed), he envisioned an arteriovenous shunts before Scribner26 and begun performing 
diagnostic renal biopsies, now an integral component of renal care.27 His diligent and 
conscientious animal experiments led him to use haemodialysis in human subjects by June 
1946. 
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The view that maintenance dialytic therapies offered realistic prospects for patients with 
ESRD remained contentious throughout 1960s with an anonymous Lancet editorial typifying 
the attitude of non-specialist physicians stating, “It had little to offer.”2 This began to change 
when the bedevilling problem of reliable access to the blood stream was solved. The 
invention of a conduit to remove arterialised blood from the wrist or ankle and replace it, via 
a connecting piece of tubing to an upstream vein, was termed an arterio-venous or 
‘Scribner/Quinton’ shunt after its creators.28 First implanted in 1960 by surgeon David Dillard 
in Seattle its effect was beyond the technical as it removed a psychological barrier to 
haemodialysis being a viable longer term therapy. The concept was updated and re-worked 
by New York physicians, Brescia and Cimino, who fashioned an autologous arterial venous 
connection positioned subcutaneously at the wrist. This causes the draining vein to 
arterialise and hypertrophy (swell), providing adequate blood flows and negating the need of 
the external connectors that the original shunt relied.29 An admiring editorial by Scribner30 
ensured that within the dialysis community, its use spread quickly. Indeed a mature, good 
quality arterio-venous fistula remains the optimal and recommended type of haemodialysis 
access.31 
 
1.3 Early historical aspects: Peritoneal dialysis 
In 1923 Georg Ganter, working in Würzburg, published the first animal trials of peritoneal 
dialysis to treat advanced renal disease. He ligated the ureters of guinea pigs and rabbits 
and showed that biochemical parameters could be improved by instilling solute into the 
abdominal cavity. He took this experience onto the first human patient. Over the following 20 
years there were little progress in the field until interest was again sparked after reports of an 
‘artificial kidney machine’ being used by Kolff, Alwall and Murray. The technical difficulties of 
this early form of intermittent haemodialysis drove others researchers to develop 
alternatives. In 1946, Frank, Seligman and Fine reported the first successful use of 
peritoneal lavage in a patient, yet became frustrated by a supply shortage in the materials 
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required and in the unacceptable peritonitis (infection within the lining of the abdomen) rates. 
Different techniques and improved catheter design helped somewhat but practical peritoneal 
dialysis remained elusive. Arthur Grollman, working in Dallas, developed and extolled the 
concept of a ‘dwell-time’: leaving the fluid in the abdominal cavity for a period of time before 
exchanging it and performed a lot of experiments on dogs and humans.32 However it was 
Morton Maxwell, based in Los Angeles, who commercialised the process and made its 
reproducible as he approached local manufactures to supply reliable, sterilised fluid, tubing 
and used a standardized catheter.  
 
Incremental developments occurred over the next few decades before the innovation of the 
semi-permanent indwelling peritoneal catheter opened the opportunity for patients to dialyse 
at home and underlined that peritoneal dialysis was a long-term option for patients with 
ESRD. The introduction of a Tenckhoff catheter, with its two anchoring cuffs, is still used in 
modern practice.  
 
1.4 Early historical aspects: Kidney transplantation 
“Seldom in the history of medicine” has a pair “two differing life-saving treatments for the 
same previously fatal disease appeared almost simultaneously.”33 Alexis Carrel (1873-1944), 
in 1906, tried xeno-transplantation by transplanting a kidney from a goat and a pig into 2 
renal failure patients’ brachial vessels. Neither patient survived. In 1936 the first human 
transplants (allotransplantation) was performed by an Ukranian surgeon called Yuri 
Yurijevich Voronay (1895-1961) on a series of 6 patients. As he had not appreciated the 
deleterious effects of harvesting kidneys long after death; none of the grafts functioned. 
 
The momentous first successful kidney transplant was performed by Murray and colleagues 
in Boston on a pair of identical twins on the 23rd December 1954.34 The first in the UK was 
performed in Edinburgh in 1960.35 However the lack of effective immunosuppressants meant 
that transplants other than those between identical twins remained experimental for some 
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time.36 A major breakthrough in transplantation came with the introduction of azathioprine37,38 
and then cyclosporine (a calcineurin inhibitor) in the 1980s.39-41 These provided more 
consistent and tolerable immunosuppression thereby avoiding the problems associated with 
prolonged courses of high dose cortico-steroids and significantly reducing the morbidity from 
acute rejection.41 The technical aspects of the transplant operation itself has changed little 
over time but the organisational structure of clinical transplantation, with all it ancillaries 
stakeholders (implanting surgeons, explanting retrieval teams, transplant immunology, 
nephrologists, NHS Blood and Transplant and critical care clinicians) have all contributed to 
improving transplantation rates and outcomes. Wolfe showed that even in high-risk 
individuals, including patients with diabetes, there were mortality benefits of a successful 
kidney transplantation which surpassed the risks of continuing dialytic therapies: a report 
which increased the numbers considered suitable for a transplant.42  
 
1.5 Developments of dialytic therapies in the United Kingdom 
In the United Kingdom, the ‘artificial kidney machine’ were brought to London by Kolff 
himself in 1946 as he wanted to share his experiences with Eric Bywaters (1910-2003) and 
Jo Joekes (1914-2010) who had had seen the devastating effects of renal failure from crush 
injuries during the Blitz.43 However their early experiences were comparable to conservative 
therapies, colloquialized to the “Bull regime”, consisting of a vile cocktail of fluid and nutrients 
ingested via a nasogastric tube. The treatment even recommended that vomitus from the 
patient was dutifully collected, filtered through lint, and then returned.44 Other than brief 
experimentation by Dr. E. M. Darmady (1906-1989), a Portsmouth based pathologist turned 
renal physician, who travelled and used a self-built dialyser between 1947-1948,45 there 
would be no more dialysis offered in the NHS for about 10 years.  
Dialytic therapies re-surfaced in Leeds, where Dr. Frank Parsons (1918-1989) had been 
appointed Registrar to Professor Pyrah who had recently acquired a flame photometer to 
allow more accurate fluid replacement in the setting of oligo-anuric renal disease. Parsons 
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felt “dejected and disillusioned” at the fatal outcomes of many patients in acute renal failure 
and so he studied the work of a team based in Boston who were using the artificial kidney.46 
With Pyrah support he was sent on a secondment and over 4 months in 1954 he learnt the 
practical aspects of dialysis and even supervised the treatment of a young man in his 
twenties who would later that year receive the first living renal transplant from his identical 
twin brother.46 He returned to Leeds and persuaded the governors of the hospital to 
purchase a Kolff-Bingham machine alongside co-founding a research unit, funded by the 
Medical Research Council (MRC). At the meeting the MRC secretariat stated that they had 
been advised that “there was no place for an artificial kidney in British medicine.” However 
once Parsons had described his experiences of its lifesaving potential of haemodialysis in 
America he was told, “Parsons, try it, but remember that the country is against you.”46 
Parsons’ unit in Leeds grew and whilst it probably did dialyse patients with ESRD as well as 
acute renal failure, the first dedicated chronic dialysis unit for ESRD was opened in the 
Spring of 1961 at Royal Free Hospital in London under the direction of Stanley Shaldon.47 
Others units, mainly based at university hospitals, followed across the country. These early 
English pioneers were working in a sceptical atmosphere, in which their trade was 
considered not cost-effective neither viable in the long term, a sentiment epitomised in a 
second Lancet editorial in 1965 which commented that, “limited resources should not be 
squandered on mass-dialysis.”2 
 
Nevertheless, there was an obvious demand for a therapy that had life-preserving qualities. 
The Oxford Kidney Unit (OKU) was formally opened in 1967 although its first chronic patient, 
Jean Tarver, began peritoneal dialysis, on Christmas Eve in 1966.27,48 Jean was supported 
by her husband and local Member of Parliament who lobbied the then Regius Professor of 
Medicine at Oxford to buy a kidney dialysis machine which was sourced in the Summer of 
the units’ inaugural year. Jean duly switched to haemodialysis, a treatment which she relied 
exclusively upon for the next 35 continuous years, out-surviving the founder of OKU. 
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By the 1970s and early 1980s there was a recognisable, albeit small, network of university 
based hospitals offering dialytic therapies to acute and chronic renal patients and the 
number of these centres and the types of patients that were taken on for dialysis programs 
was set to grow considerably. 
 
1.6 Progress from the 1980s to date 
These early dialysis units were dealing with high demand and struggled to grow their service 
as they were constrained by the limited public sector financial settlement witihn the socio-
political context of Thatcherite Britain. This led to some selection of patients who received 
RRT, often excluded due to old age or comorbidity. Patients were also required to be self-
caring in order to be able to dialyse themselves at home.49 A controversial and rather 
sensationalist audit performed by the Medical Services Study Group of the Royal College of 
Physicians, published in 1981 gave some examples of why patients, under the age of 50, 
were not being offered RRT;  
“Orphan. Neuropathy. Severe retinopathy and poor vision” 
 
“Very unintelligent”  
 
“Blind. Insulin dependent diabetes 21 years. Other diabetic complications.”4 
 
 
This audit received stern rebukes from the practising nephrologists50-55 and indeed the 
accompanying editorial said the conclusions were, “wrong and may mislead” but felt the 
British Medical Journal had a duty to publish it.56 A nihilistic attitude, held by clinicians 
outside nephrology may have contributed to another factor of late (or indeed no) referral to 
RRT services as they held the belief that RRT did not offer a long term option.57,58 
Furthermore, this report followed heightened public awareness of the issues around 
procuring organs for transplantation, generated from a BBC Panaroma programme on brain 
death, which had a motif of,  
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"If the patient wasn’t dead, when he was wheeled into the operating 
theatre, he certainly is now."59 
However, despite the benefits of treatment, there was an under-resource of RRT facilities. 
The Office of Health Economics reporting that, in 1980, there was a need to grow capacity in 
the system, suggesting a need for an initial increase from about thirty to forty new persons 
per million population (pmp). Yet even in 1982 there was recognition by the chief medical 
officer that the 40 pmp figure was “an underestimate.”60 The 1980s saw renal units squeeze 
extra capacity into their RRT programs by promoting home therapies (principally peritoneal 
dialysis) to all new patients. In the 1980s the benefits of a successful kidney transplant 
started to become apparent, relieving pressure on limited dialysis funding.61 
Across the 1980s and 1990s dialysis technology evolved, with newer better machines and 
updated materials such as the introduction of biocompatible membranes,62 the move from 
acetate to bicarbonate based dialysate solutions63,64, identification of toxic effects of 
aluminimum65-67 and increasing ease by which machines could monitor the ultrafiltration rate 
all helped improve the tolerability of the therapy. Another advance was the introduction of 
recombinant erythropoietin, which solved the perpetual anaemia that these early patients 
suffered, helping them avoid the risks of multiple risk of blood transfusions.68,69 Viable 
alternatives to dialysis access also became available in the form of tunnelled central venous 
catheters.70 The kidney’s critical role in calcium homeostasis was also discovered in the 
1970s and derviations of activated 1,25 di-hydroxycholecaliferol71-73 was introduced into 
clinical practice in the late 1970s early 1980s, helping to alleviate some of the adverse 
effects of the bone disease characterised in ESRD patients.74 
 
Since the turn of the century modern renal services have included designated facilities in all 
acute hospitals with universal and open referral pathways to specialists renal units for all 
General Practitioners. Age and comorbid illnesses are rarely barriers to referral for 
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consideration for RRT; these decisions are now individualised to the patient needs and 
indeed are increasingly becoming a patient led decision. 
 
1.7 Background literature 
Patients with ESRD are known to have higher overall mortality rates than that observed in 
general population.  
Linder first described the accelerated vascular disease which pertains to advanced CKD75, 
and subsequent work has focused on confirming ‘traditional’ vascular risk factors are too 
contributory to this heightened risk; namely smoking76, LDL-C77 and hypertension.78 The 
association of hypertension, (defined variably in the literature) are more complicated in 
advanced CKD, especially with patients on dialysis. Echocardiographic studies of patients 
with CKD stages 4 and 5 (i.e. eGFR <30mls/min/1.73m2) have been shown to have evidence 
of abnormal cardiac function, yet many patients have no overt symptoms. One other 
surrogate of subclinical cardiac disease, is the cardiac biomarker troponin. Herrington et al. 
used the SHARP dataset and after the adjustment of usual confounders, found a ‘U-shaped’ 
relationship of reverse causality, between systolic blood pressure and cardiovascular 
disease.78 Yet, after stratifying patients into those with a raised troponin or not they observed 
a strong log-linear relationship: each 10 mmHg higher systolic BP corresponding to a 27% 
increased risk of cardiovascular disease (hazard ratio, 1.27; 95% confidence interval, 1.11–
1.44). 
CKD stage 5 also has a host of other inter-related factors which likely contribute towards 
overall mortality risk, compared to the general population. Increasingly recognised is fluid 
overload, with a large international demonstrating a cumulative 1-year fluid overload 
exposure to be predictive of a higher death rate across pre-defined BP categories; (<130 
mmHg: HR, 1.94; 95% CI, 1.68 to 2.23; 130–160 mmHg: HR, 1.51; 95% CI, 1.35 to 1.69; 
>160 mmHg: HR, 1.62; 95% CI, 1.39 to 1.90.79 
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The ERA reported that non-vascular mortality had a 8.1 times higher age-adjusted risk of 
mortality, similar to the 8.8 increase for vascular mortality) and this aspect of increased risk 
is often overlooked.80,81 It is common knowledge that non-vascular causes of death such as 
malignancy share a number of shared risk factors, namely smoking, adiposity, and physical 
inactivity, yet RRT itself does exposure patients to additional insult on their immune systems 
and in the transplant setting and in the treatment of autoimmune disease its overt 
manipulation with immuno-suppressants. 
 
 
1.7.1 Temporal trends in all-cause mortality in ESRD patients 
Temporal trends analyses of treated ESRD populations have been generally limited to 
registry-based reports. These previous studies have been over a relative short period of 
time, have been unable to adjust for co-morbidity, or have been unable to identify a directly 
comparable control population.9,11,81,82 
 
The UK-Renal Registry does report age-stratified survival percentages for incident cohorts 
since 1997 in its annual reports. These has shown steady improvements in survival, but the 
UK-Renal Registry is unable to adjust these analyses by any comorbidity metric, as no 
appropriate data were recorded in earlier cohorts and the UK-RR has no data before 1997.83  
 
Longitudinal data from the United States Renal Data System (US RDS) used abridged life 
tables to report improvements in the survival of dialysis patients over the last 40 years 
(1977-2007) with the average life-years lost reducing from 23.6 years (95% CI, 23.1-24.0) in 
1977 to 19.7 (19.5-19.8) years in 2007.9 Although reporting the age-specific life years lost 
partially controls for the changes in the age structure of the RRT population there was no 
adjustment for changes in comorbidity profile despite reporting increases in the prevalence 
of diabetes from 9 to 38% in the ESRD.9 
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Similarly, in a Japanese prevalent dialysis population the age-standardized rates of all-cause 
mortality fell from 184 per 1000 person years between 1988 to 97 in 2013, but again no 
adjustment for co-morbidity was performed.84 This lack of comorbidity adjustment may lead 
to underestimates of temporal declines in mortality rates and makes assessment of the 
magnitude of excess risk to a general population much less reliable.85 
 
Data from the European Renal Association/European Dialysis Transplant Association 
(ERA/EDTA) reports includes information from 18 national and regional renal registries. 
They calculated unadjusted and adjusted 5-year survival probabilities between an early era 
of 1998-2002 and a more modern era from 2003-2007. A 15% improvement (HR=0.85, 
95%CI, 0.84-0.86) from the earlier to more modern period was reported. They were able to 
adjust age, sex, country and primary renal disease (PRD), a surrogate that is often used as 
a proxy for some comorbid illness but reported missing information in upto 15% of its 
incident ESRD patients have an unknown cause to their renal failure.10 Furthermore, 
reporting rates of PRD differ in each country and key comorbidities such as vascular disease 
or diabetes which were not the PRD were not captured.10 
 
1.7.2 Vascular and non-vascular mortality in ESRD patients 
 
Lindner first described an accelerated atherosclerosis process in haemodialysis patients in 
197475 and established that ESRD patients have considerably higher absolute risks of 
cardiovascular (CV) disease than age-matched general population individuals.86,87 Indeed 
cardiovascular disease as a group is the commonest reported cause of the death for ESRD 
patients.83 Exploring this, Australian renal registry data studied medium-term temporal trends 
in CV mortality and included general population data for comparison. The age-specific 
relative risks (RR) of CV mortality in the dialysis population versus to the general population 
(whose rates were derived from Australian national mortality data) rose over the 14 year 
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period (1992-2005) amongst 55-64 years olds, from 32 to 50/100 persons years.11 There 
was, however, no opportunity to adjust for any differences or temporal changes in the 
comorbidity profile of these two populations. 
 
There is recognition that adjustment for comorbidity, often referred to as “case-mix” provides 
fairer comparisons of mortality, and the collection of a standardized comorbidity dataset for 
ESRD patients is advocated in the UK and Europe.88-90 The lack of comorbidity data for 
English ESRD patients has prevented the UK-RR adjusting its survival data and it has no 
data prior to 1998 so cannot provide longer term temporal trends.5 The reported paucity of 
baseline co-morbidity data for incident RRT led the UK-RR them to augment patient level 
data from the UK-RR with directly linked data from all-England Hospital Episode Statistics 
(HES).88 This demonstrated a reduction in the number of renal-centres designated as prior 
“outliers” for their respective three-year mortality rates in incident patients when the HES-
derived co-morbidity variables were incorporated into the adjustment model. Furthermore, 
this data showed that even in the limited period for which it had data, 2002-2006, there was 
an improvement in survival with an adjusted hazard ratio being 22% lower in 2006 compared 
the 2002 reference group. 88 
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1.8 Detailed thesis aims 
This thesis with its access to the unique resource of ORLS and all-England HES proposes to 
identify and then calculate mortality rates for a treated ESRD population across almost 40 
years and compare the proportional changes in mortality to a general population using 
standardisation techniques which includes a comorbidity adjustment. The complete aims are 
to:-  
 
1. Derive and validate a cohort of end-stage renal disease (ESRD) patients exclusively 
from anonymised, individually-linked prospectively collected hospital inpatients 
datasets 
Oxford has the earliest national resource of this kind allowing the inclusion of patients 
from the early and modern era of renal medicine offering a unique opportunity to study 
morality trends over the long term. Comorbidities, identified from prior inpatient 
hospitalisations prior to start of RRT will be extracted to permit their use as covariates in 
subsequent mortality analyses. As no prior study has used the proposed derivation 
method before, the baseline characteristics will be validated (using both direct and 
indirect methods) against other repositories which holds data on English ESRD patients.  
 
2. Analyse the temporal trends of age, sex and comorbidity adjusted mortality rates in 
the ESRD cohort  
 
 
3. Concurrently derive a comparative general population to provide an opportunity to 
compare trends between the ESRD and general populations 
The opportunity for analogous standardization between two different populations, that of 
an ESRD and general population helps assess whether any trends in mortality rates  
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observed in the ESRD are greater, similar or smaller to those observed in a 
corresponding general population. 
 
4. Demonstrate other uses of routinely collected hospital inpatients datasets in renal 
epidemiology 
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1.9 Bullet Points of Chapter 1  
 
 Treatment for ESRD in the form of transplantation and dialysis are relatively new 
therapies to the NHS, being cautiously introduced into the NHS in the 1960s and 
1970s. 
 
 The demographics of these early patients were much younger and less comorbid than 
what is seen in current nephrology practice.  
 
 The short to medium term trends of modern RRT patients have shown modest 
improvements. 
 
 Prior mortality trends have not, and indeed not been able to, compare any changes 
observed in an ESRD population to that of a comparable general population.
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Chapter 2  Cohort derivation 
Method of cohort derivation of English newly 
treated end-stage renal disease patients and 
contemporaneous general population hospital 
controls from the Oxford Record Linkage 
Study (1970-1996) and all-England Hospital 
Episode Statistics (2000-2008) 
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2.1 Abstract 
Background 
Patients receiving treatment for end-stage renal disease are frequently admitted to hospital 
which offers an opportunity to identify a cohort of treated ESRD patients derived exclusively 
from hospital inpatient datasets. The methodology used to derive such a cohort and similar 
methods to identify a comparative general population cohort are presented. 
Methods 
An incident cohort of treated ESRD patients was identified retrospectively from two routinely 
collected hospital inpatients datasets, the Oxford Record Linkage Study (ORLS; 1970-1996) 
and all-England Hospital Episode Statistics (HES; 2000-2008), using specifically designed 
algorithms which incorporated clinical codes relevant to renal disease, transplantation and 
dialysis from International Statistical Classification of Diseases and Related Health Problems 
(ICD) versions 7-10, and Office of Population Censuses and Surveys Classification of 
Surgical Operations and Procedures (OPCS) versions 2-4. A large set of contemporaneous 
general population hospital controls were also identified from the same datasets identified 
from the time of an index hospital admission for a variety of minor ailments or procedures. 
Results 
In all-England HES 56.3 million individual patient records were scrutinised of which 140,616 
had mention of a renal replacement therapy (RRT) related code. A clinical algorithm then 
searched the linked records of these patients to confirm whether they were receiving 
maintenance RRT (dialysis or transplant), differentiating them from patients admitted with 
presumed admissions with dialysis-dependent acute kidney injury. Basic demographic 
details, and uniquely prior major comorbidities, identified in a fixed period of retrospective 
follow-up from the start date of RRT were also extracted. Patients under 18 years old, those 
dying within 90 days of starting RRT, or those identified as having prevalent RRT were then 
excluded. 42,730 such patients were finally identified in all-England HES and with similar 
methods ORLS identified a further 2,192 patients.  
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To permit subsequent comparative analyses, 5.6 million contemporaneous general 
population hospital controls were identified from the same datasets over the same period. 
Conclusions 
Deriving a large cohort of incident ESRD commencing RRT from linked routinely collected 
hospital inpatient data in Oxford and England between 1970-2008 is technically feasible.  
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2.2 Introduction 
The term ‘record linkage’ was first coined by H.L. Dunn in 1946.91 He introduced it with the 
following metaphor, 
“Each person in the world creates a book of life. This book starts with birth and ends with 
death. Its pages are made up of the records of the principal events in life. Record linkage is 
the name given to the process of assembling the pages of this book in to a volume.” 
For the purpose of this body of work the term “linked” or “linkage” requires further 
clarification. Individuals’ consecutive hospital admission records need linking together (intra-
individual linkage) and hospital admission datasets as a whole require linkage to other 
healthcare datasets, such as the national mortality data (inter-dataset linkage). With both 
these components a storybook of health, disease and ultimately death can be assembled. 
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2.3 Datasets 
2.3.1 Oxford Record Linkage Study, 1963-1998 
The systematic collection of prospectively, routinely collected, individually-linked hospital 
inpatient data hospitals began, in Oxford, and has evolved into its current form, all-England 
Hospital Episode Statistics (HES). Sir Ernest Donald Acheson pioneered its use, envisaging 
a construct to inform, track and potential treat society from a unit of individuals, families or 
the community as whole.92 Importantly he foresaw the importance of linked data as opposed 
to Hospital In-Patient Enquiry (HIPE) which only recorded a random sample of unlinked 
admissions which was unable to distinguish events at a person level. Acheson founded the 
Oxford Record Linkage Study (ORLS) in 1962 whilst working at the Nuffield Department of 
Medicine at the Radcliffe Infirmary.93 It was conceived with four aims:94 
1. To study the feasibility and cost of prospectively accumulating information on key 
health events in cumulative personal files 
2. Develop computer methods capable of record linkage across medical disciplines 
3. To study applications of the files in medical and operational research 
4. If successful as a pilot study, promote its extension on a national basis  
At its inception, ORLS only collected data on hospital admissions from central Oxfordshire 
but it expanded and enveloped neighbouring counties as depicted in Figure 2-1. 
1963-1965  Oxfordshire 
 
1966-1974  East Berkshire 
 
1975-1986  Wycombe 
Kettering 
West Berkshire 
Northamptonshire 
 
1987-1998  Aylesbury 
Milton Keynes 
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By 1998, these eight districts covered a total population of 2.5 million with high quality data 
being manually and then electronically imputed by a dedicated set of clinical coders.95 These 
data are now archived, computerised and fully anonymised. It is curated by the Unit of 
Health Care Epidemiology, now embedded within the Big Data Institute, Li Ka Shing Centre 
for Health Information and Discovery, University of Oxford. All its data are anonymised but 
encrypted identifiers were used to link successive records for the same individual.96 No 
access to the original patient identifiers is possible and was never sought. 
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UA=Unitary authority 
Figure 2-1: Expanding coverage of Oxford Record Linkage Study 
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2.3.2 All-England Hospital Episode Statistics, 1998-2011 
Hospital Episode Statistics (HES) is a vast warehouse of clinical and administrative data 
which records hospital inpatient admissions with complete nationwide coverage of all 
National Health Service (NHS) institutions in England, including acute hospitals, primary 
care trusts and mental health trusts. HES was conceived after a report of a working group, 
chaired by Edith Körner was convened to make recommendations on health service 
informatics, as the need for high quality national admission data on hospital was increasingly 
recognised. The Körner commission published a series of reports between 1982 and 1987 
envisaging a system analogous to a “well-made jigsaw”, which would accurately reflect the 
evolving informatics needed by healthcare management, auditors and researchers. It would 
have to perform the complex tasks of efficient administration, effective healthcare planning 
and genuine accountability across the entire NHS.97,98 In 1987 the implementation phase of 
the so-called Körner recommendations began, on a regional basis only, with each local 
health authority collecting and storing their own records. From 1996, these local reservoirs of 
data were abolished and a nationwide cleaning service (NWCS) was provided to pool and 
collate the records nationally, achieving Acheson fourth aim. This process continues to date 
and is co-ordinated by Secondary Users Service (SUS) under the auspices of the NHS 
Digital.  
 
Over the period where the national systems were being harmonised, ORLS researchers 
steadfastly maintained two key elements. First, as it already had an existing system of 
reliable linkage with an experienced and dedicated team of clinical coders capable of 
capturing admissions across all inpatient disciplines, it could integrate the Körner 
recommendations into its normal work platforms. Secondly and unlike other regions in 
England ORLS did not destroy its regional data between 1987 and 1998, and so uniquely it 
has uninterrupted linked data from the 1960s to the 1990s. Its data offers important and 
unique opportunities for epidemiological research. 
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This combined resource of ORLS and all-England HES has long-standing ethical approval in 
place from the Central and South Bristol Multi-Centre Research Ethics Committee 
(04/Q2006/176; Figure 8-2) for epidemiological analyses, including those proposed in this 
thesis. 
 
2.3.3 Data acquisition, Information security and safeguarding data  
The Unit of Healthcare Epidemiology (UHCE) is a department within Nuffield Department of 
Population Health (NDPH) in the Division of Medical Sciences, at the University of Oxford. 
UHCE designed and owns the data collected in ORLS. It was curated by Professor M. 
Goldacre until his retirement on 31St March 2015 whereby formal custodianship of the 
dataset transferred to Professor M. Landray, who is one of my co-supervisors. 
 
When UHCE started receiving national, all-England, data from HES, a System Level 
Security Policy (SLSP) was established for the so-called “UHCE National Linked Database.” 
All the data UHCE received was and remains fully encrypted with all identifiable personal 
data (NHS number, local hospital number, postcode, date of birth) having been pseudo-
anonymised, with the encryption key held by NHS Digital. The SLSP listed the security 
measures which UHCE conformed to. 
 
2.3.4 Physical measures of security 
1. The UHCE is situated on a University research campus. This campus is patrolled by 
University security staff 24 hours per day, 365 days per year.  
 
2. There are CCTV cameras on the campus monitored by the security staff.  
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3. When the offices are closed, the building is securely locked. The building is protected 
with an intrusion alarm installed by a security company and connected to the security 
patrol staff and the local police station. Infra-red motion sensors which trigger the 
alarm are in place throughout the building.  
 
4. When the offices are closed, there is full coverage and full weekend coverage of the 
site by the University security staff. The University security services conduct full 
external site patrols during the day and night.  
 
5. Out of normal working hours, access to the building requires the use of an electronic 
key card which is allocated to a specified person, and its use can be audited.  
 
6. During working hours, access to the offices from the outside requires the use of an 
electronic key card.  
 
7. The two Windows servers were kept in the development office, since they were used 
on a daily basis while the database is being developed and populated. This room 
was securely locked when empty and accessible only by physical key lock.  
 
2.3.5 Logical measures for access control and privilege management 
 
1. Login identities and passwords are required to access to the Servers and are 
restricted to those staff authorised by the Director. No default users (e.g. GUEST) are 
permitted.  
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2. Any datasets that contain the encrypted partial identifiers or sensitive data (e.g. HES) 
are stored and processed only on the UHCE Development server. (Note: such data 
were not necessary to complete this thesis) 
 
3. Only authorised users using desktop PCs within the UHCE have access to the data 
on the UHCE Live server. Further logins and extra passwords are required to access 
the data.  
 
4. The media access control (MAC) of every personal computer on the local-area 
network (LAN) was registered centrally in the departmental firewall. No other 
machines could connect to the network. This required me to have virtual desktop as 
my office was not located in UHCE premises. 
 
5. All partial identifier fields were encrypted at source before they were received them 
from the Data Supplier.  
 
6. Windows Servers stored and processed the data. The operating system and data 
drives were and remain encrypted with BitLocker which is built in to the operating 
system. BitLocker requires a combination of a Trusted Platform Module (TPM) chip, 
which is unique to every machine, and a USB Key which must be present in the 
machine to decrypt the drives, ensuring that the disks cannot be used in any other 
machine. A recovery key is also created when the files are encrypted which can be 
used on its own to decrypt the files – this is kept in a secure location on site in a 
separate location to any data-files including backups, and is only to be used to 
recover backup data in case of server failure.  
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7. After daily use, each BitLocker USB Key was removed and stored in a key-coded 
safe. The secure code is known only to authorised members of staff and changed on 
a three monthly basis.  
 
8. Access is granted to each user individually and appropriate permissions assigned on 
a per-person basis, allowing access rights to be tightly controlled and monitored.  
 
9. All staff, employed in NPDH are mandated to complete online information 
governance training and assessment. 
  
NDPH reconfigured and erected a new premises during my thesis and with this a review of 
the unit’s information security policy was undertaken to align itself to the Information 
Governance Toolkit now updated by HSCIC/NHS Digital. This transition was completed in 
Spring 2016. UHCE servers are now currently stored in specifically designed server storage 
units within the Li Ka Shing Centre for Health Information and Discovery’s Big Data Institute. 
The servers continue to use “BitLocker”, a form of full-disc encryption aforementioned. 
UHCE information governance standards have been assessed by NHS digital, a report of 
which is in the Supplemental material, Figure 8-1: Information Governance Toolkit from NHS 
Digital. 
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2.4 Nomenclature used in hospital inpatient datasets 
ORLS and HES datasets recorded demographic, clinical and administrative data. The 
clinical data included types of admissions (emergency, day case, elective), dates of any 
admission and discharge, specialty of the supervising consultant and principal or ‘primary’ 
diagnosis which led to the admission together with upto 17 other secondary diagnoses. The 
codes of any procedures performed were recorded alongside its date (i.e. Procedures were 
only ever incident events). Other pertinent data included codes ascribed to specific 
hospitals/providers. For this thesis these additional codes were used in the derivation 
algorithm for the ORLS era, 1965-1999. 
 
In HES, a hospital “spell” is made up of one or more contiguous finished consultant episodes 
(FCE), hereafter referred to as “episodes”. A spell is a complete inpatient admission from the 
date of admission and discharge from the hospital/provider. An episode is defined as the 
complete time a patient has under a specific consultant and their speciality.  
 
The inpatient records in ORLS also captured the complete time a patient was admitted in 
hospital or under a specific provider (from admission to discharge) but there was only a 
single record per admission (i.e. ORLS records captured all episodes in one record). For 
synchronisation purposes, an ORLS inpatient record was seen as equivalent to a complete 
HES spell. 
 
Information on mortality for both datasets was made possible because of their linkage to the 
Office of National Statistics (ONS) which provided, as Dunn would have described it, a 
robust and reliable “end chapter” to a patient’s story. 
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2.5 Time periods covered by the cohorts  
The derivation of the treated ESRD cohort included adults (≥18 years old) who commenced 
maintenance RRT between 1st January 1970 - 31st December 1996 in ORLS, and between 
1st January 2000 - 31st December 2008 
in HES, which included a regional 
subset, termed HES Oxford. HES 
Oxford closely approximates the area 
previously covered by ORLS. All 
patients had a fixed period of upto 5 
years of retrospective follow-up to 
identify prior co-morbidities and upto 
three years of follow-up, meaning 
observations began from 1st January 
1965 and finished on 31st December 
2011 (Figure 2-2).  
Figure 2-2: Summary of datasets used to 
derive study populations 
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2.6 Diagnostic and procedurals manuals 
The versions of the diagnostic and procedural coding systems used by the datasets to 
record deaths, diagnoses and operations changed through the decades from ICD 
(International Statistical Classification of Diseases and Related Health Problems) versions 7 
to 10 and OPCS (Office of Population Censuses and Surveys Classification of Surgical 
Operations and Procedures) versions 2 to 4 (Figure 2-3). 
 
Clinical diagnostic terms relevant to renal disease were manually mapped through these 
various versions. Clinical terminology in nephrology has evolved and modern terms such as 
“acute kidney injury” are not even listed in ICD-v10, an analogous term “acute renal failure” 
is preferred. However, in older manuals, for example in ICD-v8 (used in ORLS for hospital 
admission diagnoses between 1968-1978) the preferred term was “acute nephritis”.  
 
Similarly the modern classification and grading of “chronic kidney disease” was introduced 
by K/DOQI (Kidney Disease Outcomes Quality Initiative) in 200299 and last updated by 
KDIGO (Kidney disease; Improving Global Outcomes) in 2012100 and is embedded into ICD-
v10 at the fourth character level (N18.0, N18.1, N18.2, N18.3, N18.4, N18.5, N18.9, which 
designates CKD not otherwise specified, stage 1, stage 2, stage 3, stage 4, stage 5 and 
unspecified respectively). In ICD-v7 to 9, the diagnostic term would have been “chronic renal 
failure”. This singular overarching term would have included all dialysis-dependent ESRD 
patients and any pre-dialysis patients with established renal disease as there was no fourth 
character to the code which could differentiate between the two. Hard copies of all 
appropriate ICDs manuals were available for review. A second clinician (WH), familiar with 
managing patients with ESRD cross checked all the derivation code that were proposed to 
be used in the extraction process. 
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The Unit of Healthcare Epidemiology provided hard copies of OPCS versions 1, 2 and 3 
which were scanned to preserve the resource and then reviewed before being converted, by 
me, into a format which enabled them to be integrated into the derivation procedures. An 
electronic version of OPCS version 4 was used. 
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Figure 2-3: Time periods covered by clinical coding manuals used to record death, diagnoses and procedures 
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2.7 Procedures performed to identify an ESRD cohort in HES, 2000-2008 
This involved three steps: 
1. Identifying patients likely to have been receiving renal replacement therapy 
 
2. Confirming that renal replacement therapy was for the treatment of ESRD, rather 
than recoverable AKI 
 
3. Restricting the cohort to an adult and incident cohort of treated ESRD patients all 
with upto three years follow-up (i.e. removing prevalent ESRD patients; those who 
had started RRT before the HES dataset began) 
A summary flowchart of the procedures is found in Figure 2-4. 
 
2.7.1 1
st
 HES Step: Identifying codes and potential patients treated with 
ESRD and/or renal replacement therapy 
For the first step, diagnostic and procedural codes relevant to RRT and ESRD were 
manually cross-mapped through the versions of coding manuals. The diagnostic RRT codes 
were identified from the ICD versions 7-10 and categorised into terms relating to 
transplantation (incident or prevalent) or dialysis (including terms for haemodialysis, 
peritoneal dialysis and dialysis ‘unspecified’). Procedural codes relevant to RRT were 
identified from the OPCS versions 2-4 and categorised into similar categories: dialysis and 
transplantation. A summary list of the descriptions of these codes is shown in Table 2-1.  
In the HES derivation, the codes for ESRD and renal replacement therapy were searched for 
in all patients at the episode level of each hospital admission. Patients with no mention of 
any of these ‘RRT-related codes’ were excluded, reducing potential patients to from 56 
million to 140,616. Patients identified as having residency (identified through postal districts) 
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outside England (n=1,598) were then excluded as there was potential of discontinuity of 
follow-up. 
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Table 2-1: Diagnostic and procedural codes used to identify patients with renal disease in 
versions of A) International Statistical Classification of Diseases and Related Health 
Problems and B) Office of Population Censuses and Surveys Classification of Surgical 
Operations and Procedures 
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2.7.2 2
nd
 HES Step: Distinguishing maintenance from temporary RRT 
Thereafter, the records of the remaining 139,018 patients were interrogated using steps 
designed at confirming that the pre-defined criteria of “maintenance RRT” were satisfied. 
This was necessary as clinical coding manuals have not reliably distinguished between 
dialysis that was delivered in the setting of severe acute kidney injury and regular dialysis 
provided as part of maintenance treatment for ESRD. It would have been wrong to assume 
that the co-existence of clinical discharge codes for CKD and dialysis represented 
maintenance dialysis as CKD is itself a strong risk factor for AKI.101 A series of hierarchical 
rules designed to confirm whether maintenance RRT had occurred were therefore 
employed. 
Rules for defining ‘maintenance RRT’ in all-England HES 
Maintenance RRT Rule 1, Kidney transplantation:  
The occurrence of any code included in RRT type = ‘Prevalent kidney 
transplantation’ or ‘Incident kidney transplantation’ (Table 2-1). 
Explanatory note: Transplantation is only ever performed in patients with ESRD. 
This was the first rule satisfied in 21,485 patients. 
 
Maintenance RRT Rule 2, Maintenance peritoneal dialysis:  
The occurrence of a RRT code = Peritoneal Dialysis, or survival of at least 90 days 
from the insertion of a peritoneal dialysis catheter (Table 2-1).  
Exception to maintenance RRT Rule 2: Those who fulfilled rule 2 (peritoneal dialysis) 
as their first RRT event, but did not subsequently fulfil any of the other rules and had 
a diagnosis of AKI associated with all their PD spells were not considered a 
maintenance RRT patient. 
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Explanatory note: Peritoneal dialysis is rarely used to treat AKI and the insertion of a 
peritoneal dialysis catheter, in the absence of term for AKI, was considered 
maintenance RRT. 
This was the first rule satisfied in 21,384 patients. 
 
Maintenance RRT Rule 3, Definite maintenance dialysis:  
The occurrence of a hospital inpatient episode with any code which included in RRT 
type ‘Dialysis’ in a participant who had: 
3.1) A diagnosis of ESRD (Table 2-1) any time prior to, or within 365 days after the 
start of the episode 
 Or  
3.2) The insertion of an arterio-venous (AV) fistula or graft (Table 2-1) any time prior 
to, or within 365 days after the start of the episode 
Explanatory note: Patients who were identified as having a code for dialysis in the 
context of a prior mention of end-stage renal disease or evidence of permanent 
haemodialysis access creation were considered to have commenced maintenance 
RRT. Tunnelled central venous catheters were deliberately not included in rule 3.2 as 
these can be inserted for a variety of other reasons whereas an AV fistula or graft is 
almost only used for long-term dialysis. Similarly, including patients with only a record 
of permanent haemodialysis access (i.e. a arteriovenous fistula or graft) but without a 
record of RRT was not considered appropriate as these conduits are inserted upto 12 
months before patients are anticipated to start maintenance and may never be 
subsequently used. 
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This was the first rule satisfied in 46,895 patients. 
Maintenance RRT Rule 4, Probable maintenance dialysis: 
The occurrence of at least two episodes with any code included in RRT type = 
‘Dialysis’, with at least 90 days between the start of the first ‘Dialysis’ episode and the 
start of any subsequent spell containing a ‘Dialysis’ code that did not have a record of 
a acute renal disease diagnosis in that hospital spell (Table 2-1).  
Explanatory note: Those who fulfilled rule 4 (probable dialysis) as their first RRT 
event and did not subsequently go on to fulfil any of the other rules should be 
considered ‘Possible dialysis’. 
This was the first rule satisfied in 5,792 patients. 
This series of rules was applied to the 139,018 patients of which 43,462 did not fulfil any rule 
and were therefore excluded, leaving a total of 95,556 patients who were confirmed to be 
receiving maintenance RRT. 
 
2.7.3 3
rd
 HES Step: Distinguishing incident from prevalent RRT patients 
The cohort was then restricted to incident RRT patients by excluding those who were 
identified as having as prevalent transplant (n=14,420). The cohort was then also restricted 
to patients starting maintenance RRT between 2000 and 2008, removing a further 31,049 
patients, leaving 42,730 patients. A flowchart of the derivation steps for the HES ESRD 
cohort is provided in Figure 2-4. 
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Figure 2-4: Treated end-stage renal disease cohort derivation (all-England HES 2000-2008) 
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2.7.4 Exclusion criteria applied to All-England HES derivation, 2000-2008 
The cohort was then restricted to adults (≥ 18 years old) only. 
In less than 5% of patients, missing demographic data at the defined start date of the cohort 
prevented their inclusion. 
Incident RRT patients who died within 90 days of starting maintenance RRT were excluded 
(see Figure 2-4). 
 
2.7.5 Defining entry date to the cohort 
For each patient that met the criteria that defined maintenance RRT, the date of first 
maintenance RRT was defined as the earliest date of: 
 The date of first incident transplantation code 
 
 The start date of the episode for first record of peritoneal dialysis, or the date of 
insertion of a peritoneal catheter, when not in the context of acute kidney injury 
 
 The start date of the first episode of dialysis that was used to define maintenance 
dialysis 
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2.8 Procedures performed to identify an ESRD cohort in ORLS, 1970-1996 
Analogous steps from those in all-England HES were performed to derive the earlier cohort 
of incident ESRD patients with some modifications required because of differences in the 
datasets. The full steps and rules are described below: 
 
2.8.1 1
st
 ORLS Step: Identifying codes associated with advanced renal 
disease, ESRD and/or renal replacement therapy 
An initial screen for potential patients was performed by searching all hospital records held in 
ORLS for a ‘renal-related code’. This included a broader range of terms from that used in the 
HES derivation and included terms for advanced CKD, applicable in the earlier coding 
manuals (Table 2-1). Of a total of 4.1 million records, 3.2 million patients had no renal-
related code, reducing the potential number of patients to 955,089. Of these, 36,475 were 
excluded as they had residency outside the area covered by ORLS, leaving 918,614 patients 
whose records were scrutinised further to find evidence which could confirm maintenance 
RRT.  
Additional variables used only in ORLS to identify potential ESRD patients  
Alongside renal-related codes, other variables that were recorded in ORLS were also 
extracted. This included various combinations of speciality and locality/provider codes. 
These additional variables were included, in addition to the broader inclusion of terms used 
in the initial screen of records, to minimise the chances of missing maintenance RRT 
patients. The additional variables included inpatients records with a speciality code of “33” 
which referred to ‘intermittent haemodialysis’ and was only ever observed in patients with 
hospital admissions to the Churchill hospital, between 1970-1978, the regional RRT centre 
at that time. Two provider codes, “3215” and “1208” referred to Northampton and Dellwood 
satellite dialysis units respectively and the dates from which these codes were used were 
consistent when these units opened, (1989-1994 and 1979-2000 respectively). Any patients 
with these provider codes were entered into the confirmation or 2nd step. The combination of 
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a speciality code “361” [Nephrology] was frequently observed to co-exist with regular 
hospital admissions where there was a primary diagnosis of ‘79993’. 79993 was a code used 
by the coders between 1987-1994 and was observed to be very common in patients who 
were having regular admissions under a nephrologists at the Churchill hospital. As there was 
a high degree of suspicion these represented possible ESRD patients, they were all 
progressed in the subsequent steps. Before the speciality code of nephrology was ascribed, 
two other speciality codes (-99 and 13) appeared to be common in patients attending Oxford 
hospitals. Therefore in conjunction with diagnostic codes indicative of advanced CKD (as 
defined in Table 2-1), any patients with this combination of codes were also put forward into 
the subsequent steps. See summary Table 2-2 for full details of the additional variables used 
to screen ORLS data for any potential maintenance RRT patients. 
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Table 2-2: Additional information extracted from hospital records used in place of missing variables in Oxford Record Linkage 
Study (1970-1998) 
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2.8.2 2
nd
 ORLS Step: Distinguishing maintenance from temporary RRT 
918,614 entered from step one (see subsections 2.8.1 and Figure 2-5) in this confirmatory 
step designed to ensure that “maintenance RRT” was being satisfied. The series of rules 
were analogous to the HES rules but when modified, an explanatory note is provided. 
 
Rules for identifying maintenance RRT rules in ORLS 1970-1996 
Maintenance RRT Rule 1, ORLS-Kidney transplantation: 
The occurrence of any code included in RRT type = ‘Prevalent kidney 
transplantation’ or ‘Incident Kidney Transplantation’ (see Table 2-1)  
Explanatory note: No difference to the rules in the HES derivation. 
This was the first rule satisfied 553 patients. 
 
Maintenance RRT Rule 2, ORLS-Maintenance peritoneal dialysis:  
The occurrence of a record RRT = Peritoneal Dialysis with a code for CKD any 
time prior to or within 365 days of the start of the record (Table 2-1). 
Explanatory note: This differed subtlety from the rule applied in HES as there was 
not a procedural code for peritoneal dialysis catheter insertion and there was 
limited use of the fourth character codes specific to ESRD in ICD-9, so the clinical 
term was widened to include all CKD codes. Again, when AKI codes were 
mentioned in the same hospital episode, this did not satisfy the criteria of 
maintenance RRT.  
This was the first rule satisfied 640 patients. 
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Maintenance RRT Rule 3, ORLS-Definite maintenance dialysis:  
The occurrence of a record with any code included in RRT type = ‘Dialysis’ (Table 
2-1) in a participant who has had: 
ORLS Rule 3.1) A diagnosis of ESRD (Table 2-1) any time prior to, or within 365 
days after the start of the record 
Or 
ORLS Rule 3.2) The insertion of an AV fistula or graft (AVF_AVG) (see Table 
2-1) any time prior to, or within 365 days after the start of the record 
Explanatory note: No difference to the rules in the HES derivation. 
This was the first rule satisfied 933 patients. 
 
Maintenance RRT Rule 4, ORLS-Probable dialysis:  
The occurrence of at least two episodes with any code included in RRT type = 
‘Dialysis’, with at least 90 days between the start of the first ‘Dialysis’ record and 
the start of any subsequent record containing a ‘Dialysis’ code that did not have a 
record of acute renal failure diagnosis in the record (see Table 2-1)  
Explanatory note: Those patients who fulfilled criteria of ‘probable dialysis’ as 
their first RRT event and do not subsequently go on to fulfil any of ORLS Rule 3 
should be considered ‘Possible dialysis’.  
This was the first rule satisfied 1,614 patients. 
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Maintenance RRT Rule 5, ORLS-Dialysis with mention of CKD: 
The occurrence of an episode with any code included in RRT type = ‘Dialysis’ 
(Table 2-1) in a participant who has had:  
ORLS Rule 5.1 A diagnosis indicative of advanced CKD (see Table 2-1) any time 
prior to, or within 365 days after the start of the episode. 
Explanatory note: Those who fulfilled ORLS rule 5 as their first RRT event and 
who did not subsequently go on to fulfil any of the other rules ORLS rules 1 to 4 
should be considered as ‘possible’ dialysis. 
This was the first rule satisfied 1,238 patients. 
 
2.8.3 Modifications of the rules for identification of maintenance RRT 
patients in the ORLS 
Age restriction 
Due to restrictions in chronic dialysis provision early within the cohort, an age exclusion was 
applied to patients entering the cohort before 1990.  
1970-1975  exclude those starting RRT with age  >=60 years 
 
1975-1979  exclude those starting RRT with age  >=70 years 
 
1980-1984        exclude those starting RRT with age  >=80 years 
 
1985-2008  no age restriction was applied 
Of the 918,614 patients whose records were interrogated to confirm of maintenance RRT 
913,636 were excluded with a further 1,569 excluded after clinician review. This review 
subjected records of individualised patients to be reviewed to inform the presence of ESRD 
and start date of RRT. 
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Clinical adjudication of all ORLS patients 
All potential patients identified in ORLS were subject to a manual review of all their linked 
anonymised hospital admissions that were stored in ORLS.  
This additional step was designed to ensure that the pattern of admissions was consistent 
with an RRT patient and allowed manual attribution of the fact or start date of RRT in ORLS 
when agreed with two clinicians familiar with the care of patients with renal disease. This 
was necessary because of aspects of selection which are difficult to set as automated rules.  
For example it became apparent during the review that the ‘Dellwood’ centre, as well have 
having some inpatient beds for haemodialysis was a rehabilitation hospital where some 
patients were admitted for convalescence following an injury or illness.  
 
2.8.4 3
rd
 ORLS Step: Distinguishing incident from prevalent RRT patients 
3,409 patients entered the third step where only adults or patients with patients were 
identified, (removing 483 patients) and any patient dying within the first 90 days of their RRT 
start date were removed. 
Then patients identified as entering the cohort with a functioning transplant, termed 
“prevalent transplantation” were also excluded, a total of 278 more patients.  
Explanatory note: It is likely that these patients may have moved from outside the catchment 
of ORLS, where they had their incident transplant operation, to then moving into the 
catchment area of the ORLS where subsequent admissions were captured. 
 
2.8.5 Defining entry date to the cohort 
For each patient that met the criteria that defined maintenance RRT, the date of first 
maintenance RRT was as per the derivation in HES but had the additional oversight of a 
clinical review of all hospital inpatients records.  
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A summary of the derivation flowchart applied to ORLS is provided in Figure 2-5. 
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Figure 2-5: Treated end-stage renal disease cohort derivation (ORLS 1970-1996) 
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2.9 Internal validation of the rules which defined maintenance RRT 
To assess the validity of these specific algorithms or ‘rules’ designed to confirm maintenance 
RRT subsequent hospital admissions of patients included into the final cohort were reviewed 
to see if they ever fulfilled any of the other rules in their future hospital episodes. Patients 
first identified in ‘rule 1’ (i.e. kidney transplantation) were not tested as this unambiguously 
defines ESRD.  
Table 2-3: Internal validation of the rules which confirmed maintenance RRTTable 2-3 
describes the proportion of patients identified as undergoing maintenance dialysis and 
subsequent not fulfilling any other rule.  
 
Table 2-3: Internal validation of the rules which confirmed maintenance RRT 
 
 
In all-England HES, consistently  less than 5% of patients, no matter what maintenance RRT 
rule (2:‘peritoneal’, 3:‘definite’, 4:‘probable’) was used to initially identify them as receiving 
maintenance RRT did not, in any future inpatient hospital admissions, satisfy other criteria of 
maintenance RRT. In ORLS period of derivation, this proportion was larger constituting 
mainly patients identified by rule 4:‘probable’ and ORLS rule 5:‘dialysis with mention of 
CKD’. However all patients identified in ORLS had the advantage of individual clinical review 
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of hospital episodes. Furthermore external and some direct validation of the cohorts is 
described in Chapter 4 Validation. 
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2.10 Procedures performed to identify general population hospital controls, 1970-
2008 
To permit comparative analyses of the ESRD cohorts with the general population, a large set 
of contemporaneous general population hospital controls were derived from the same 
datasets using a method previously developed described and adopted previously by 
UHCE.96 Patients admitted to hospital for a minor medical condition or procedures were 
selected across the whole cohort as these are more likely to be representative of the general 
population than those admitted for serious diseases. Any hospital control who ever 
underwent maintenance RRT was excluded. A list of the mapped codes used to identify the 
general population hospital controls is found in Table 2-4.  
The benefit of this approach is that the comparative population has the same opportunities to 
have prior co-morbid illnesses identified from their respective prior hospitalisations, and any 
such illnesses would have been captured in a consistent way, by the same body of trained 
clinical coders, allowing more reliable mortality trend analyses.  
 
Defining the index date for the general population hospital controls 
Entry into the cohort was defined as the start date of the episode in which a specified 
diagnosis was recorded or the date of the minor procedure. In patients where there was 
more than one control event, the episode of care which was included in the analysis as the 
control event was selected at random (i.e. a control participant could only be included once).  
 
Other criteria applied to general population controls, 1970-2008 
To ensure consistency with the ESRD cohort, general population controls had to be aged 18 
years or older as were those patients who died within 90 days of their index event. 
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Table 2-4: Diagnoses and procedures used to identify the index admission for control 
population, by coding manual 
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2.11 Extraction of baseline characteristics for ESRD and general population 
Age 
Patients’ exact ages were calculated from their date of birth as identified at the start date of 
maintenance RRT or, for hospital controls, the admission date for the minor conditions or 
procedure. 
Sex 
The sex of the patient (male or female) was captured at the first hospital admission. 
Ethnicity 
Ethnicity was not recorded in ORLS.  In all-England HES the UK-Renal Registry ethnicity 
categories were applied to the 18 data variables of ethnic categories in HES. There were 
classified into groups as per Table 2-5. 
 
Comorbidities 
Comorbidities were extracted from hospitalizations prior to the index date with a fixed period 
of 5 years of retrospective follow-up in ORLS and 2 years in HES. Comorbidities based on 
Table 2-5: Categories of ethnicity coding used in Hospital Episode 
Statistics 
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the Charlson102,103 index were identified from any diagnostic and procedure codes on 
admission records at the time of entry into the cohort and for a ‘fixed period’ of retrospective 
follow-up (i.e. interrogating admission data over a set number of years which preceded the 
defined start date of maintenance RRT).  
Comorbidities were grouped into: (i) diabetes mellitus (type 1 and 2 combined); (ii) vascular 
disease, including major coronary disease, heart failure, cerebrovascular disease and 
peripheral arterial disease; and (iii) non-vascular disease including liver disease, cancer, 
chronic obstructive pulmonary disease (COPD), peptic ulcer disease, hemi- or paraplegia 
and connective tissue disease. A table of codes which defined the comorbidities and its 
mapped terms is provided in Table 2-6. For further details, including the rationale for the 
duration of the retrospective follow-up and how clinical coding practices have changed see 
section Chapter/Section 3.5.1, starting at page 103. 
 
Index of Multiple Deprivation 
The socio-economic status of participants was only possible to identify in HES. Here, the 
Index of Multiple Deprivation (IMD) was used. IMD is a measure of multiple deprivation 
assessments at the super-local level. It has seven domains:  
1) Income  
2) Employment  
3) Health and disability  
4) Education  
5) Crime  
6) Barriers to housing and services  
7) Living environment 
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IMD version 2004, ranked the 32,482 geographical areas in England by deprivation (rank 1 
being the highest deprivation).104 The IMD rank score was extracted using data recorded on 
the episode when maintenance RRT was deemed to have begun or on the admission for the 
minor comorbidities/procedures for hospital controls.  
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 Table 2-6: Coding of comorbidity by International Classification of Disease (ICD) diagnoses and Office of Population 
Censuses and Surveys (OPCS) procedures 
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2.11.1 Renal characteristics pertinent to ESRD cohort only 
Initial RRT modality 
The modality assumed at the start date of maintenance RRT depended on the rule that 
defined the start of maintenance RRT: 
If rule 1 (i.e. kidney transplantation) in HES or ORLS identified the start of 
maintenance RRT then the patient was assumed to have received a pre-emptive 
renal transplant. 
 
If rule 2, 3 or 4 identified the start of maintenance RRT then the patient was assumed 
to be receiving dialytic therapies. 
 
Attempts were made to try and reliably establish which dialytic therapy (haemo- or peritoneal 
dialysis) was the initial modality first but this was not possible. Current data suggests that 
once differences in case-mix are adjusted for, then the survival is not modified by dialysis 
modality.105,106 
 
Primary renal disease 
For each identified participant a primary renal diagnosis (PRD) was derived using episode 
diagnoses reported in the admission that defined maintenance RRT and any preceding spell 
(with the exception of polycystic kidney disease (PKD) and other hereditary causes which 
could have been identified in any episode). 
If more than one PRD was present then the PRD which was selected based on the following 
hierarchy: 
Polycystic kidney disease 
Other hereditary 
Glomerulonephritis 
Diabetic kidney disease 
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Systemic disease 
Tubulo-interstitial disease (including cases of obstructive uropathy) 
Miscellaneous 
Hypertension/ischaemic 
Unknown 
 
If none of these diagnoses were present, and the patient had diabetes mellitus as a 
comorbidity at the date of the start of maintenance RRT, then diabetic kidney disease was 
selected, otherwise the PRD was considered to be ‘unknown’.  
For the purposes of subsequent presented data: Other hereditary, Systemic disease, 
Tubulo-interstitial disease, Miscellaneous and Hypertension/ischaemic should be considered 
as an ‘Other known diagnosis’ category. A table showing the mapped terms for the main 
groups of primary renal disease is presented in Table 2-7. 
  
Table 2-7: Diagnostic codes used to identify main groups of primary renal disease 
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2.12 Extraction of outcomes; mortality data 
ORLS and all-England HES have linked data from the national mortality data held by the 
Office for National Statistics (ONS). This provided the fact of death, date of death, and the 
proscribed underlying cause of death (UCD) for all patients. The UCD is defined by the 
World Health Organization (WHO) as, “the disease or injury that initiated the train of events 
leading directly to death, or the circumstances of the accident or violence which produced 
the fatal injury.” In addition, HES and ORLS held ancillary data on the codes recorded in the 
various parts of the medical certificate of death, but did not distinguish whether diagnoses 
were in Part I and Part II (i.e. whether they were direct or contributory causes). 
For the proposed cause-specific mortality analyses, deaths were grouped as in Figure 2-6 
using the mapped codes in Table 2-8. These categories were chosen to be clinically relevant 
and large enough to generate enough events.  
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Figure 2-6: Coding of death categories by International Classification of Disease (ICD) version 
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Table 2-8: Coding of death categories by International Classification of Disease (ICD) version 
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2.13 Discussion and conclusions 
This chapter has described the specific procedures, which identified a combined cohort of 
44,922 Oxford and English incident ESRD patients who survived 90 days from starting 
maintenance RRT. This is unique, as no reports of other ESRD cohorts, identified 
exclusively from routinely collected hospital inpatient datasets has been found in the 
literature. Furthermore the concurrent identification of over 5 million general population 
hospital control patients will permit comparative analyses. The datasets have linkage to 
national mortality registry data providing an opportunity to analyse longitudinal mortality 
trends, an invaluable epidemiological tool providing an assessment of health risk and 
provide evidence whether there has been progress of a given period of time. Mortality trends 
assist in identifying factors that are related to differences in patient mortality, although can 
only yield these results based on variables which are measured. Almost uniquely in ESRD 
epidemiology, has the disease of interest seen such a change in the characteristics of 
patients selected to receive treatment and this poses certain challenges. As age and certain 
comorbidities are both determinants of selection to receive RRT and mortality in patients 
with ESRD,6-8,107-110 any longitudinal analyses should ideally be adjusted for these secular 
changes in order to be informative. 
  
Defining the actual study population that is being studied is critical as there are large 
differences in mortality rates between those who receive treatment for ESRD, as oppose 
who do not. The death rates among those with patients with untreated ESRD, either 
because they have no access to renal replacement services or have chosen to have non-
dialysis care in the setting of symptomatic uraemia is unsurprisingly high, with patients 
generally dying in a matter of days or weeks, depending on residual renal function. 
Therefore including untreated patients into any mortality statistics of an entire ESRD 
population would therefore increase the overall death rates. In contrast, if the deaths of 
those withdrawing from dialysis were excluded, or patients with a stable 
Cohort derivation  [Page 80]       [80] 
 
eGFR<15mls/min/1.73m2 (which would fulfil the recent formal biochemical definition of 
ESRD) but who have not begun RRT then the deaths rates would be lower as this level of 
renal function rarely directly leads to death. 
Isolated standardized mortality statistics of ESRD populations are rarely useful – it is only 
when there are compared to death rates in other populations and/or have a longitudinal 
component that they become more informative. This thesis proposes to do both of these 
things, making its results more reliable. For example, the age stratified cardiovascular 
mortality rates (per 1000 person-years) for dialysis patients aged 35-44 years RRT was 
reported to be 21.2 yet it is only when you know the same age specific rates in a 
comparative general population of 0.2 per 1000py that the magnitude of the absolute excess 
for age-matched dialysis patients is apparent.81 Furthermore comparing relative indices, in 
this narrowly focussed example would give a ‘100 fold’ increase in age specific rates, which 
is rather sensationalist.111 There were small numbers of deaths and other than age, no 
attempt was made to adjust for the other comorbidities of such patients such as a presumed 
significantly higher rate of type 1 diabetes. Moreover, these analyses did not have data to 
describe changes in rates over time as the data were analysed at a single time point. 
 
2.13.1 Limitations of using routinely collected healthcare data 
This thesis includes ESRD patients who have been positively selected onto a RRT 
programme and survived 90 days from the start of maintenance RRT. It does not include 
ESRD patients that have been refused or declined RRT whereby non-dialysis/‘conservative 
has been decided upon. Hospital inpatient records do not provide such a distinction as often 
these decisions are made in the outpatient setting. The exclusion of patients who died within 
the first 90 days of starting maintenance RRT is typically done in registry data and will allow 
fairer comparisons of this English data to other resources. The 90 day period is clinically ( 
yet arbitrarily) chosen, as the actual start date of maintenance dialysis can be rather difficult 
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to determine. Many patients begin in the setting of an acute illness from which their prior 
remaining renal function is lost and they do not recover or in the case of peritoneal dialysis at 
what point patients training finishes and they begin full therapy is a matter of debate.  
This observational data does not hold other common variables which are known to effect 
mortality, LDL-C, blood pressure, smoking habits and measures of adioposity.  
This thesis therefore proposes to study the mortality trends of incident patients receiving 
treatment for ESRD (in the form of maintenance dialytic therapies or a kidney transplant). It 
will exclude maintenance RRT patients who died within 90 days (an arbitrary period used in 
nephrology to remove biases introduced by early mortality on RRT) and compare mortality 
rates to a set of contemporaneously derived general population hospital controls.  
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2.14 Bullet points of Chapter 2  
 
 Permission to access fully anonymised and encrypted, prospectively-collected, 
individually-linked hospital admission data from ORLS (1965-1999) and all-England 
HES (1998-2011) data were obtained 
 
 Diagnostic (ICD) and procedural (OPCS) coding manuals covering the period 1965-
2011 period of proposed study were sourced and transcribed into usable formats 
 
 Diagnostic and procedural codes relevant to renal disease and its’ treatment were 
identified  
 
 A three stage process of a) identifying potential ESRD patients, b) confirming 
maintenance RRT and then c) identifying adults starting incident RRT was 
developed. This was applied to HES (2000-2008) and adapted to ORLS ( 1970-1996) 
periods of study. 
 
 Major comorbidities grouped into a) diabetes, b) vascular and c) non-vascular  were 
identified in a fixed period of retrospective follow-up from the index date to the cohort. 
 
 An extraction of a contemporaneous general population controls was also performed  
 
Baseline characteristics  [Page 83]       [83] 
 
Chapter 3  Baseline characteristics 
Baseline characteristics of cohorts of 45,000 
treated ESRD patients and 5.6 million general 
population hospital controls from Oxfordshire 
and England 1970-2008 
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3.1 Abstract 
Background 
The characteristics of patients starting renal replacement therapy (RRT) has changed 
substantially over the 40 years since 1970. A description of these changes for a cohort of 
treated end-stage renal disease (ESRD) patients are presented in parallel to secular 
changes observed in a contemporaneous set of general population hospital controls. The 
impacts of changes in datasets over time on the ascertainment of comorbidities are also 
explored. 
Methods 
The baseline demographics, comorbidities and renal characteristics of an incident cohort of 
treated ESRD adults derived from routine hospital inpatients datasets; Oxford Record 
Linkage Study (ORLS; 1970-1996) and all-England Hospital Episode Statistics (HES; 2000 
2008) are presented. The characteristics of a large set of contemporaneous general 
population hospital controls are reported for comparison. 
Results 
In total 44,922 new treated ESRD RRT patients were identified: 2,192 from ORLS and 
42,730 from HES. The median age at start of RRT for Oxfordshire patients rose from 46 
years (IQR 36-60) in 1970-1985 to 61 years (IQR 46-72) in 2006-2008. The proportion of 
females receiving RRT has remained largely unchanged at about 40%. The proportion of 
ESRD patients identified as having comorbid illness at the start of RRT increased steeply. 
The crude prevalence of diabetes increased from 6.7% in 1970-1990 to 33.9% in 2006-2008; 
vascular disease prevalence from 10.0% to 28.3%; and non-vascular disease from 7.8% to 
27.5%. Similar changes were observed in the Oxfordshire and all-England ESRD cohorts. 
Among 5.6 million general population hospital controls, median age at entry into the cohort 
increased from 40 years (29-57) in 1970-1990 to 47 years (33-64) in 2006-2008. The 
prevalence of major comorbidities also increased in this population: diabetes prevalence 
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rose from 0.8% to 4.1%, vascular disease from 2.0% to 3.6% and non-vascular disease 
3.6% to 9.8%.  
Conclusions  
Since 1970, when RRT was introduced in Oxfordshire, the age structure and comorbidity 
profile of treated ESRD patients has changed dramatically, reflecting the increased provision 
and access to RRT. The magnitude of the secular changes observed in the ESRD and 
general population hospital controls, especially with respect to age and the prevalence of 
comorbid illnesses, means that any assessment of mortality trends needs to adjust for these 
key determinants of mortality to be interpretable. 
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3.2 Introduction 
A retrospective adult cohort of incident ESRD patients, receiving renal replacement therapy 
(RRT) has been derived from routinely collected hospital inpatients datasets over a period of 
40 years. Their baseline demographic characteristics are presented and discussed 
alongside baseline characteristics of a large set of general population hospital controls. 
 
3.3 Methods 
For a full description of the cohort derivation, see Chapter 2  In brief, an algorithm was 
specified to identify, between 1970 and 2008, a cohort of newly treated adult (≥18 years) 
ESRD patients, using routinely collected hospital inpatient datasets. Between 1970 and 1996 
patients were identified from Oxford Record Linkage Study with a similar derivation process 
being expanded into all-England Hospital Episode Statistics (HES) between 2000 and 2008. 
This included a regional subset of HES, hereafter termed “HES Oxford”.93 HES Oxford 
Figure 3-1: Datasets used to identify retrospective cohorts of end-stage renal 
disease patients 
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closely approximated the geographic area covered by ORLS. Full details of the criteria used 
to identify these patients can be found in Chapter 2 Cohort derivation. A summary flowchart 
of the available data is provided in Figure 3-1. 
To allow mortality rates from the new treated ESRD cohort to be compared to a group of 
contemporaneous adults, hospital controls who were never recorded as undergoing RRT 
were selected so as to be reasonably representative of the general population by using 
admissions for a range of minor conditions, a full list of such conditions can be found in 
Table 2-4.  
Basic demographic data (age, sex, ethnicity and socio-economic status (SES) were taken 
from the hospital admission records at the start of maintenance RRT. Comorbidities based 
on the Charlson102,103 index were also identified from diagnostic and procedure codes on 
admission records at the time of entry into the cohort and for a ‘fixed period’ of retrospective 
follow-up (ie, interrogating admission data over a set number of years which preceded the 
defined start date of maintenance RRT). Comorbidities were grouped accordingly: (i) 
diabetes mellitus (including type 1 and 2); (ii) vascular disease, including major coronary 
disease, heart failure, cerebrovascular disease and peripheral arterial disease; and (iii) non-
vascular disease including liver disease, cancer, chronic obstructive pulmonary disease 
(COPD), peptic ulcer disease, hemi- or paraplegia and connective tissue disease (Table 
2-6). 
For the derived ESRD cohort in HES, two specific renal characteristics were also derived: a 
presumed primary renal disease (PRD) and an initial RRT modality. PRD was categorised 
into polycystic kidney disease, glomerulonephritis, diabetic kidney disease, or other/unknown 
cause, and an initial RRT modality was dichotomised into either being dialysis or kidney 
transplant, which by definition indicated a presumed pre-emptive transplant. 
Identifying the socio-economic status of the cohort was also only possible in HES and 
involved deriving the index of multiple deprivation (IMD version 2004) which ranked the 
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32,482 geographical areas in England by deprivation (rank 1 being the highest 
deprivation).104 
 
3.3.1 Statistical Methods 
Number and proportions are presented for categorical variables. The age distribution was 
not normally distributed and so medians with interquartile cutoffs are presented. To assess 
whether baseline characteristics changed significantly over time, tests for the differences 
across the year groups were performed using Chi-squared (2) tests for binary variables and 
Kruskal-Wallis test for age. 
 
  
Baseline characteristics  [Page 89]       [89] 
 
3.4 Results 
3.4.1 Demographics of ESRD cohort 
The ESRD cohort included 44,922 treated ESRD patients identified over the 40 year period 
of which 2,192 patients were identified from ORLS and 42,970 from all-England HES, 
including 2,328 from HES Oxford (Figure 3-1 & Table 3-1). 
 
Age 
The median age of patients starting RRT in Oxfordshire rose by 18 years; from 49 years 
(interquartile cut offs, 36-60) in 1970-1990 to 61 years (46-72) in 2006-2008. If the initial year 
group were divided, it is apparent that this increase began early; median age increased from 
46 years in 1970-1985 to 56 years in 1986-1990, and 59.5 years in 1994-1996 (Figure 3-2). 
Consequently, in 1970-1990, only 25% of new patients were older than 60 years compared 
to nearly 50% of patients from 2000 onwards. Similarly, between 1970 and 1990 the 
proportion of patients commencing RRT who were ≥70 years was 8.2%, increasing to nearly 
one third by 2006-2008. Similar trends were observed in HES Oxford and in all-England data 
from 2000 (Table 3-1). 
 
Gender 
There has been no significant change in the overall proportion of females across the entire 
ESRD cohort, contributing approximately 40% across both cohorts (p for trend over time = 
0.20 for ORLS/HES Oxford and p=0.50 for all-England-HES) (Figure 3-2 & Table 3-1). 
 
Ethnicity 
Ethnicity data were not reliably recorded in ORLS. From 2000-2008 the proportion of HES 
Oxford patients with any known ethnicity increased from 81.3% to 96.0%. Of those with a 
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recorded ethnicity the proportion of non-whites increased from 13.2% in 2000-2002 to 15.9% 
in 2006-2008 but patients of white ethnicity predominated in all year groups at between 84-
86%. In all-England HES data, of these patients with known ethnicity, approximately 80% 
were of white ethnicity. There were, on average, greater proportions of Blacks (6.6% vs 
4.0%) and South Asians (8.5% vs. 7.0%) recorded in all-England HES than HES Oxford 
(Table 3-1). 
  
Socio-economic status 
In HES Oxford, the largest proportion of patients was identified from the highest IMD quintile 
(43-45%) with nearly two thirds of patients consistently being derived from the two most 
affluent quintiles. The SES structure in HES Oxford remained largely unchanged between 
2000 and 2008. The SES structure in all-England stood in contrast where there was a more 
even distribution of patients across each IMD quintile. The proportions of patients from each 
IMD quintile were very different in HES Oxford compared to all-England, reflecting that 
Oxfordshire includes many districts that were classified as ‘least deprived’. The distribution 
of patients from the each IMD quintiles did not appear to change over the decade of all-
England HES. 
 
Comorbidity 
The reported prevalence of baseline major comorbid illness all increased significantly over 
time across the Oxfordshire cohort over time. The proportion of patients with diabetes was 
5.8% between 1970 and  1985, increasing to 8.1% by 1986-1990, then doubling to 16.8% by 
1991-1996 and it then doubled again by 2006-2008 (Figure 3-2). Overall the prevalence of 
diabetes it increased over 4-fold from 6.7% in 1970-1990 to 33.9% in 2006-2008 (Table 3-1). 
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Prior vascular disease nearly trebled, from 9.1% in 1970-1984 to 25.2% in 2006-2008. This 
constituted rises in peripheral vascular disease from 3.0% to 12.9%, major coronary disease 
from 2.6% to 8.3%, congestive heart failure from 5.2% to 10.5% and cerebrovascular 
disease from 1.4% to 3.5%. 
 
The proportion of new ESRD patients with non-vascular comorbidities increased from 7.8% 
in 1970-1990 (and even lower at 5.5% in 1970-1985, (Figure 3-2) to 24.9% in 2006-2008 
which largely constituted a rise in the prevalence of COPD (1.3% to 10.3%) and smaller 
increases in the prevalence of all other non-vascular comorbidities: cancer (2.9% to 7.6%), 
connective tissue disease (2.0% to 4.9%), liver disease (0.5% to 2.3%), peptic ulcer disease 
(1.6% to 1.9%) and hemi-paraplegia (0.2% to 1.5%).  
A summary of baseline comorbidities are presented in Table 3-1 and graphically in Figure 
3-2.
Baseline characteristics        [Page 92]
        
 
Figure 3-2: Baseline characteristics of new treated end-stage renal disease patients, by year 
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Table 3-1: Baseline characteristics of new treated end-stage renal disease patients, by region and year 
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Renal Characteristics of the derived ESRD cohort 
Initial RRT modality 
The data suggested that the proportion of patients identified as commencing maintenance 
RRT via dialytic therapies has reduced, on absolute scale, by 3.4%: from 94.6% in 1970-
1990 to 91.2% in 2006-2008 with a reciprocal increase in the proportions of patients 
identified as starting with a transplant, from 5.4% to 8.4%. This observed pattern of an 
increasing proportion of pre-emptive transplantation in HES Oxford was similar to that in all-
England, yet the proportions of patients identified as starting maintenance RRT with a 
transplant in all-England were, on average, lower. The test for trend across the year groups 
of was non-significant in Oxford, p = 0.08 but in all-England, where there were many more 
pre-emptive transplants performed, a significant trend was identified, p= 0.002 (Table 3-1). 
 
Presumed primary renal disease 
The proportion of patients with an identifiable ‘presumed’ PRD increased over time, from 
21.5% in 1970-1990 to 46.9% in 2006-2008. The proportion of ESRD patients with a 
presumed PRD of diabetic kidney disease rose from 1.6% in 1970-1990 to 22.1% in 2006-
2008. The proportion with presumed glomerulonephritis as the cause of ESRD was 9.3% in 
1970-1990, rising to 14.5% by 2006-2008. The proportion of patients with polycystic kidney 
disease fell slightly from 10.5% in 1970-1990 to 8.4% by 1991-1996, 8.6% by 2000-2002, 
and 7.5% in 2003-2005 before increasing back to 10.4% by 2006-2008. 
All-England data were similar to HES Oxford with roughly one fifth of patients having diabetic 
kidney disease, 8-10% having polycystic kidney disease with a little over 50% having other 
known or unknown diagnoses (Table 3-1). 
The difficulties in consistently identifying primary renal diagnosis, especially in ORLS with 
upto three quarters not being able to be identified, limited its use as variable to take forward 
into the proposed comparative mortality analyses, as there was not a comparative variable in 
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the general population. ESRD data repositories have substituted knowledge of prior co-
morbid illnesses at the start of a RRT career with PRD to use as co-variable in mortality 
analyses but as 10-15% of patients have an unknown aetiology of ESRD and you cant have 
more than one PRD (you couldn’t have PKD and diabetes) then there are obvious 
limitations.  
3.4.2 Stratified baseline characteristics within ESRD cohorts; by initial RRT 
modality 
In the period covering ORLS, pre-emptive transplants were relatively uncommon with only 
66 performed between 1970-1990, equating to 3.3 per annum (p.a.) and then 72 in the 
subsequent 6 years between 1991-1996, equating to 12/pa. In HES Oxford, the absolute 
numbers of pre-emptive transplant recipients continued to increase to 44 (14.7/pa) in 2000-
2002, to 55 (18.3/pa) in 2003-2005 and 74 in 2006-2008 (24.6/pa). Patients who were 
identified as receiving a kidney transplant as their initial modality of RRT were more likely to 
be younger, less morbid than those starting on dialytic therapies (Table 3-2 & Table 3-3). 
Pre-emptive transplant recipients had a median age at start of RRT of 36, (IQR, 26-45) rising 
to 45 (from 2000) compared to dialysis patients who had a median age of 50 (37-61) in 
1970-1990 rising to 62 (49-73) by 2006-2008 (Table 3-2 & Table 3-3). The proportion of 
females who were identified as receiving a transplant as their initial mode of RRT was, in 
general, lower than that those starting via dialysis but remained fairly static over the period of 
the cohort (Table 3-2 & Table 3-3). 
The IMD quintile of patients who received a transplant as their initial RRT modality both in 
Oxford and all-England were more likely to come from less deprived areas than those 
starting on dialysis. Of all-England patients identified as receiving a transplant as their initial 
RRT, the proportions residing from the most deprived (IMD 1) districts fell from 16.4% to 
12.6% (Table 3-2 & Table 3-3).  
The prevalence of major comorbidities was considerable less in patients identified as having 
a transplant as opposed to dialysis. Vascular disease among those who received a pre-
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emptive transplant had on average, a 5.7% prevalence, compared to 28.1% in patients 
starting on dialytic therapies. Non-vascular disease was identified in 11.2% of those 
receiving pre-emptive transplants as opposed to 25.8% in those that started via dialytic 
therapies (Table 3-2 & Table 3-3). 
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Table 3-2: Baseline characteristics of new treated end-stage renal disease patients with transplantation being the first recorded modality of 
renal replacement therapy 
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Table 3-3: Baseline characteristics of new treated end-stage renal disease patients in which dialysis was the first recorded modality of 
renal replacement therapy 
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3.4.3 Demographics of general population hospital controls 
The general population hospital control cohort consisted of 5,613,781 patients who entered 
the cohort at the time of a minor condition or procedure. This 5.6 million included 532,019 
patients identified in the ORLS (1970-1996) and 5,081,762 patients from all-England HES 
between 2000-2008, of which 253,069 patients were from HES Oxford (Figure 3-1 & Table 
3-4). 
Age 
The median age of patients at entry into the Oxfordshire general population cohort rose by 
seven years from 40 years (29-57) in 1970-1990 to 47 years (33-64) in 2006-2008. 
Compared to the ESRD cohort, the age structure of the general population controls therefore 
did not change to the same magnitude. Nevertheless, the proportion of patients over 60 
years increased from a quarter to one third between 1970-1990 and 2006-2008, whilst the 
proportion of patients over 70 years increased by about a half from 12.5% in 1970-1990 to 
19.0% in 2006-2008 (Table 3-4). 
 
Gender 
The proportion of females who contributed to the general population hospital controls was 
higher than ESRD cohorts and decreased slightly from the 56.9% in 1970-1990 to 50.0% 
from 2003 onwards (Table 3-4). 
 
Comorbidity 
The general population cohort were much less comorbid than the ESRD population. 
However even within the general population the prevalence of comorbidities increased 
substantially. 
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The prevalence of diabetes rose 4-fold in the hospital controls from 0.8% in 1970-1990 to 
4.1% in 2006-2008 (Table 3-4).  
 
The proportion of general population controls identified as having baseline vascular disease 
increased from 2.0% in 1970-1990 to 3.6% in 2006-2008. This constituted a doubling of the 
reported prevalence of major coronary disease (0.6% to 1.2%), congestive heart failure 
(0.6% to 1.2%) and cerebrovascular disease (0.4% to 0.8%) and a more modest increase in 
peripheral arterial disease, from 0.6% to 1.0%. General population control patients identified 
from HES Oxford data had, in general, a 20-30% lower proportion than that in all-England 
patients, but yet there were similar increases were in Oxford and all-England patients over 
time (Table 3-4). 
The prevalence of comorbidities which saw the largest absolute increases were serious non-
vascular disease, rising by 6.2% from 3.6% in 1970-1990 to 9.8% in 2006-2008. Increases in 
prevalence of COPD constituted, by far, the largest portion of this observed increase, rising 
about six-fold from 0.9% to 6.3% (Table 3-4). 
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Table 3-4: Baseline characteristics of general population hospital controls, by year 
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3.5 Discussion 
The characteristics of incident RRT patients have changed substantially over the over the 
past 40 years since 1970, with changes in Oxford since 2000 mirroring trends observed in 
all-England. In the 1970s, maintenance RRT was a prioritised treatment available to younger 
and healthier patients contrasting the modern era where the median age at starting RRT has 
risen to over 60 years with approximately a third of all incident patients having diabetes 
recorded in prior hospital admissions.  
 
There were substantially less dramatic changes in the characteristics of the large set of 
hospitalised general population controls. They too have, on average, become older and 
reportedly more comorbid over time, but the magnitude of these changes, (especially in age 
and prevalence of comorbid illness) are less than that observed in the derived ESRD cohort. 
As age, sex and comorbidities are key predictors of mortality107,112 when comparing mortality 
trends between these populations these characteristics needs to be appropriately adjusted 
before any temporal changes can be fairly interpreted. This has not been possible in 
previous studies using ESRD registry data as any such data either lacked or had incomplete 
data on comorbid illness and there was no opportunity for comparable data to be drawn from 
a general population.  
 
The collection and reporting of comorbidity variables to the core database, the UK-Renal 
Registry, have improved but remain poor. For example, in 2007 only 3 out of 50 English 
renal centres provided 100% data whilst 20 centres provided <10% including 9 centres 
reporting no comorbidity data at all.113 European10 and US renal registries114 have generally 
included the PRD as a surrogate for comorbidity in their adjusted analyses but no other large 
study has had access to comorbidity data for an ESRD renal population alongside those of 
any comparative population over such a long period of time. Moreover the availability of  
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the large set of contemporaneously derived general population hospital controls permits 
analogous standardization. 
The large changes in the characteristics of RRT patients principally reflect the increased 
access and provision of RRT over these 40 years.
3,27,49
 Consequently, the selection onto 
dialysis programs has become less stringent with more comorbid patients being much more 
commonly offered maintenance RRT including kidney transplantation.42 The general 
population are also living longer and as age is among the most significant risk factor for the 
development of ESRD this has resulted in more patients developing ESRD.115,116 Similarly, 
the epidemic of type 2 diabetes and its associated obesity and albuminuria contribute to the 
increasing prevalence of ESRD as they are all established risk factors for the development 
of the disease.117-119 These changes have happened in the context of better survival from 
cancer120, cardiovascular disease121 and increased funding for RRT programmes49 resulting 
in older patients, with increasing comorbidity now constituting the majority of patients 
commencing RRT.5 
 
3.5.1 Comorbidity ascertainment from routinely collected hospital inpatients 
records 
The identification of prior 
comorbidity using electronic 
healthcare records in a CKD 
population has been tested before in 
a Scottish, but not-English, CKD 
cohort.122 In this analysis the 
researchers had access to direct 
linkage to inpatient clinical notes for 
their comparsion.122 Electronic 
records identified comorbidities in a 
Table 3-5: Level of agreement of individual 
components of pre-dialysis CKD cohort between 
hospital inpatients records and clinical notes 
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retrospective period of 5 years whilst there was an unlimited period of prior review in the 
clinical notes.  Agreement between comorbidity derived from administrative data and clinical 
notes was measured using a kappa statistic. Cerebrovascular disease, ischaemic heart 
disease and diabetes had good to fair agreement (i.e. κ>0.6), whilst non-vascular diseases 
such as cancer, connective tissues and chronic obstructive pulmonary disease all had less 
agreement, (i.e. >0.5 κ <0.6) (Table 3-5). Subgroup analyses revealed that agreement 
broadly improved with more advanced renal disease,122 presumably because of increased 
number of inpatient episodes. Combining these individual comorbidities, based on the 
Charlson comorbidity index102, showed that 73% of patients had comorbidity scores within 
plus or minus one point of the clinical notes.123 No other studies have published the validity 
of utilising derived comorbidity for an English cohort of patients with advanced renal disease, 
identified from HES or its predecessors, and incorporated them as covariates in mortality 
analyses.  
 
3.5.2 Duration of retrospective period used to ascertain of major comorbidities  
One of the unique features of this thesis is that there was the opportunity to derive baseline 
comorbidities from a retrospective period before starting RRT. They were extracted using a 
‘fixed’ period of retrospective follow-up prior to the entry date to ensure that patients starting 
RRT in any given year had a consistent period of retrospective follow-up during which 
identify comorbidity. Having an unrestricted retrospective period would have meant that 
patients starting RRT in 2008 could have had upto 10 years of potential prior follow-up in 
contrast to patients in 2000 only having a maximum of 2 years (as HES data began in 1998). 
This would introduce ascertainment bias of prior comorbidities.124,125 Understanding whether, 
and how, altering the duration of this retrospective period affected the proportions of 
comorbid illnesses was therefore investigated. However these efforts came to little as 
comparing studies from other healthcare systems,126 perhaps in different medical conditions 
and pertaining to different coding manuals was not thought to be appropriate.125,127 However, 
data from the HES analysed by the Dr. Foster Unit, concluded that differences in hospital 
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standardized mortality ratios (HSMR) could be from differences in coding practice or a 
difference of comorbidity between hospitals. Yet the authors did reflect that and commented 
thankfully that, “gaming of comorbidity via secondary diagnoses is not common in England.” 
There has been other initiatives that may have contributed to coding practice changes which 
are particular to the NHS. The introduction of “Payment by Results” (PbR) scheme which 
saw a phased introduction into the NHS during 2003/2004 provided a financial incentive for 
hospital trusts in England to improve the coding of comorbidities.128,129 Furthermore, the 
instructions given to coders in ORLS and HES on the type of comorbidities that should be 
recorded in a given admission differed. In ORLS, comorbidity was only recorded if it was 
directly relevant to the admitting diagnosis whilst in HES the recommendation was (and 
remains) to capture “any condition that affects the management of the patient and 
contributes to an accurate clinical picture within the current episode of care.”
130
  
The impact of clinical coding practices and their effects on the ascertainment of 
comorbidities were therefore considered separately in each dataset in an attempt to 
understand whether there was a constant risk fallacy.131 
 
3.5.3 Clinical coding practices in all-England Hospital Episode Statistics 
Between 2000-2002 the median number of hospital episodes prior to patients index date into 
the cohort was 3 (IQR 2-6) increasing to 4 (2-8) by 2006-2008. The number of concurrent 
diagnostic codes per each episode increased from a mean of 3.4 (SD 1.4) in 2000-2002 to 
4.5 (2.0) in 2006-2008, an increase of almost one third. When stratified by age this increase 
in the median number of diagnoses per episodes was more apparent in older patients. The 
proportion of patients with only one episode to identify of prior comorbid illness increased 
from 6% in 2000-2002 to 9% in 2006-2008 (Table 3-6). 
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3.5.4 Effect of different durations of retrospective periods in HES 
In all-England HES, data were available from 1998. The median duration of potential (i.e. 
unrestricted) retrospective follow-up accrued by patients before their start date of 
maintenance RRT increased from 1.3 years (IQR 0.1-2.4) in 2000-2002 to 3.3 (0.9-5.1) in 
2003-2005, to 5.4 (2.0-7.8) by 2006-2008 (Table 3-7). 
For the 2003-2005 group of incident patients, the effect of lengthening the retrospective 
follow-up period from two to five years would have had only a small increase in the capture 
of prior diabetes from 30% to 31%, for prior vascular disease the proportions would have 
increased from 27% to 31% and for prior non-vascular disease from 25% to 29% (Table 
3-7). On a relative scale, this represented increases of 3.3%, 12.9% and 16.0% respectively. 
Had an unrestricted period been used then this relative change would have been 3.3%, 
18.5% and 20%.   
For the 2006-2008 year group, increases from two to five year period of retrospective follow-
up would have resulted in absolute increases in prevalence of baseline diabetes by 1% (34% 
to 35%), vascular disease 5% (28% to 35%) and serious non-vascular disease by 4% (28% 
Table 3-6: Number of episodes available for retrospective follow-up prior to start of 
RRT to identify comorbidities (with number of diagnoses per episode), by year and by 
age at start of RRT 
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to 32%; Table 3-7). On a relative scale, this represented increases of 2.9%, 17.9% and 
14.2% respectively. Had an unrestricted period of retrospective follow-up been used then 
relative increases, from 2 years, would have been 2.9%, 28.6% and 25% respectively. 
 
3.5.5 Clinical coding practices in Oxford Record Linkage Study 
The median number of prior hospital episodes captured in ORLS/all-England HES increased 
by about one third, from 3 (2-5) in 1970-1990 to 4 (2-7) by 1991-1996, and a significant trend 
was observed overall across nearly all the separate age groups (Table 3-6). The median 
number of codes recorded per hospital episode also increased from 1.2 (SD 0.8) in 1970-
1990 to 1.5 (1.0) in 1991-1996, an increase of about one-quarter. There were also 
reductions in the proportion of ESRD patients recorded as having only one hospital episode 
prior to their index date: decreasing from 24% to 14% between 1970-1990 and 2006-2008 
(Table 3-6). 
 
Table 3-7: Baseline comorbidities by different durations of retrospective follow-up prior 
to start of RRT, by year 
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3.5.6 Effect of different durations of retrospective periods in ORLS 
In ORLS, data were available from 1965. The median duration of potential (i.e. unrestricted) 
retrospective follow-up accrued by patients before their start date of maintenance RRT 
increased from 1.9 years (IQR 0.0-8.2) in 1970-1990 to 5.6 (0.2-14.8) in 1991-1996, (Table 
3-7). To ensure patients in each year group were afforded the same opportunity to ascertain 
comorbidity, the effect of different durations of retrospective follow-up prior to start of RRT 
were again explored. In ORLS, 2 years provided substantially less ascertainment of major 
comorbidities compared to 5 years and an unrestricted period. 
Taking the 1970-1990 year group, if a 2 year period of retrospective follow-up, as oppose to 
5 years (see below for reasons),  was chosen then the prevalence of diabetes, would have 
fallen from 6.7% to 5.7%, vascular disease from 10% to 8.0% and vascular disease 7.8% to 
5.7% respectively. On a relative scale, this represented decreases of 14.9%, 20.0% and 
26.9% respectively. If an unrestricted period of retrospective follow-up had been applied to 
the 1970 to 1996 year groups then the absolute decrease in the ascertainment of major 
comorbidity would have been greater: 2.6% for diabetes, 4% for vascular disease and 5.3% 
for non-vascular disease. On a relative scale, this would have represented a potential under-
ascertainment of the prevalence of baseline co-morbidity of 45.6% for diabetes, 50% for 
vascular disease and 93.0% for non-vascular disease (Table 3-7).  
For the 2003-2005 group of incident patients, the effect of lengthening the retrospective 
follow-up period from two to five years would have had only a small increase in the capture 
of prior diabetes from 30% to 31%, for prior vascular disease the proportions would have 
increased from 27% to 31% and for prior non-vascular disease from 25% to 29% (Table 
3-7). On a relative scale, this represented increases of 3.3%, 12.9% and 16.0% respectively. 
Had an unrestricted period been used then this relative change would have been 3.3%, 
18.5% and 20%.   
For the 2006-2008 year group, increases from two to five year period of retrospective follow-
up would have resulted in absolute increases in prevalence of baseline diabetes by 1% (34% 
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to 35%), vascular disease 5% (28% to 35%) and serious non-vascular disease by 4% (28% 
to 32%; Table 3-7). On a relative scale, this represented increases of 2.9%, 17.9% and 
14.2% respectively. Had an unrestricted period of retrospective follow-up been used then 
relative increases, from 2 years, would have been 2.9%, 28.6% and 25% respectively. 
 
3.5.7 Rationale for the final decision on the duration of retrospective period used 
to ascertain major comorbidities  
The ‘fixed’ period of retrospective follow-up in this cohort – 5 years in ORLS and 2 years in 
HES – was decided based on the four points: 
1. It maximised the use of available data (as it allowed the derivation to go back to 1965 
in ORLS and 1998 in HES); 
 
2. It offered suitable timeframes in which the vast majority of comorbid illness could be 
identified; 
 
3. It accommodated the different coding practices and data structures between ORLS 
and HES. 
 
4. Allowing external validation to other data reposities who hold data on mortality of 
ESRD patients.  
 
 
3.5.8 Limitations 
Some limitations in the cohorts are noteworthy. First, ORLS and HES do not hold other 
variables (e.g. smoking status) which are known to affect mortality, as well as some other 
important clinical and laboratory metrics (e.g. blood pressure, LDL-cholesterol and body-
mass index).
132-138
 It will therefore not possible to adjust for all baseline differences in 
subsequent longitudinal analyses and the lack of ethnicity or SES data in ORLS also 
precluded its inclusion into regression models. Secondly, pragmatic but informed decisions 
were made on the durations of retrospective follow-period used in the ascertainment of 
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comorbidities which means there is loss of some information about comorbidity in each year 
of the cohort. Using an unrestricted period would though, result introducing a bias when 
mortality rates are adjusted as the degree of under-ascertainment of comorbidity would have 
progressively decreased over time. Lastly, the cohort is dependent on NHS admissions and 
would not include those admitted for privately funded care. However, private RRT is rare.61 
 
3.6  Conclusions 
The types of patient receiving maintenance RRT has changed significantly across the 40-
year from 1970 with patients becoming significantly older and more comorbid. The 
magnitude of this secular change in the ESRD population is larger than that observed in a 
large set of general population controls. As comorbidities are key determinants of survival in 
both populations the benefit of having a uniform approach to identifying these comorbidities 
was applied and should provide an opportunity to perform more reliable standardization of 
mortality rates from descriptive analyses. 
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3.7 Bullet points of Chapter 3  
 
 44,922 incident ESRD patients were identified between 1970-2008 
 
 Over almost 40 years in Oxford, the age at start of RRT increased 15 years, from 
46 (IQR 36-60) in 1970-1985 to 61 (46-72) years by 2006-2008 
 
 The crude prevalence of major comorbid illness identified in patients prior to them 
starting maintenance RRT between the first (1970-1990) and last (2006-2008) 
year groups were as follows:  
o Diabetes increased from 6.7% to 33.9% 
o Vascular disease increased from 10.0% to 25.2% 
o Non-vascular disease increased from 7.8% to 24.9% 
 
 The magnitude of these proportion changes was not mirrored in the a large set of 
general population hospital controls  
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Chapter 4  Validation 
“Validation” of treated end-stage renal 
disease cohorts derived from routinely 
collected English hospital inpatient data 
(1970-2008) 
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4.1 Abstract 
Background 
Whether it is possible to derive cohorts of maintenance renal replacement therapy patients 
from English routinely collected hospital inpatients datasets is unknown. 
Methods 
A set of clinical definitions, mapped through versions of clinical coding manuals and 
incorporated into a specifically designed derivation algorithm was applied to two datasets: 
the Oxford Record Study Linkage (ORLS; between 1970-1996) and all-England Hospital 
Episode Statistics (HES; between 2000-2008). This identified a retrospective cohort of 
44,922 English ESRD patients who had commenced maintenance RRT and survived at least 
90 days. Indirect and direct validation techniques were employed using summary data from 
the UK-Renal Registry (UK-RR) 2007-2010, UK-Transplant Registry (UK-TR) 2000-2011 
and Oxford Kidney Unit’s (OKU) electronic patient records 1970-2008 (i.e. reference 
datasets) and data from randomised trials of patients with renal disease (SHARP 2003-
2010) and 3C (2010-2013) and linkage to HES, respectively.  
Results 
a) HES-based cohort: Between 2007-2010, which covered the period when the UK-RR had 
full coverage of English renal centres, demographics of the derived all-English ESRD 
cohorts were similar to that reported in the UK-RR. In 2010, for example, both datasets had 
a median age of 64 years, near equivalent proportions were female patients (UK-RR: 38% 
vs. HES: 37%) and broadly similar ethnicity structure (White ethnicity 77% vs. 78%; Black 
6% vs. 7%). Between 2000-2011, 20,248 kidney transplants were identified from HES 
compared to 20,248 reported to the UK-TR (a relative difference of 1.6%).  
b) ORLS-based cohort: In Oxfordshire between 1970-2008, a similar numbers of patients 
with comparable demographic structures were recorded in OKU data compared to those 
identified from ORLS. The age and sex standardized three-year mortality rates between 
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OKU and the derived Oxfordshire ESRD cohort also mirrored each other: between 1970-
1990 OKU had a 3-year mortality rate of 33.7% (95% CI, 29.5-37.8%) compared to 35.6% 
(31.4-39.9%) in ORLS with rates falling to 22.9% (19.8-25.9%) and 22.4% (18.8-26.0%) by 
2006-2008, respectively. 
c) Direct validation using data from SHARP with its linkage to HES demonstrated that the 
algorithm identified 321 out of 346 (92.8%) participants whom had been adjudicated as 
having maintenance RRT, corresponding to a kappa statistic of 0.84 (0.81-0.88) (ie excellent 
agreement) and using similar methods even greater agreement on the fact of 
transplantation, 0.92 (0.89-0.96). 
 
Conclusions 
Direct validation using HES-linked trial data suggested that a clinical algorithm could be used 
to derive a cohort of maintenance renal replacement therapy patients from HES. Summary 
statistics of patient numbers and basic demographics from the cohorts of treated ESRD 
patients derived exclusively from routinely collected hospital inpatient data are similar to 
those in summary statistics from the UK-RR, UK-TR, and OKU. The data used in this thesis, 
although not free from error, therefore appears to be sufficiently reliable to identify a cohort 
of treated ESRD patients to allow broad-brush descriptions of long-term changes in mortality 
rates.
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4.2 Introduction 
“Validation” of cohorts derived from routinely-collected healthcare data is recommended in 
the RECORD reporting guidelines (REcording of studies Conducted using Observational 
Routinely-collected health Data)139 as it can provide reassurances that any data used are 
reliable and representative of the condition being studied.140 This chapter details the 
methods and results of analyses that were performed to help “validate” whether a 
retrospective cohort of treated ESRD patients could be reliably derived from mortality-linked 
English routinely collected hospital inpatient data between 1970-2008.  
 
Coding of inpatient activity is mandated for all patients admitted to English NHS hospitals. A 
systematic review in 2012, performed by the Dr Foster Unit, claimed that discharge coding 
accuracy was, “robust enough to support its use in research”, although the authors did note 
that there was variation in the accuracy of coding depending on which condition or 
procedure is being studied128 but showed evidence that the quality of coding has improved 
over time.141 Operations and procedures are generally more accurately captured than 
diagnoses as they are typically distinct entities occurring on a specific date whilst the start of 
a diagnosis can be uncertain.128,142 Procedural codes may also be easier for coders to 
identify in hospital notes as they frequently have separate documentation and are not 
intertwined into the often evolving clinical narrative of a medical admission and the process 
of making a secure diagnosis.143 
 
Identification of a treated ESRD cohort in routinely collected hospital admission data (i.e. 
dialysis-dependent ESRD patients or those with a functioning kidney transplant) posed an 
substantial challenge as ESRD is a heterogeneous condition without a simple set of unique 
diagnostic or procedural codes. Nevertheless, there is precedent, but not for English 
patients. Electronic healthcare data have been used to identify treated ESRD patients in 
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Canadian hospital admission data yet they also combined inpatient data with corresponding 
reimbursement data.144 This Canadian study found that two ‘outpatient claims of dialysis’ 
identified over 97.5% of maintenance dialysis patients, with a positive predictive value (PPV) 
of 0.81 (95% CI 79-82). In the UK, HES data have been used to identify retrospective 
cohorts of transplant patients but not maintenance dialysis patients.145 This body of work 
aimed to identify treated ESRD patients, ie dialysis and kidney transplant population in 
England over the 40 years since 1970. Validation of this endeavour is uncertain. I aimed to 
use summary data from the UK-Renal Registry (UK-RR) 2007-2010,113,146-148 UK-Transplant 
Registry (UK-TR) 2000-2011,149 Oxford Kidney Unit’s (OKU) electronic patient records 1970-
2008 (i.e. reference datasets) to assess the reliability of the ORLS & HES derived cohorts. 
Validation studies using data from UK participants of a kidney transplantation and separately 
a CKD randomised-controlled trials, both with direct linkage to HES data (the 3C study 
(CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy, 2010-2013) 
and SHARP (Study of Heart and Renal Protection, 2003-2010] respectively) were also 
undertaken.150-153 
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4.3 Methods/Procedures 
The methodology and baseline characteristic of the ESRD cohort are described in Chapter 2 
Chapter 2 ‘Cohort derivation’ and Chapter 3 ‘Baseline characteristics’. Briefly, a large 
retrospective cohort of incident ESRD patients was derived from routinely collected hospital 
inpatient datasets: Oxford Record Linkage Study (1970-1996) and all-England Hospital 
Episode Statistics (HES) 2000-2008 which included a regional subset, termed HES (Oxford) 
which closely approximated to the area previously covered by ORLS.  
 
Indirect “validation” of these treated ESRD cohorts was performed using summary data 
extracted from other repositories that hold data on treated ESRD patients: UK-Renal 
Registry’s (UK-RR) annual reports,113,147,154 UK-Transplant Registry database149 and the 
Oxford Kidney Unit’s electronic patient database.  
 
Direct validation using HES-linked trial data was also utilised using data from English 
participants in randomised controlled trials. In SHARP, there was a pre-specified trial 
outcome of the start of maintenance RRT. The linked-HES data for these patients was 
processed as per the derived algorithm used to identify this anonymised cohort and 
compared. Direct validation of patients’ primary renal diagnosis was performed among 
patients with kidney transplants, recruited to the 3C clinical trial.150,155 In 3C, the nurse-
reported primary renal diseases were grouped into either diabetic kidney disease, polycystic 
kidney disease and glomerulonephritidies which were then compared to what was identified 
in linked hospital admissions using a kappa statistic of agreement. Full details of the 
methodology used to define identify presumed PRD from HES is found in Chapter 2 
subsection 2.11.1. 
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4.3.1 Cohort comparisons with UK-Renal Registry data 2007-2011 
The UK-Renal Registry, which was founded in 1996, records demographic, clinical and 
laboratory information on all patients commencing on RRT in England and Wales and has 
published annual reports since 1998.156 Before this, cross-sectional (and usually voluntary) 
surveys of RRT patients were reported to the European Renal Association/European 
Dialysis and Transplant Association (ERA/EDTA).157 HES obtained complete coverage of 
NHS hospitals in England from 1998, whilst the UK-RR achieved complete coverage of 
English renal centres from 2007. This means comparisons with the derived all-England HES 
ESRD cohort were restricted to between 2007 and 2010.113,146-148 Summary statistics 
including the number of patients, demographics (age, sex and ethnicity), initial RRT modality 
and PRD were manually extracted from UK-RR annual reports and compared to those 
identified from HES using standard statistical terms. See Chapter 2  for full details of these 
definitions with note that the seventeen codes for ethnicity in HES were mapped to the UK-
RR format.88,158 
 
4.3.2 Cohort comparisons with UK-Transplant Registry data 2000-2011 
The National Health Service Blood and Transplant (NHSBT) service curates the UK National 
Transplant Database (UK-TR) which records details of all organ transplant recipients in the 
UK. The Human Organ Transplants Act in 1989159 makes it a statutory requirement that all 
transplants operations performed in the United Kingdom be recorded centrally. A data 
request was placed with the statistical team at NHSBT asking for the number of, by month 
and year, isolated kidney transplants (excluding multi-organ allografts) performed in England 
between 2000 and 2011. Kidney transplants from other countries within the United Kingdom 
were excluded as this activity would not be captured by all-England HES. The counts of 
kidneys transplants provided by the UK-TR were compared against this. Kidney 
transplantation was identified in all-England HES using Classification of Interventions and 
 Validation  [Page 119]      [119] 
 
Procedures version 4 (OPCS-4) codes M01.2, M01.3, M01.4, M01.5 M01.8 and M01.9 
mentioned in any hospital episode over the 12 year comparison period, 2000 and 2011. 
 
4.3.3 Cohort comparisons with OKU-derived treated ESRD cohort 1970-1996 
The Oxford Kidney Unit (OKU) was founded in 1967 and all patients living in the wider 
Oxfordshire area would have been principally managed by the OKU. The Royal Berkshire 
Hospital started its RRT program in 1987 but Oxford remained the tertiary renal unit for 
transplantation and any dialysis access invasive surgery. The clinical notes of early ESRD 
patients in Oxfordshire were kept in paper form in OKU offices and clinical coders from 
ORLS had full access to these paper records (personal communication with the retired 
curator of the ORLS dataset: Professor Michael Goldacre). From 1986, the OKU introduced 
a computerised system, called “PROTON” which was one the first electronic patient record 
systems.160 When adopted, all OKU patients who had previously received maintenance RRT 
were retrospectively added, thereby providing an electronic record of all treated ESRD 
patients (importantly though without any reliable record of comorbidity) in the wider 
Oxfordshire region (communication with Associate Professor C.G.Winearls, co-director of 
OKU 1988-2000). Anonymised data were extracted from PROTON on all the incident 
maintenance RRT adults who had survived 90 days from their documented start date of 
maintenance RRT. The number of new patients and their basic demographics (age and sex) 
were then compared to treated ESRD patients identified in ORLS and HES (Oxford). The 
geographic areas served by OKU expanded differently to the area covered by ORLS, and 
so, whilst the datasets cannot cover exactly the same region there was considerable 
geographical overlap. 
In addition to comparing the number of patients and their demographics, a Poisson 
regression model was used to calculate and then compare the age and sex adjusted three-
year mortality rates of the OKU (1970-2008) RRT patients and the Oxfordshire derived 
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ESRD cohort (ie ORLS and HES Oxford), standardised to the age and sex of an ‘average’ 
1970-2008 RRT population. See Table 5-2 for full details of the characteristics of the 
reference population used for this and the appendix for a more detailed description of 
statistical methods used. 
 
4.3.4 Cohort comparisons with directly linked data from the SHARP study 
The SHARP study (Study of Heart and Renal Protection) was a prospective randomised 
controlled trial conducted by the University of Oxford. 9,270 eligible patients with established 
CKD from 18 countries were randomised and allocated to take either daily cholesterol-
lowering therapy with a combination tablet containing simvastatin 20mg plus ezetimibe 
10mg, or matching dummy "placebo" tablets for an average of 5 years.153 The SHARP study 
completed follow-up in 2010,152 and the 1,622 English participants (of which 1,139 were pre-
dialysis at randomisation) had signed informed consent permitting long-term linkage to 
routinely collected hospital admission data from HES. The fact, date and modality of first 
RRT for these pre-dialysis patients was confirmed by trained (and blinded) clinical 
adjudicators using clinical documents collected from study centres.  Kappa statistics were 
used to compare adjudicated trial outcomes to what the derivation algorithm proposed.  
 
4.3.5 Cohort comparisons with directly linked data from 3C Study 
The 3C (CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy) Study 
was a prospective randomised controlled trial conducted by the University of 
Oxford.150,151,161,162  Eligible patients, at the time of receiving a renal transplant (and therefore 
by definition having treated ESRD) signed informed consent which included expressed 
permission to previous and subsequent hospital admissions, the national death register  
(ONS) and cancer registries. These linked data were used to directly validate some of 3C’s 
participants’ baseline characteristics.  
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4.4 Results 
4.4.1 Cohort comparisons with UK-RR data 2007-2011 
Basic demographics 
Between 2007 and 2010, 22,340 incident RRT patients were reported to the UK Renal 
Registry, compared to 21,905 patients which had been identified, via the algorithm, in all-
England HES, a difference of 435 or 1.9% (Table 4-1). The median age of patients who 
started maintenance RRT between was between 63 years and 64 years in both HES and 
UK-RR. The proportion of females was also approximately equivalent in both datasets at 
between 38 and 40% Table 4-1). 
The ethnicity field was more incomplete in the UK-RR, with “unknown” reported in a quarter 
of patients in contrast to HES which captured between 94-95% of patients’ ethnicity. In 2010, 
when UK-RR ethnicity data were more complete, the proportions of patients reported to be 
of White and Black ethnicity were 77% and 6% in all-England HES vs. 78% and 7% in UK-
RR, respectively (Table 4-1). 
 
Renal characteristics 
Initial RRT modality 
Between 2007 and 2010, the proportion of incident patients recorded by the UK-RR as 
receiving a pre-emptive transplant rose by 2%, from 5% in 2007 to 7% in 2010. This was a 
lower proportion than that captured in HES which identified 8% in 2007 rising to 10% by 
2010 (Table 4-1). 
 
Presumed primary renal disease 
Between 2007 and 2010, diabetes nephropathy was assigned as the primary renal disease 
(PRD) in 20-21% of incident patients were reported to the UK-RR. This compares to 17-20% 
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among those that were identified in all-England HES data over the same period. Polycystic 
kidney disease was recorded as the PRD in 6-7% in the UK-RR compared to 8-9% across 
all years in HES. The proportions of PRD ascribed to ‘glomerulonephritis’ varied more; the 
UK-RR recorded steady rates of 10%, 11%, 11% and 11% compared to proportions of 14% 
in 2007 in HES, increasing to 23% by 2010. Both datasets suffered from incomplete 
information with over 50% of PRD being grouped into a category which included unknown 
and unavailable (Table 4-1). 
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Table 4-1: Baseline characteristics of all-England adults being treated for end-stage renal disease, recorded in all-England Hospital 
Episode Statistics and the UK Renal Registry, by year 
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4.4.2 Cohort comparisons with UK-Transplant Registry data 2000-2011 
Between 2000 and 2011 the number of isolated kidney transplant operations in England 
recorded to the UK Transplant Registry was 20,579 compared to 20,248 identified in all 
England-HES, a difference of 331 grafts or 1.6%. Between 2000 and 2005 HES captured 
less transplant activity than the UK-TR by an average difference of 86 (0.42% of the total 
transplants) transplants per year. By 2006-2011, these differences were qualitatively 
different with HES identifying more kidneys transplants than the UK-TR. HES captured, on 
average 30 more transplants per year (1.6% of total transplants) than the UK-TR over this 
period (Table 4-2). 
  
Validation       [Page 125] 
   
 
 
Table 4-2: Number of kidney transplant operations in England recorded in all-England Hospital Episode Statistics and the UK 
Transplant Registry, by month and year 
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4.4.3 Cohort comparisons between ORLS and OKU-derived ESRD cohorts 
1970-2008 
Basic demographics: ORLS period 
Between 1970-1990, OKU recorded 1,347 patients compared to the 1,220 new treated 
ESRD patients that were identified in ORLS, a difference of 127 patients (9.4% of the total). 
Despite the slightly different geographical boundaries of the two resources, the median age 
at the start of RRT in the 1970-1990 was 49 years with near equal proportions of female 
patients at between 40% and 41%. The age structures were also comparable with half of all 
patients being under 50 years and a quarter being over than 60 years in both databases 
(Table 4-3).  
Between 1991 and 1996, ORLS identified 972 new maintenance ESRD patients whilst OKU 
recorded 967 patients, a difference of 5 (0.5% of the total). There were similar proportions of 
female patients (38% in ORLS vs. 39% in OKU). ORLS patients, during this period, had a 
median age that was 4 years older: median age 59 years (IQR, 44-69) vs. 55 years (42-67) 
in OKU. 
Basic demographics: HES (Oxford) period 
Data from OKU were then compared to the regional subset of all-England HES covering 
wider Oxfordshire, so-called HES (Oxford), during the period from 2000 to 2008. During this 
time, HES (Oxford) identified 448 more incident ESRD patients than OKU. These patients 
were, on average older than those patients recorded by OKU: 61 years vs. 59 years in 2000-
2002, 61 years vs. 58 years in 2003-2005 and 61 years vs. 56 years in 2006-2008 
respectively. Aligned to the difference in median age, the age structure of two datasets 
showed HES (Oxford) had consistently larger proportions of patients aged 70 years and a 
smaller proportion of patients under 50 years (Table 4-3). 
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Table 4-3: Demographic of treated end-stage renal disease patients in Oxfordshire, by dataset 
Figure 4-1: Age and sex standardized three-year mortality rates in new treated end-stage renal disease 
patients, by dataset 
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Three-year standardized mortality rates in Oxfordshire 1970-2008 
The three-year age and sex standardized mortality rates for patients identified from ORLS 
and HES (Oxford) mirror those calculated from OKU. In OKU the three-year age and sex 
standardized mortality rate in 1970-1990 was 33.7% (95% CI 29.5–37.8%) compared to 
35.6% (95% CI, 31.4–39.9%) in OKU, reducing to 22.9% (19.8–25.9%) in ORLS/HES 
(Oxford) and 23% (18.8–22.4%) in OKU by 2006-2008 (Table 4-5). 
 
Table 4-5: Age and sex standardized three-year mortality rates in new treated end-
stage renal disease patients, by dataset 
 
 
 
Year Group Oxford Kidney Unit  
(%) (95% CI) 
Oxford Record Linkage 
Study (%) (95% CI) 
1970-1990 35.6% (31.4-39.9) 33.7% (29.5-37.8) 
1991-1996 26.9% (23.2-30.7) 30.9% (27.4-34.5) 
2000-2002 24.7% (20.7-28.8) 26.5% (22.8-30.3) 
2003-2005 22.4% (18.9-25.9) 25.4% (21.9-28.8) 
2006-2008 22.4% (18.8-26.0) 22.9% (19.8-25.9) 
Standardized to the age and sex structure of an 'average' 1970−2008 RRT population. See Table 5-2 for details 
Table 4-4: Baseline characteristics of adult incident maintenance renal replacement therapy patients in Oxfordshire 
and surrounding counties, by data source and year 
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4.4.4 Cohort comparisons with directly linked data from the SHARP study 
There were 1,622 patients, from England, randomised in SHARP. Of these 1,139 (70.2%) 
were pre-dialysis patients at randomisation. When the number of adjudicated events of 
maintenance dialysis were compared to those in all-England HES using derivation algorithm 
(and definition of maintenance as described in Chapter 2) there was excellent agreement 
with a kappa statistic of 0.84 (95% CI, 0.81-0.88), see Table 4-6. Absolute differences in the 
start date of these events showed in the 274 out of the 321 (85.4%) mutually identified cases 
of maintenance RRT in HES had a start date within three months of that reported in SHARP. 
Direct comparison of adjudication confirmed site-reported maintenance dialysis vs Hospital 
Episode Statistics in SHARP Study 
Table 4-6: Direct comparison of adjudication confirmed site-reported maintenance 
dialysis vs Hospital Episode Statistics in SHARP Study  
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Direct comparison was also made looking at the level of agreement on whether these pre-
dialysis SHARP participants had received a kidney transplant as identified in HES. The level 
of agreement was again excellent, kappa statistic 0.92 (0.89-0.96) (Table 4-7). In 129/132 
(97.7%) mutually identified transplants, the date of the implantation, identified in HES was 
within one month of its respective trials’ adjudicated date, which improved to 99.2% 
(131/132) for dates within two months. 
 
Table 4-7: Direct comparison of adjudicated-confirmed kidney transplant in 
randomised trial vs Hospital Episode Statistics identified kidney transplantation in 
SHARP participants 
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4.4.5 Cohort comparisons of primary renal disease with directly linked data 
from 3C Study 
All-England HES had excellent agreement with a kappa statistic of 0.92 (95% CI, 0.88-0.96) 
when compared to the PRD of polycystic kidney disease which was recorded by study 
nurses on the electronic case report forms. The 2 x 2 is shown in Table 4-8.162 
 
 
 
Table 4-8: 2 x 2 table of agreement of the recording of polycystic kidney 
disease. Comparison from 3C database and all-England HES 
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4.5 Discussion 
This chapter describes various methods used to assess the reliability of using routine 
healthcare data to derive a representative cohort of English treated ESRD patients between 
1970 and 2008. The excellent level of agreement between the clinically adjudicated SHARP 
trial ESRD outcomes and maintenance RRT derived from HES using the clinical algorithm 
demonstrates the reliability of the identification rules used to derive the final ESRD cohort. 
Comparisons of the number of incident patients, their basic demographics and renal 
characteristics with the UK-RR, UK-TR and OKU data suggest that the derived cohorts, 
although unlikely to be completely free from error, are broadly representative of patients 
receiving RRT across this whole period.  
In particular, the number of kidney transplants identified in HES closely approximated the 
number reported by UK-TR and validation work in 3C confirmed that HES accurately records 
this procedure.157 
 
Cohort comparisons with UK-Renal Registry data 2007-2011 
The UK-RR annual reports provided data from which the counts, demographics and renal 
characteristics of the derived all-England ESRD cohort could be compared. These results 
suggested that the number of new treated ESRD patients that were identified was within 2% 
of the UK-RR number, and there was a broadly comparable sex and age structure which are 
proposed covariates for subsequent mortality analyses. 
 
Comparisons with UK-Transplant Registry, 2000-2011 
In particular, the number of kidney transplants identified in HES closely approximated the 
number reported by UK-TR confirming that HES can accurately this seminal procedure 
performed exclusively in ESRD patients. A successful transplant remains the optimal 
treatment for patient with ESRD and it was important that these events were validated to 
  
Validation  [Page 133]      [Page 133] 
 
ensure that any analyses where the fact of transplantation is an important variable were 
possible.42 The high accuracy of HES data in recording transplantation may be a result of the 
fact that procedure and operation notes are easily identifiable in hospital records and 
therefore may be well coded.128 The small differences in the absolute counts may reflect 
coding errors or geographic differences, including the possibility that an ESRD patient who 
lives in Wales or Scotland may have been a recipient of a kidney transplant from an English 
Transplant centre. Such a patient would have been excluded by the HES algorithm but 
would have been included in the UK-TR summary statistics. Similarly if a non-UK citizen 
living abroad came to the UK and received a kidney transplant then this would be recorded 
by UK-TR but not HES. The under-counting of kidney transplants in HES relative to UK-TR 
between 2000-2005 is in contrast to some over-counting between 2005-2011. Without direct 
validation techniques, the precise reasons for this are not known yet it is possible that coders 
may have erred when patients are called in for a transplant but do not go on to receive it. 
 
Comparisons with Oxford Kidney Unit data, 1970-2008 
The electronic records kept by the Oxford Kidney Unit provided an opportunity to indirectly 
“validate” the characteristics of ESRD patients in the early decades of this study, a period 
when there was no UK-RR data. From 2000 onwards, the discrepancy in counts may be 
explained by the slightly different geographic areas that were being covered and that referral 
patterns from primary care will not be bound by ORLS’s geographic landscape. The 
extremely similar age and sex adjusted mortality rates though do provide important 
reassurance that this older dataset still can reliably identify maintenance RRT patients.  
 
Comparisons using directly linked data from SHARP study 
Directly linked data confirmed that the HES derived algorithm reliably identified the fact of 
and date of kidney transplantation. This built on the indirect validation which compared 
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counts of transplantation, using data from UK-TR and are outlined in section 4.4.2 and 
internal validation in section 2.9 which described the proportion of patients identified by the 
proscribed ‘rules of maintenance RRT’ who latter went on to fulfil other such rules including 
transplantation.  
It was crucial that transplantation, which is known to reduce the mortality of ESRD patients 
was captured accurately.42 Any slight differences may have represented cross-border issues 
whereby residents in North Wales may receive a transplant in North West English hospitals 
(in Merseyside) or the perhaps when potential transplant recipients are called for a 
transplant but it never took place and the coders mis-attributed the true nature of the 
admission. 
The direct comparison of SHARP data in regards to commencement of maintenance dialysis 
demonstrated similarly provided reassuring results. It suggested that the iterative process 
used to confirm RRT was being provided as a maintenance therapy, as opposed to it being 
provided for potential recoverable renal failure was a necessary step. 
 
Comparisons of primary renal disease using directly linked data from 3C Study 
This very high level of agreement for the most common inherited cause of ESRD was the 
impetus to explore other uses of the dataset, with analyses of a disease association study in 
patients with polycystic kidneys being described in Chapter 6 and published in Supplemenal 
Appendix 1.3.163-167 This level of agreement is manifestly different from patients whom have 
presumed diabetic nephropathy in combination with hypertension and ischaemic changes 
where a nurse-recorded primary renal disease is more likely to differ from the patients’ 
understanding on the complex (and often multiplicative) nature of their primary cause of 
renal disease. As there was uncertainty about the reliability of primary renal diagnosis 
derived from routine healthcare data, it was not used as a variable in the prospective 
mortality analyses in the subsequent results chapter.  
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Limitations 
The main limitation of using any routinely collected hospital inpatient data are its anonymised 
nature, preventing wholescale direct validation of the whole derived cohort on an individual 
patient-level basis with another data resource. This prevents direct confirmation of the fact 
and date of starting maintenance RRT. Between 2000 and 2006, validation of the numbers 
of patients, their demographics and renal characteristics were also not possible for the all-
England derived HES ESRD population, because lack of nationwide coverage by the UK-
RR. Validation work of patients identified in the early epoch relied on electronic data entered 
manually by clinicians in OKU. 
 
The start date of RRT is an important variable and may be subject to some error, when 
derived from hospital inpatient data, as although many hospitals appeared to record each 
haemodialysis sessions as day-admission, others may not. Therefore among those centres 
not recording every dialysis session there may be some uncertainty and this may partly 
explain the overestimation of pre-emptive transplants in HES; reflecting difficulties in 
identifying patients who began dialytic therapies and particularly PD as an outpatient.168 
 
Lastly, assessment of the reliability of comorbidity data for the early patients was not 
possible as it was not reliably recorded on PROTON or by the UK-RR. The UK-RR has 
proposed that they link their data to HES in order to improve reporting of comorbidity and 
they have been able to do this for incident patients identified between 2002 and 2006 and 
permission to these data were only temporary.88  
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4.6 Conclusions 
A retrospective cohort of treated ESRD adults can be identified using data exclusively from 
routinely collected hospital inpatients data. Indirect validation techniques were principally 
used to compare summary statistics of counts and demographics details of the ESRD cohort 
as the anonymous nature of the data precluded comprehensive direct validation. 
Nevertheless direct validation of the algorithm was possible for a subset of English patients 
who reached ESRD during follow-up of a randomised trial in which permissions had been 
sought to use linked hospital data for research purposes. This provided further evidence that 
the ESRD cohort derivation procedures were sufficiently reliable to proceed with prospective 
analyses. The various analyses described in this chapter suggest that the derived ESRD 
cohort is indeed representative of a contemporaneous ESRD population and that any errors 
are not in a specific age, sex or ethnic group. Moreover, the similarity of ORLS/HES Oxford 
and OKU mortality rates over the 40-year period are particularly reassuring.   
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4.7 Bullet points of Chapter 4  
 Direct and indirect techniques of validation were used as recommended by the 
RECORD Statement. 
 
 The indirect methods included comparisons of the derived data to summary statistics 
taken from other data repositories. 
 
 Comparisons with the UK Renal Registry, between 2007-2010, showed the same 
median age at 64 years, near equivalent  proportions of female patients (UK-RR: 
38% vs. HES: 37%) and broadly similar ethnicity structure (White ethnicity 77% vs. 
78%; Black 6% vs. 7%). 
 
 Comparison with NHSBT, between 2000-2011, showed that the number of renal 
transplants identified in HES was within 2%. 
 
 Direct validation techniques were undertaken using linked HES data from SHARP 
participants. This provided excellent levels of agreement: kappa 0.84 (0.81-0.88) for 
identification of maintenance RRT and even better for the fact of transplantation.
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Chapter 5  Main results; mortality trends 
Mortality trends in 45,000 English End-stage 
renal disease patients, 1970-2010 
This chapter largely contains the material that has been published in the peer-reviewed 
journal. Impact factor 8.306 (2018) See Appendix section 1.2 or the links below 
 
Main Article:  
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance 
renal replacement therapy. Storey, Benjamin C. et al. Kidney International, Vol 93 (5),1165-
1174  
  
Online supplementary materials: 
Supplementary materials 
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5.1 Abstract 
Background  
To compare long-term mortality trends in end-stage renal disease (ESRD) populations 
versus the general population after accounting for differences in age, sex and comorbidity. 
Methods 
Cohorts of 45,000 ESRD patients starting maintenance renal replacement therapy (RRT, ie, 
dialysis or transplantation) and 5.6 million controls selected to represent the general 
population were identified from two large electronic hospital inpatient datasets: the Oxford 
Record Linkage Study (1965-1999) and all-England Hospital Episode Statistics (2000-2011). 
All-cause and cause-specific 3-year mortality rates for both populations were calculated 
using Poisson regression and standardized to the age, sex, diabetes and other comorbidity 
structure of an ‘average’ 1970-2008 RRT population. 
Results  
The median age at initiation of RRT in 1970-1990 was 49y (interquartile cutoffs 36–60y) and 
63y (49–73y) by 2006-2008. Over that period, there were increases in the prevalence of 
vascular disease (from 10.0 to 28.3%) and diabetes (from 6.7 to 34.3%). After accounting for 
these age, sex and comorbidity differences, standardized 3-year all-cause mortality rates in 
treated ESRD patients between 1970 and 2011 fell by about one-half (relative decline 51%, 
95%CI 41–60%; absolute decline from 40.7% to 20.0%), steeper than the one-third decline 
(34%, 95%CI 31–36%; absolute decline from 8.6% to 5.7%) observed in the general 
population. Declines in 3-year mortality rates were evident among those who received a 
kidney transplant and those who remained on dialysis. In both the ESRD and the general 
population, mortality rates among people with diabetes have declined more steeply than 
those without. 
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Discussion 
Since 1970, all-cause mortality rates among those on maintenance RRT have declined more 
steeply than rates in the general population. Similarly, mortality among people with diabetes 
have also declined more rapidly than those without diabetes, both among those on RRT and 
in the general population. Nevertheless, mortality rates for those with diabetes and 
particularly those with ESRD remain high.  
  
  
Main results; mortality trends  [Page 141] 
5.2 Introduction 
Maintenance dialysis programmes for end-stage renal disease (ESRD) began in the United 
Kingdom in the 1960s.1-3 Until the 1980s, renal replacement therapy (RRT, ie, dialysis or 
kidney transplantation) was restricted to ESRD patients who were considered the most 
economically active and those with diabetes or other comorbidities were often not referred or 
treated.4 This contrasts with the situation 50 years later when the median age of patients 
starting maintenance RRT is 65 years and diabetes is the leading cause of ESRD.5  
 
Examining long-term temporal mortality trends helps describe past and current serious 
health risks. Their interpretation is difficult in RRT populations as comparisons between 
treated ESRD and other populations need to take account of the substantial secular changes 
in the prevalence of comorbid illnesses which influence both mortality6-8 and the likelihood of 
receiving RRT. To date, no large study has standardized mortality rates in treated ESRD and 
general population cohorts to the same comorbidity as well as age/sex structure. Therefore, 
although data from ESRD registries in the United States 1977-2007,9 Europe 1998-2007,10 
Australasia 1992-2005,11 and UK 2002-20115 have all shown modest improvements in 
mortality for people with treated ESRD, it is unclear whether the magnitude of this change is 
comparable to that those observed in the general population during the same period.12 
 
The Oxford Record Linkage Study (ORLS) was established in 1963 and recorded 
information about all hospital inpatient admissions in Oxfordshire and the surrounding 
counties.13 Hospital Episode Statistics (HES) succeeded ORLS and established nationwide 
coverage from 1998. Mortality trends among new maintenance RRT patients and a set of 
general population controls, extracted from these two datasets are presented.  
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5.3 Methods 
The Central and South Bristol Multi-Centre Research Ethics Committee (04/Q2006/176) has 
granted ethical approval for these analyses of linked hospital inpatient data. Retrospective 
cohorts of new maintenance RRT patients (‘new treated ESRD’) and general population 
hospital controls were derived from two routinely collected hospital inpatient datasets with 
linkage to national mortality data. The ORLS collected information on hospital admissions in 
Oxfordshire from 1963, expanding to surrounding counties to cover a population of 2.5 
million.169 Nationwide individual patient linked HES data replaced ORLS in 1998 recording 
information about admissions from all National Health Service hospitals in England. 
Analyses include a period from 1st January 1965 to 31st December 2011 (with cohort follow-
up starting from 1st January 1970). 
 
Both ORLS and HES record detailed information about hospital admissions including: patient 
demographics, dates of admission and discharge, admitting speciality, the primary diagnosis 
and relevant secondary diagnoses (all coded using the International Statistical Classification 
of Diseases and Related Health Problems [ICD] versions 7 to 10), and all inpatient 
procedures accompanied by their dates (coded using the Office of Population Censuses and 
Surveys [OPCS] Classification of Surgical Operations and Procedures versions 2 to 4). 
 
Algorithms incorporating diagnostic, procedural and speciality codes relevant to renal 
disease, dialysis and transplantation to identify adults aged ≥18 years in ORLS who started 
RRT between 1970-1996, and in HES between 2000-2008 were developed. Those patients 
whose records indicated dialysis was for acute kidney injury or who died within 90 days of 
starting RRT were excluded (as is standard in the study of incident ESRD cohorts). For full 
details of cohort derivations see Chapter 2 or the summary derivation flowchart in Figure 2-4 
and Figure 2-5). To allow mortality rates from the new treated ESRD cohort to be compared 
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to a group of contemporaneous adults, hospital controls who were never recorded as 
undergoing RRT were selected so as to be reasonably representative of the general 
population by using admissions for a range of minor conditions including inguinal hernias, 
soft tissue knee complaints, tonsillectomy, etc. (full list of conditions in Table 2-4). Hospital 
controls provided the advantage that comorbidity could be identified from admission records 
(information that is incompletely recorded in vital statistics). Baseline information on age, sex 
and ethnicity (categorised into White, Black, South Asian, other and unknown, and only 
reported in HES) was extracted.170 A presumed primary renal diagnosis (polycystic kidney 
disease, glomerulonephritis, diabetic kidney disease, or other/unknown cause), initial RRT 
modality (dialysis or transplant) and co-morbidities based on the Charlson index88,102 were 
identified from diagnostic and procedural codes on admission records at the time of entry 
into the cohort and for a fixed period of retrospective follow-up beforehand. For the purpose 
of adjustment, comorbid illnesses were classified as (i) diabetes mellitus (combining type 1 
and 2); (ii) vascular disease, including major coronary disease, heart failure, cerebrovascular 
disease and peripheral arterial disease; and (iii) serious non-vascular disease including liver 
disease, cancer, chronic obstructive pulmonary disease (COPD), peptic ulcer disease, hemi- 
or paraplegia and connective tissue disease (definitions in Table 2-6). 
 
The reliability of routine hospital admission data for the identification of new treated ESRD by 
comparing the number of transplants in ORLS and HES with the UK-Transplant Registry 
(Table 4-2)149, the cohort sizes and characteristics with UK-Renal Registry (Table 4-4) 
annual reports,113,146-148 and data (including mortality rates) collected from Oxford Kidney 
Unit databases compiled prospectively since 1967 (Table 4-4, & Table 4-5) were assessed. 
Subsequent mortality was identified from linked national mortality data. The primary outcome 
was all-cause mortality, and secondary outcomes were cause-specific mortality identified 
from the Underlying Causes of Death and separated into vascular (cardiac and non-cardiac) 
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and non-vascular mortality (renal disease [ie, death from renal failure or its causes], cancer, 
infection, and other/unspecified; definitions in Figure 2-6). 
 
5.3.1 Condensed statistical analyses  
Patient follow-up was separated by year of cohort entry into five groups: 1970-1990, 1991-
1996, 2000-2002, 2003-2005, and 2006-2008 (ie, there was a gap between the two cohorts 
between 1997-1999). The different number of years covered by each group ensured similar 
numbers of patients in the two ORLS groups (1970-1996) and, separately, in the three HES 
groups (2000-2008). All-cause and cause-specific mortality rates for each group were 
estimated using Poisson regression adjusted for age, sex and comorbidities. Three-year 
mortality rates are presented as it ensured data from those starting dialysis as late as 2008 
could be included. Age was included as a continuous variable using linear and quadratic 
terms. To account for the Poisson regression assumption that the mean and variance of the 
rates are equal, robust standard errors were calculated.171 Marginal standardization172 was 
used to adjust mortality rates to the characteristics of an ‘average’ 1970-2008 RRT 
population, defined using the entire ORLS RRT cohort and a random sample from each of 
the HES year groups such that the standard population had approximately equal numbers of 
RRT patients from each decade (characteristics in Table 5-2). To allow for comparisons of 
change in mortality over time between the ESRD and general population cohorts, 
percentage change in 3-year mortality rates between the 1970-1990 and 2006-2008 groups 
(ie, over approximately 25 years) were presented with 95% confidence intervals (CI) for the 
ORLS and a HES cohort which closely matched the ORLS catchment area (referred to as 
“HES Oxford” in Figures). For the all-England HES and the “HES Oxford” cohorts, 
percentage changes in 3-year mortality rates between the 2000-2002 and 2006-2008 groups 
(ie, over about 10 years) are presented so mortality trends from Oxfordshire and surrounding 
counties can be compared to all-England data.  
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To explore mortality rates among those who received a transplant and those who did not, 
subsequent analyses were stratified by including an interaction term between year group 
and transplantation status by three years. This allowed estimation of separate rates for 
transplant recipients and those who remained on dialysis. Subgroup analyses by prior 
diabetes were performed using a similar method. 
 
In sensitivity analyses, 1-year, 2-year, 4-year and 5-year mortality rates were also calculated 
for comparison. Three-year mortality rates standardized to a 2006-2008 English RRT 
population were also provided. All analyses used SAS v9.3 (SAS Institute, Cary NY, USA) 
and R v3.2.1.  
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5.4 Expanded statistical methods  
Firstly, it was considered whether it would be appropriate to study a mortality rate or a 
mortality risk. A rate was decided upon as it is more clinically informative and appropriate for 
in temporal trend analyses. To calculate rates there were two standard regression models 
that could have taken into account time to event: Cox or Poisson. Cox models the hazard of 
an outcome without specifying the form of the baseline hazard function. Estimation of the 
underlying baseline hazard would be required to obtain absolute rates from this model. 
However, it is possible to generate absolute rates directly from Poisson regression 
parameter estimates so it was decided to use this model for this study. 
 
5.4.1 Data processing before proceeding to regression model 
For each patient identified in the ESRD study population covariates and outcome variables 
were generated including fact of and date of death (including a ‘time to event’ variable) and 
binary variables for the presence or not of individual comorbid illnesses identified prior to 
start of maintenance RRT. 
Patient follow-up was separated by year of cohort entry into five groups: 1970-1990, 1991-
1996, 2000-2002, 2003-2005, and 2006-2008. The different number of years covered by 
each group ensured similar numbers of patients in the two ORLS groups (1970-1996) and, 
separately, in the three HES groups (2000-2008). Three-year mortality rates were presented 
as it ensured data from those starting dialysis as late as 2008 could be included as they 
were followed-up until 31st December 2011. 
In baseline data, proportions were presented for the categorical variables. As age was not 
normally distributed, medians with interquartile cutoffs were presented. To assess whether 
baseline characteristics changed significantly over time, tests for the differences across the 
year groups were performed using Chi-squared (2) tests for binary variables and Kruskal-
Wallis test for age. 
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5.4.2 Choice of regression model; Poisson 
The outcome of interest was decided to be a 3 year mortality rate to be calculated using 
Poisson regression with the addition of an offset variable. Poisson regression models the 
natural log of the expected count as a linear function of the selected independent 
variables.173 A rate is just the expected count for an outcome (i.e. death) per a given unit of 
time. The offset takes into account that individual patients were followed up for different 
lengths of time.  
Before its adoption, the assumptions that underlie a Poisson distribution were explored: 
1. It excludes negative numbers 
A 3 year mortality rate cannot be <0% 
2. The occurrence of an event does not affect the probability that a second event can 
occur, i.e. the events are random and therefore independent of each other. 
You cannot die twice so the first part of this assumption is not violated. 
Similarly when any given ESRD patient dies this does not generally affect the 
chances of other patients dying. 
3. The variance is equal to the mean 
This was mitigated by usage of robust standard errors, see below. 
It became apparent that the variance was not equal to the mean, which violated one of the 
main assumptions of Poisson regression. In light of this, in conjunction with statistical 
colleagues, a negative binomial method was proposed and trialled but felt not to be 
appropriate. The problem encountered with the negative binomial model was that the 
estimated means were markedly different from those obtained using Poisson regression and 
gave values that were implausible, such as 3 year mortality rates >100%.  In this scenario, 
the mean rate from Poisson was deemed more reliable as the assumption of the mean and 
variance being equal does not influence the maximum likelihood estimates of parameters in 
a Poisson regression. The negative binomial was therefore abandoned with a Poisson model 
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incorporating robust standard errors used thereafter.171 Robust standard errors have been 
shown to be an appropriate method of dealing with the violation of the assumption of  
equidispersion.174  
Likelihood ratio tests were conducted to select appropriate variables to be included into the 
model. A stepwise selection technique was used with both forward and backward steps. Age 
was included as a continuous variable using linear and quadratic terms. Various other 
polynomials of age were explored and deemed unnecessary whilst grouping age into age 
bands (i.e. 30-34, 35-39 etc…) was considered but rejected principally as there was not 
sufficient statistical power in the ORLS dataset with very few patients aged over 80 years 
identified in earlier year groups. Sex was included in the model as it is accepted that it 
influences survival in the general population and is typically incorporated into mortality 
statistics reported in renal registries. Thereafter each individual comorbid illness was entered 
and it became apparent that diabetes made a significant difference, tested by calculating the 
difference in twice the log-likelihood statistic before and after its inclusion with a significance 
threshold of p<0.05. Other individual comorbidities were similarly assessed and offered little 
improvement yet when grouped into broader categories of vascular and serious non-
vascular (as tabulated in Table 2-6) they reached statistical significance and were thus 
included.  
IMD and ethnicity were not explored as there was no data collected in ORLS. 
 
5.4.3 Final covariates used for analyses. 
Age was included as continuous variable using linear and quadratic terms; 
Sex was dichotomised (male and female); 
Baseline major comorbidity which was treated as a binary variable and grouped into; 
diabetes, vascular disease or serious non-vascular. 
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5.4.4 Standardization techniques 
Indirect standardization calculates the strata specific observed/expected death rates within a 
reference population and then apply these rates to a given study population. Then one 
would ordinarily calculate an observed/expected ratio (the standard mortality ratio; SMR) 
multiplying it by the crude rate in the reference population to provide adjusted mortality 
rates.175 This traditional indirect standardization was not felt to be flexible enough (for 
example it would have been necessitated age groupings and other strata of comorbidities). 
Marginal standardization is a regression equivalent whereby the regression coefficients 
estimated using the study population are applied to each of the individuals in the reference 
population giving a probability of the interest outcome (i.e. death within three years) for each 
patient.172,173 These individuals’ probabilities were then summed to get a total expected 
death ‘count’. This total was then divided by total person years follow-up to give the 3-year 
standardized mortality rate. This is the mortality rate that would have been observed had the 
study population been forced to be in a particular year group; standard errors for these rates 
were also generated. The detailed statistical plan was published in the associated 
manuscript, see Appendix section 1.2. 
The key advantage of marginal standardization is that it gave rates that were applicable to 
the population being studied. For example, a common alternative approach is to set 
confounding variables to the overall mean values and then base standardized rates on 
these. But no real patient has these values (as you can get the sex variable as being, 0.4, 
referring to a patient being 40% female and 60% male). This makes the rates less applicable 
and tangible for practicing nephrologists. 
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5.4.5 Reference population 
Due to the large change in baseline characteristics in the incident ESRD population an 
‘average RRT’ population was selected as the most appropriate reference population. This 
was defined using the entire ORLS RRT cohort and a random sample from each of the HES 
year groups such that the standard population had approximately equal numbers of RRT 
patients from each decade. Changing the reference population to be more reflective of a 
modern incident ESRD population was studied as a sensitivity analyses and indeed 
increased the absolute mortality rates reductions but not the proportional decline from 1970-
1990 to the 2006-2008 year groups (see Table 5-2 for baseline characteristics of an average 
RRT population and Figure 5-7 for the effect on mortality rates that changing the reference 
population used for the purposes of standardization). 
 
5.4.6 Further analyses, use of an interaction term 
To explore mortality rates among those who received a transplant and those who did not, 
subsequent analyses were stratified by including an interaction term between year group 
and transplantation status by three years. An interaction effect is when the outcome variable 
is differentially affected by the presence (or not) of another variable, in this case kidney 
transplantation. Including an interaction term of kidney transplantation allowed estimation of 
separate rates for transplant recipients and those who remained on dialysis.  
Subgroup analyses by prior diabetes, age (<60, ≥60) and sex were performed using a 
similar method, and are accompanied by standard heterogeneity tests which compared the 
proportional reductions in mortality over time between the subgroups. 
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5.4.7 Sensitivity analyses 
1-year, 2-year, 4-year and 5-year mortality rates were also calculated for comparison and 
presented as survival probabilities which were calculated by subtracting the adjusted 
mortality rates from 100. 
 
All analyses used SAS v9·3 (SAS Institute, Cary NY, USA) and R v3·2·1 and were 
conceived in conjunction with the units’ dedicated team medical statisticians. 
Analogous statistical methods were performed to calculate standardized rates for the 
general population hospital control cohorts in ORLS and HES Oxford and separately for the 
both the ESRD and control population in all-England HES. 
 
5.4.8 Missing data 
Missing data is common in observational data of this kind. In this thesis only patients that 
had age and sex recorded at their index admission were included. Missing data for baseline 
comorbidities could not be assessed as it was unknown as to whether the absence of a 
comorbidity code meant the patient actually had no comorbid illness or whether the clinical 
coders missed any relevant codes. Attempting to incorporate multiple imputation models into 
the ESRD cohort and then also the very large general population would require significant 
computing power and time and was not deemed practicable or feasible. If any presumed 
missing data occurred at random then the results and analyses would be the same. 
Analyses were performed looking at the effect of changing the period of retrospective look-
back period on the prevalence of baseline co-morbidity and justification of the period finally 
used can be found in Chapter 3.5.2. Other determinants of all-cause mortality that were 
recorded included socio-economic status and ethnicity yet these were not included in ORLS 
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database and so could not be incorporated into the analyses across the whole period. They 
were, though, utilised and included in the disease association study of PKD in chapter 6.
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5.5 Results 
5.5.1 Summarized baseline characteristics 
Full discussion on the baseline characteristics of the ESRD cohort can be found in Chapter 3   
ESRD cohort 
Between 1970-2008, 44,922 new ESRD patients started maintenance RRT (2192 in ORLS 
1970-1996 and 42,730 from all-England HES 2000-2008) and 5,613,781 general population 
controls (532,019 from ORLS and 5,081,762 from HES) were identified. Indirect validation 
included observing closely matched numbers of kidney transplant operations recorded in 
HES and the UK-Transplant Registry149 (Table 4-2); closely matched cohort sizes, 
demographics and renal characteristics when HES data were compared to summary English 
data from the UK-Renal Registry (Table 4-1);113,146-148 and similar age and sex adjusted 3-
year mortality rates for ORLS/“HES Oxford” and for Oxford Kidney Unit (Table 4-4, Table 
4-5). For fuller details on the validation of the cohort, see Chapter 4  
 
In Oxfordshire, the median age at start of maintenance RRT increased from 49y 
(interquartile cutoffs 36-60y) in 1970-1990 to 61y (46-72y) by 2006-2008. Consequently, 
while only one-quarter of patients starting RRT from 1970-1990 were aged ≥60y, by 2006-
2008 this proportion was more than one half (Figure 3-2 & Table 3-1). Of those starting RRT, 
the proportion that were female remained at about 40% across all time periods (Figure 3-2) 
but the proportion with any major comorbidity rose steeply from 1970 to 2008. In particular, 
diabetes prevalence among those starting RRT increased from 5.5% during 1970-1985 to 
33.9% in 2006-2008, whilst prior vascular disease increased from 9.1% to 25.2% (Table 3-1 
& Figure 3-2), constituting increases in peripheral arterial disease from 3.0% to 12.9%, major 
coronary disease from 2.6% to 8.3%, and admission for heart failure from 5.2% to 10.5% 
(Table 3-1). Prior cancer was recorded in 2.9% of RRT patients during 1970-1990 and 7.6% 
of patients during 2006-2008. The demographics and comorbidity of treated ESRD patients 
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in Oxfordshire who started RRT between 2000-2008 were broadly similar to those observed 
in the rest of England (Table 3-1).  
 
General population cohort 
Compared to new ESRD patients, general population controls were on average younger and 
more likely to be female. General population controls in the later time periods were older and 
had more comorbidity than general population controls from the earlier periods (Table 3-4). 
 
5.5.2 All-cause mortality; unadjusted 
ESRD cohort 
Of the 1,220 new ESRD patients starting RRT in 1970-1990, 267 (crude 3-year mortality rate 
24.8%) died within the first three years. For the 878 Oxfordshire patients and 15,946 all-
England patients starting RRT in 2006-2008, 221 (28.7%) and 4,482 (38.2%) died within 
three years, respectively. Crude mortality rates – which do not take account of secular 
changes in age, sex or comorbidity of those who received maintenance RRT – showed an 
average increase in mortality between 1970-1996, followed by the beginnings of a decline 
(Table 5-3A & Figure 5-7A) from 2000 onwards.  
 
General population cohort 
Since 1980, crude three-year mortality increased in the general population hospital controls 
by 32%, from 3.8% (3.7-3.9%) in 1970-1990 to 5.0% (4.8-5.2%) in 2006-2008 (Figure 5-7A). 
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5.5.3 All-cause mortality; age and sex standardized 
ESRD cohort 
After standardization by age and sex, a continuous decline in 3-year mortality rates from 
1970 became evident: from 33.7% (30-38%) in 1970-1990 to 22.9% (20-26%) by 2006-2008; 
a 32% proportional reduction (Table 5-3B & Figure 5-1). 
 
General population cohort 
Similarly in the general population following age and sex adjustment mortality rates declined 
smoothly by 20%, from 5.5% in 1970-4.4% in 2006-2008 (Figure 5-1 & Table 5-3B). 
  
5.5.4 All-cause mortality; age, sex and comorbidity standardized 
ESRD cohort 
The addition of comorbidity as a covariate resulted in the mortality rates steepening (Figure 
5-7C & Table 5-3D). When standardized to an average RRT population, 3-year mortality 
rates fell on an absolute scale by 20.7% (from 40.7% in 1970-1990 to 20.0% in 2006-2008), 
and relatively by 51% (95% CI, 41%–60%) over this period (Figure 5-1 & Table 5-3C). Had a 
more modern RRT population been chosen as the reference population for standardization 
then the absolute decline would have increased to 31%, with no change in the proportional 
reduction (Table 5-3D). 
All-England data from 2000 mirrored findings in Oxfordshire data from the same period 
(Figure 5-1).  
 
General population cohort 
Comorbidity adjustment also steepened the declines mortality rates in the general 
population. On an absolute scale this caused rates to fall by 2.9% (from 8.6% in 1970-1990 
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to 5.7% in 2006-2008), corresponding a 34% (95% CI, 31%–36%) proportional decline 
(Figure 5-1). 
 
5.5.5 Sensitivity analyses, one to five year standardized mortality rates 
ESRD 
Examination of 1-year, 2-year, 3-year and 5-year mortality rates were performed as 
sensitivity analyses and showed steep, and relatively linear, declines in mortality rate, no 
matter what duration of prospective follow-up was applied (Figure 5-8).  
 
5.5.6 Impact of transplantation on mortality in ESRD patients 
Kidney transplantation was introduced in Oxfordshire in 1975. The 3-year standardized 
mortality rate among these early transplant recipients was substantially lower than for those 
who remained on dialysis (15.3% versus 41.8% during 1970-1990), and fell over time such 
that the 2000-2008 3-year standardized mortality rates for transplanted patients were 4.6% 
(Figure 5-2). Three-year mortality also substantially and continually declined among ESRD 
patients who remained on dialysis. The trend in declines in three-year mortality rates were 
similar in both the Oxfordshire and all-England data over the period 2000-2008. 
 
5.5.7 All-cause mortality, stratified by baseline characteristics 
By prior diabetes 
In the general population, there were steeper reductions in mortality over time in people with 
diabetes or not (heterogeneity p<0∙0001 for Oxfordshire and p<0∙0001 for all-England). The 
same was not observed among treated ESRD patients in Oxfordshire over 25 years 
(heterogeneity p=0∙41), but there was evidence of steeper declines in mortality rates among 
people with diabetes from 2000 in England (heterogeneity p=0∙01). Although the absolute 
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difference in mortality rates between those with and without diabetes has become 
substantially smaller between 1970-2011 (Figure 5-3 & Table 5-4). 
 
By sex 
In the general population hospital controls there were significantly steeper reductions in 
standardized mortality rates in males than females, p<0.0001 in Oxfordshire (since ~1980) 
and since 2000, in all-England, p<0.0001. The same was not observed in the ESRD 
population where the proportional declines in all-cause mortality rates, since 1980 were 
similar in male and females, 52% (36-61%) and 54% (41-67%) respectively, p=0.56  
respectively with similar non-significant changes found in Oxfordshire (p=0.98) and England 
(p=0.91) since the turn of the century (Figure 5-4 & Table 5-5). 
 
By age 
Patients aged <60 years in the general population and ESRD cohorts had similar 
proportional declines to respective patients aged ≥60 years although the absolute magnitude 
of these reductions was greater in the ESRD cohort. In the general population patients <60 
years had a 32% (25-39%) proportional decline whilst patients ≥60 years had a 34% (31-
36%), p=0.63. Over the same period, patients aged <60 years in the ESRD population had a 
52% (36-68%) reduction in mortality rates whilst patients ≥60 years were observed to have a 
53% (41-64%) reduction (Figure 5-5 & Table 5-6), p=0.98.  
This pattern was different in more recent analyses from all-England ESRD patients, where 
those <60 years saw significantly greater proportional declines than those ≥60 years, 32% 
(26-38%) vs 24% (20-28%), p=0.03 (Figure 5-5); likely due to higher survival rates in 
younger patients who more frequently received kidney transplants. 
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5.5.8 Cause specific mortality analyses 
Vascular mortality 
Among new ESRD patients, 3-year mortality rates from vascular causes fell from 12.2% 
between 1970-1990 to 7.4% by 2006-2008, representing a 25-year relative reduction of 
about 40% (95% CI 19%–60%) since 1980, which included about a 31% (95% CI 2–60%) 
reduction in cardiac mortality and 55% (95% CI 28–82%) reduction in non-cardiac vascular 
mortality (Figure 5-6). 
 
In general population controls, 3-year mortality from vascular mortality declined from 4.1% in 
the 1970-1990 group to 1.9% by 2006-2008. This represented a relative 25-year decline in 
3-year vascular mortality of 53% (95% CI 50–56%), which included a 58% (95% CI 55–61%) 
decline in cardiac and 45% (95% CI 40–50%) decline in non-cardiac vascular mortality 
(Figure 5-6). Between 1970-2011, declines in cardiac mortality have therefore been steeper 
in the general population than new ESRD patients. Again, all-England data from 2000-2011 
mirrored findings from Oxfordshire 2000-2011. 
 
Non-vascular mortality 
In new ESRD patients, 3-year mortality from non-vascular causes declined steeply and 
continuously since 1970 from 28.4% in the 1970-1990 group to 12.6% by 2006-2008 (Figure 
5-6). On a relative scale this represented is a 25-year decline of 56% (95% CI 45–66%) 
since 1980. The commonest underlying non-vascular causes of death were from renal failure 
or its causes (eg, chronic, diabetic, hypertensive and polycystic kidney diseases). Such 
mortality fell from 16.8% to 4.9% between the 1970-1990 and 2006-2008 groups, a relative 
decline of 71% (95% CI 61–81%). Declines in other common non-vascular causes were 
more modest. These included a reduction of 27% in infectious mortality (95% CI -14–68%; 
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absolute decline from 3.3% to 2.4%) and a reduction of 50% in cancer mortality (95% CI 
21%–80%; absolute rates 4.2% and 2.1%) (Figure 5-6). 
 
In general population controls, the declines in 3-year non-vascular mortality were more 
modest than the corresponding declines in new ESRD patients. Three-year standardized 
mortality rates fell from 4.6% in 1970-1990 to 3.8% by 2006-2008, which on a relative scale 
represents a 25-year 17% (95% CI 13–21%) decline since 1980. This included a 25-year 
26% relative reduction in death from cancer (95% CI 20–31%; absolute decline from 2.1% to 
1.6%), and 30% relative reduction in infection-related mortality (95% CI 22–37%; absolute 
decline from 0.7% to 0.5%) (Figure 5-6). 
 
In treated ESRD patients, the steeper proportional declines in non-vascular mortality 
compared to those in the general population (56% vs. 17%, Figure 5), and shallower 
declines in vascular mortality (17% vs. 40% respectively) resulted in the proportion of all 
deaths ascribed to vascular disease rising from 29.9% in 1970-1990 to 36.8% in 2006-2008, 
whilst the proportion of all deaths ascribed to vascular disease in the general population fell 
from 47.5% to 33.3% over the same period (Figure 5-9). 
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5.6 Discussion 
A large cohort of newly-treated ESRD patients and contemporaneous general population 
controls, extracted from routine hospital admission datasets established before the start of 
maintenance RRT programs began in the UK, were used to compare changes in cause-
specific mortality, taking account of the major changes in age and comorbid illnesses of 
those selected to start RRT. Three-year absolute mortality rates from many causes have 
remained high among people on maintenance RRT, but on a relative scale, overall mortality 
has halved. This decline is substantially steeper than the one-third decline observed in the 
general population. As those on RRT are at much higher mortality risk than the general 
population, this translates into substantially larger reductions in absolute mortality rates. 
Nevertheless, on average, those with ESRD currently still experience mortality rates 4-5-
times higher than the general population. 
 
An important finding from this study is that the reported reductions in mortality rates have 
declined faster than reported by ESRD registries from the United States 1977-2007,9 Europe 
1998-2007,10 Australasia 1992-2005,11 and UK 2002-2011.5  These registry studies may 
have underestimated improvements in mortality by virtue of not being able to adjust for 
temporal changes in serious vascular and non-vascular comorbidities. The presented  age, 
sex and comorbidity-adjusted estimates suggest relative mortality declines of perhaps 30% 
over the 10 years from the mid-1990s, which is larger than the approximately 20% declines 
evident from contemporaneous European registry data without such comorbidity 
adjustment.176,177 Our results from HES data were, however, almost identical to the relative 
declines in comorbidity-adjusted mortality rates reported by a 2002-2006 study which used 
UK-Renal Registry HES-linked data.88 
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Over the last 40 years, there has been a progressive and steep increase in the proportion of 
people with diabetes who start RRT treatment for ESRD. There was evidence that mortality 
rates have fallen faster among people with diabetes both in the general population and in 
those on maintenance RRT, meaning the absolute gap in mortality rates between those with 
and without diabetes has progressively closed over the last few decades. Nevertheless, our 
most recent data suggest that those with diabetes are on average at about 40-50% higher 
risk than those without, irrespective of ESRD. 
 
This study includes data in the 25 years before RRT registries had complete nationwide 
coverage in England. Over the early period, the numbers of people on RRT progressively 
increased and short-to-medium mortality was still attributed, in large part, to renal failure or 
its causes. This renal mortality rate has fallen by more than a half over the last 40 years. 
Kidney transplantation may have been a key intervention in reducing such mortality.42 By 
2000, 25 years after the first kidney transplant in Oxford,178 standardized 3-year mortality 
rates among those selected to receive a kidney transplant were as low as 4-5%. However, 
those remaining on dialysis have also experienced substantial improvements in mortality 
rates over time which could be attributable to multiple incremental improvements in the way 
renal care has been delivered in dialysis units, and/or improvements in the way patients are 
prepared for RRT.57,179  
 
In contrast to the early improvements in renal mortality, reductions in mortality rates from 
infections were more delayed, beginning from the late 1990s. Focus on infection control 
measures including hand hygiene protocols, flushed connection systems for peritoneal 
dialysis catheters,180 emphasis on natural arteriovenous haemodialysis access,31,181 the 
introduction of antibiotic haemodialysis catheter locks,182,183and proactive vaccination 
programs184 may all have contributed. 
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In the stratified analyses, the proportional reductions in 3-year mortality rates in ESRD 
patients were not observed to be different between the sexes in contrast to that seen in the 
general population controls. The general population men have benefited more than women 
from the advances in the treatments of occlusive atherosclerotic vascular disease (as it is 
more prevalent in men) whilst in treated ESRD patients, irrespective of sex, there is a higher 
proportion risk of non-atherosclerotic disease such as heart failure where there are fewer 
proven therapies. 
The differences in the proportional reduction in 3-year all-cause mortality rates between 
those with and without diabetes suggests that there has been steeper proportional declines 
in the non-diabetic ESRD population than those observed in the general population without 
diabetes. This has contributed to the overall narrowing of all-cause mortality rates as the 
proportional declines in diabetic patients (either ESRD or general population) has been 
similar. The reasons for this cannot be explored further as residual confounding would distort 
assumptions. 
The finding that mortality from vascular disease has declined less steeply among treated 
ESRD populations than general populations corroborates similar observations made in 
Australasia between 1992 and 2005.11 These English results now demonstrate that this 
lesser decline in vascular mortality appears to result from slow declines in cardiac mortality. 
The reasons why improvements in cardiac mortality rates in treated ESRD populations have 
been slower than the rapid declines observed in general populations (both in this study and 
in other national representative data185) cannot be tested in the present study. Other studies 
have found effective interventions to reduce vascular mortality in high-risk people133,186,187 
may be less effective in ESRD populations (eg, lowering low-density lipoprotein 
cholesterol188), and interventions for renal-specific risk factors (eg, renal anaemia,189 low 
dialysis dose,190 and hyperparathyroidism191) do not have clear cardiovascular benefits. 
Studies also suggest there has been underuse of coronary intervention in people with 
chronic kidney disease.192 As vascular disease was found to be the underlying cause of 1-in-
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3 deaths within three years of starting renal replacement therapy (RRT), identification of the 
causes of high vascular mortality rates in ESRD patients should remain a research priority. 
 
Using and comparing data from registries of UK RRT activity and the Oxford Kidney Unit, 
data derived from routinely collected hospital admission data, although not completely free 
from error (see Chapter 4 Validation), can provide representative and reliable descriptions of 
changes in mortality rates, with our results mirroring recent HES-linked UK-Renal Registry.88 
One limitation of these data is that the general population controls were selected for having 
been hospitalized for minor conditions. This was necessary as it enabled adjustment for 
comorbidity and therefore reliable comparisons between the different populations. It cannot 
be guaranteed that the mortality rates in hospital controls were completely representative of 
mortality rates in an unselected Oxfordshire and English populations. Another limitation was 
the lack of information on certain exposures which may have changed substantially over 
time and influenced mortality, such as cigarette smoking. Finally, completion of death 
certificates may have varied with time, and in particular, that some deaths due to vascular 
causes may have been attributed to renal disease, infection or other non-vascular causes 
(and vice versa). However, a key strength of this study is that cause-specific mortality data 
from all the cohorts share the same certification and coding principles in any given year, 
making comparisons between ESRD and general populations more reliable.193-195 
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5.7 Conclusion 
In summary, the full extent of mortality declines among RRT patients since 1980 is only 
apparent when changes in comorbidity are taken in to account. This approach suggests 
mortality rates in RRT patient have halved since 1970, faster than declines in the mortality in 
the general population. Declines in 3-year mortality rates were evident among those who 
received a kidney transplant and those who remained on dialysis. However, among those on 
RRT with or without diabetes, high residual mortality risk from both vascular and non-
vascular causes remains. 
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5.8 Main illustrative materials for results 
Table 5-1: Baseline characteristics of new treated new treated end-stage renal disease patients, by year 
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Figure 5-1: Standardized three−year mortality rates in new treated end−stage renal 
disease patients and general population controls 
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Figure 5-2: Standardized three−year mortality rates in new treated end−stage renal 
disease patients, stratified by whether patient is transplanted within 3 years of 
starting renal replacement therapy 
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Figure 5-3: Standardized three−year mortality rates in new treated end−stage renal 
disease patients and general population controls, stratified by prior diabetes 
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Figure 5-4: Standardized three−year mortality rates in new treated end−stage renal 
disease patients and general population controls, stratified by sex 
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Figure 5-5: Standardized three−year mortality rates in new treated end−stage renal 
disease patients and general population controls, stratified by age 
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Figure 5-6: Standardized three−year vascular and non−vascular mortality rates in new 
treated end−stage renal disease patients and general population controls 
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Figure 5-7: Crude and standardized three−year mortality rates in new treated end−stage renal disease patients 
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Table 5-2: Baseline characteristics of end-stage renal disease populations used for standardization 
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Table 5-3: Crude and different levels of adjusted three−year mortality rates in new treated end−stage disease patients and renal general 
population controls, by year and reference population 
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Figure 5-8: Standardized one− to five−year survival probabilities in new treated end−stage renal 
disease patients 
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Figure 5-9: Three−year cause specific deaths as a proportion of all deaths 
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5.9 Supplementary material for results chapter, not in published manuscript 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5-4: Standardized three−year mortality rates in new treated end−stage renal disease patients and general population controls, stratified by 
cohort and prior diabetes status 
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Table 5-5: Standardized three−year mortality rates in new treated end−stage renal disease patients and general population controls, 
stratified by cohort and sex 
 
 
 
  
 Main results; mortality trends         [179] 
 
Table 5-6: Standardized three−year mortality rates in new treated end−stage renal disease patients and general population controls, 
stratified by cohort and age group 
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5.10 Bullet points of Chapter 5  
 RRT patients from Oxfordshire, derived from ORLS and HES (Oxford) have seen a 
halving of their three-year mortality since 1970, compared a third reduction in a 
comparative general population 
 
 Stratified analyses showed that patients with diabetes (in both ESRD and the general 
population) had larger absolute reductions and the difference in mortality between 
those with and without diabetes has become smaller 
 
 There were steeper reductions in mortality in males compared to females in the 
general population, which were not apparent in the ESRD population 
  
 In treated ESRD patients, there were steeper proportional declines in non-vascular 
mortality compared to those in the general population (56% vs. 17%), and shallower 
overall proportional declines in vascular mortality (17% vs. 40%) 
 
 The proportion of all deaths ascribed to vascular disease in ESRD rose from 29.9% 
in 1970-1990 to 36.8% in 2006-2008, qualitatively different from the comparable 
general population where the proportions of vascular deaths fell from 47.5% to 33.3% 
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Chapter 6  Other uses of the dataset  
Disease Association Study — Biliary tract and 
liver complications in polycystic kidney 
disease: a 23,000 patient disease-association 
study 
This chapter largely contains the material that has been published in the peer-reviewed 
journal. Impact factor 8.655 (2017) or See Appendix section 1.3 or the links below 
 
Main Article:  
Biliary Tract and Liver Complications in Polycystic Kidney Disease. Judge PK, Harper CHS, 
Storey BC, et al. JASN 2017, 28(9) 2738-2748 
 
Online supplementary materials: 
Supplemental material
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6.1 Abstract 
Background  
Polycystic liver disease is a well-described manifestation of autosomal dominant polycystic 
kidney disease (PKD). Biliary tract complications are less well-recognised. The local kidney 
unit reported a 50-year experience of 1,007 patients, which raised a hypothesis that PKD is 
associated with biliary tract disease. 
Methods  
All-England Hospital Episode Statistics data (1998-2012) within which 23,454 people 
recorded as having PKD and 6,412,754 hospital controls were identified. Hospitalisation 
rates for biliary tract disease, serious liver complications and a range of other known PKD 
manifestations were adjusted for potential confounders and then compared. Compared to 
non-PKD hospital controls, the rates of admission for biliary tract disease were calculated. 
Results  
All-England Hospital Episode Statistics data (1998-2012) within which 23,454 people 
recorded as having PKD and 6,412,754 hospital controls were identified. Hospitalisation 
rates for biliary tract disease, serious liver complications and a range of other known PKD 
manifestations were adjusted for potential confounders and then compared. Compared to 
non-PKD hospital controls, the rates of admission for biliary tract disease were 2.2-times 
higher in those with PKD (rate ratio [RR] 2.24, 95% confidence interval 2.16-2.33) and 4.7-
times higher for serious liver complications (RR 4.67, 4.35-5.02). When analyses were 
restricted to those on maintenance dialysis or with a kidney transplant, RRs attenuated 
substantially, but PKD remained positively associated with both biliary tract disease (RR 
1.19, 1.08-1.31) and with serious liver complications (RR 1.15, 0.98-1.33). The PKD versus 
non-PKD hospital control RRs for biliary tract disease were larger for men than women 
(heterogeneity p<0.001), but RRs for serious liver complications appeared higher in women 
(heterogeneity p<0.001). The absolute excess risk of biliary tract disease associated with 
PKD (0.73%/year) was larger than for serious liver disease (0.24%/year), cerebral 
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aneurysms (0.11%/year), or inguinal hernias (0.11%/year), but less than for urinary tract 
infections (2.20%/year).  
Discussion 
Biliary tract disease appears to be a distinct and important extra-renal complication of PKD. 
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6.2 Introduction 
Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney 
disease.196,197 It is characterised by progressive enlargement of the kidneys with multiple 
bilateral cysts and eventual loss of kidney function, often causing end-stage renal disease 
(ESRD) in middle age.196,198 Ten percent of the 60,000 patients receiving renal replacement 
therapy (RRT) in the UK and 5% of the 680,000 in the US have a primary renal diagnosis of 
PKD.199,200 PKD is a multi-system disorder with polycystic liver, a common extra-renal 
manifestation.201-203 The prevalence of liver cysts in people with PKD increases with age, 
with >90% of patients aged >40 years having at least one cyst.204 Unlike renal cysts (which 
are unaffected by sex), liver cysts are more common and numerous in pre-menopausal 
women with PKD than in men.202,204,205 Autosomal dominant PKD is also associated with 
other abdominal manifestations, including colonic diverticular disease, abdominal wall 
hernias and pancreatic cysts.203,205,206 Mild common bile duct dilatation has also been 
reported,207 but unlike the much rarer autosomal recessive form of PKD which is associated 
with non-obstructive intra-hepatic duct dilation (Caroli’s disease) and recurrent cholangitis,208 
clinically significant biliary tract complications are less well recognized in autosomal 
dominant PKD. 
 
An observation was made at the local tertiary renal centre by a senior renal clinician that, in 
addition to the infective and compressive complications caused by polycystic livers, several 
patients with autosomal dominant PKD had repeated hospitalisations for biliary tract 
disease.209 In order to explore whether their clinical observations reflected a previously 
undescribed feature of autosomal dominant PKD, the hypothesis that biliary tract disease is 
more common in PKD using routinely collected English hospital inpatient data 1998-2012 
was tested by comparing hospitalisation rates for biliary tract disease among people with 
PKD versus rates in non-PKD control populations. 
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6.3 Methods 
6.3.1 Disease-association study using routine hospital admission data (1998-2012) 
Ethical approval for analysis of the record linkage study data was obtained from the Central 
and South Bristol Multi-Centre Research Ethics Committee (04/Q2006/176, Figure 8-2) was 
already in place. Anonymised linked all-England Hospital Episode Statistics (HES) inpatient 
records with additional linkage to national mortality records were used.210 Since 1998, HES 
has recorded information on all hospital inpatient activity in England, including: dates of 
admission and discharge; demographics (including age, sex, ethnicity); measures of social 
deprivation; the primary diagnostic reason for admission with relevant secondary diagnoses, 
coded using the International Statistical Classification of Diseases and Related Health 
Problems Revision 10 (ICD-10);211 and all procedures, coded using the Office of Population 
Censuses and Surveys Classification of Surgical Operations and Procedures (OPCS) 
version 4. 
 
6.3.2 Identification of polycystic kidney disease cases 
A patient with any mention of ICD-10 codes Q61.2 or Q61.3 in HES was presumed to have a 
diagnosis of PKD. The validity of using these codes has been directly demonstrated 
previously as part of a clinical trial among kidney transplant patients, in which there was an 
excellent level of agreement (kappa statistic >0.9) between nurse-reported primary renal 
diagnosis of cystic kidney disease and PKD coded in HES162,212, (see also Chapter 2 Cohort 
derivation and Chapter 4 Validation, section 4.4.5).To reduce the chances of including 
autosomal recessive PKD in analyses, people hospitalised or starting RRT before 20 years 
of age were excluded. 
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6.3.3 Identification of control populations 
Two control populations with no mention of PKD codes in any admission were derived from 
HES records. The first was a large group of patients admitted for minor diagnoses or 
procedures (see Table 6-1 footnote for complete list with a very similar derivation process 
what is detailed in subsection 2.10). The second was any patient who was treated with 
maintenance RRT (ie, long-term dialysis or kidney transplant) for ESRD and survived for at 
least 90 days from the start of RRT.  
 
6.3.4 Outcomes 
Outcomes for relevant diseases were identified using both information encoded in any 
diagnostic position (primary or secondary) or any recorded procedure. These included: (i) 
treated ESRD; (ii) a group of other positive control diseases which have previously been 
reported to be extra-renal manifestations of PKD203,213 (including complications or treatment 
of cerebral aneurysms, abdominal wall hernias [separated into inguinal and other], urinary 
tract infections, serious cardiac valve disease, and diverticular disease); (iii) a group of liver 
diagnoses and procedures associated with PKD, including liver abscess and liver de-roofing, 
resection and transplantation; (iv) and biliary tract diagnoses and procedures, including 
cholecystitis, biliary tract stones, and cholecystectomy (see Table 6-2 for full list of ICD and 
OPCS codes used to define outcomes); and (v) a negative control disease (breast cancer) 
which has previously been reported as not associated with PKD.214 In addition, sensitivity 
analyses were performed excluding diagnostic information recorded as secondary 
diagnoses, and after excluding people who ever had a serious liver complication. 
 
6.3.5 Covariates 
The following patient characteristics were extracted from HES: age; sex; ethnicity (white, 
non-white, and not recorded); region of residence; English Index of Multiple Deprivation 
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Score (IMD);215 and comorbidity (diabetes, vascular or cancer considered separately). For 
hospital control analyses, comorbidity was derived from diagnoses and procedures recorded 
on the first admission. For the ESRD cohort, comorbidity was derived from the date of the 
start of RRT and any admission in the preceding two years. 
 
6.3.6 Statistical methods 
Baseline characteristics for each derived cohort were expressed as numbers (%) or median 
(interquartile range) and compared by standard chi-square or Kruskal-Wallis tests 
respectively. The follow-up time for each outcome began from the index date (defined as the 
date of the first admission) and ended at the earliest of date of a relevant outcome, death or 
end of the cohort follow-up (31/03/2012). Rates for each outcome were then calculated using 
Poisson regression adjusted for age as a continuous variable (using both linear and 
quadratic terms), sex, ethnicity (3 groups as above), quintiles of IMD score, region of 
residence (9 groups), prior reported diabetes, vascular disease (excluding subarachnoid 
haemorrhage) or cancer (excluding breast cancer). Changes in coding practice over time 
were controlled for by adjustment for calendar year of first admission (or, where relevant, 
year of start of maintenance RRT).  
 
To assess how much renal function may affect PKD versus non-PKD RRs, analyses were 
repeated restricted to those PKD and non-PKD controls who had already started 
maintenance RRT for ESRD, with the index date increased to the date of start of 
maintenance RRT.  
 
RRs and their 95% CIs were calculated using standard statistical methods. Separate PKD 
versus non-PKD RRs for men and women and by age groups were calculated and 
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compared using standard tests for heterogeneity and trend respectively. Analyses used SAS 
version 9.3 (SAS Institute, Cary, NY) and the R version 3.2.1 (www.r-project.org).  
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6.4 Results  
To test the hypothesis that biliary tract disease might be more common in PKD than would 
be expected compared to the general population or people with other causes of ESRD, data 
on 43.2 million people aged over 20 years with at least one hospital admission recorded in 
linked and anonymised all-England HES between 1998 and 2012 were utilized in a disease 
association study.  
From this resource, 23,454 people were admitted to hospital with a diagnostic code for PKD 
and who were deemed unlikely to have autosomal recessive form. The median age at the 
start of follow-up was 58 years (44-70), 10,789 (46%) were female and 20,011 (85%) were 
white (Table 6-1). A history of prior diabetes or vascular disease was recorded in 906 (4%) 
and 1,747 (7%) respectively.  
In comparison, 6,412,754 hospital controls were identified from an admission for one of a 
variety of minor conditions (with no mention of PKD in any admission). Hospital controls 
were on average younger (median age 48 [34-67] years) and less likely to have diabetes 
(189,858, 3.0%) or vascular disease (181,832, 2.8%; Table 6-1). 
 
6.4.1 Disease-association study of all patients (PKD vs. non PKD) 
After adjustment for age, sex, ethnicity, social deprivation, region, prior diabetes, prior 
vascular disease or cancer, and year of first admission, the rates of admission for a series of 
disease outcomes were compared among people with PKD versus without PKD (referred to 
as ‘PKD versus non-PKD rate ratios’, RRs).  
Compared to non-PKD hospital controls, adjusted rates of ESRD were 112-times higher in 
people with PKD (2.82% versus 0.03%/year; rate ratio [RR] 112, 95% CI 109-116; Figure 
6-1A).  
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All patients: Rate ratios for known/typical manifestations of PKD 
Figure 6-1 provides adjusted rates and PKD versus non-PKD RRs for a range of other 
known manifestations of PKD. These include cerebral aneurysms, inguinal and other 
abdominal wall hernias, urinary tract infections, cardiac valve disease, and diverticular 
disease (Table 6-2 provides outcome definitions), all of which were positively associated with 
PKD. 
 
All patients: Rate ratios for ‘biliary tract disease’ and ‘serious liver 
complication’ 
Compared to non-PKD hospital controls, the rates of admission for biliary tract disease were 
2.2-times higher in people with PKD (1.31% versus 0.59%/year; RR 2.24, 95% CI 2.16-2.33) 
and 4.7-times higher for serious liver complications (0.31% versus 0.07%/year; RR 4.67, 
4.35-5.02; Figure 6-1A). These equate to an absolute excess risk of biliary tract disease 
associated with PKD of 0.73%/year (95% CI 0.68-0.78%/year), which was larger than the 
absolute excess risk for serious liver disease (0.24%/year, 0.21-0.28%/year), cerebral 
aneurysms (0.11%/year, 0.09-0.14%/year), inguinal hernias (0.11%/year, 0.08-0.14%/year), 
or abdominal wall hernias (0.35%, 0.32-0.38%/year); similar to the excess risk for colonic 
diverticular disease (0.73%/year, 0.67-0.79%/year); but much less than for urinary tract 
infections (2.20%/year, 2.10-2.31%/year), Figure 6-1A. 
 
6.4.2 Sub-study of rate ratios in those with ESRD (PKD vs other PRD) 
HES does not record laboratory data, so comparisons between people with PKD and 
general population hospital controls are unable to adjust for any differences in estimated 
glomerular filtration rate between those with PKD and those without. Repeated analyses, 
including just the 68,332 people who had started maintenance RRT to adjust for any effect of 
advanced chronic kidney disease were therefore undertaken. 
 Other uses of the dataset  [Page 191] 
 
Within the treated ESRD population, 9% (5,813/68,332) were recorded as having PKD. 
People with ESRD due to PKD were on average younger (57 versus 62 years), more likely 
to be female (46% versus 38%), and less likely to have a history of prior diabetes (8% 
versus 32%) or vascular disease (13% versus 27%) than those with ESRD due to other 
causes (Table 6-1). 
 
ESRD only: Rate ratios for known/typical manifestations of PKD 
After restricting analyses to those with treated ESRD, PKD versus non-PKD RRs for the 
positive control diseases were attenuated (Figure 6-1B). Nevertheless, compared to those 
with other causes of ESRD, rates of hospitalisation among people with PKD were 2.2-times 
higher for cerebral aneurysms (0.13% versus 0.06%/year, RR 2.23, 1.53-3.26), 2.5 times 
higher for other abdominal wall hernias (1.23% versus 0.50%/year, RR 2.47, 2.19-2.80), and 
about 60 to 70% higher for both inguinal hernias (1.00% versus 0.59%/year, RR 1.70, 1.49-
1.95), and colonic diverticular disease (2.70% versus 1.64%/year, RR 1.65, 1.52-1.79; 
Figure 6-1B). Rates for serious cardiac valve disease, however, were similar among people 
with ESRD and PKD and people with other causes of ESRD (1.47% versus 1.63%/year, RR 
0.90, 0.81-1.00).  
 
ESRD only: Rate ratios for ‘biliary tract disease’ and ‘serious liver 
complication’ 
The RRs for biliary tract disease and serious liver complications were also substantially 
attenuated when analyses were restricted to those with treated ESRD, but PKD remained 
positively associated with both conditions. Compared to those with other causes of ESRD, 
rates of biliary tract disease were 19% higher among people with PKD (1.92% versus 
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1.61%/year, RR 1.19, 1.08-1.31) and 15% higher for serious liver complications (0.70% 
versus 0.62%/year; RR 1.15, 0.98-1.33; Figure 6-1B).  
 
Among people on maintenance RRT, the absolute excess risk of biliary tract complications 
(0.31%/year, 0.13-0.49%/year) in people with PKD remained larger than for serious liver 
complications (0.09%/year, -0.02-0.2%/year) and for cerebral aneurysms (0.07%/year, 0.03-
0.12%/year); became similar to the absolute excess risk for inguinal hernias (0.41%/year, 
0.29-0.54%/year); but was somewhat smaller than for other abdominal wall hernias 
(0.73%/year, 0.59-0.87%/year), colonic diverticular disease (1.06%/year, 0.85-1.27%/year) 
and urinary tract infections (1.36%/year, 1.01-1.72%/year), Figure 6-1B. 
 
6.4.3 Stratified analyses by age and sex 
All patients: Rate ratios for ‘biliary tract disease’ and ‘serious liver 
complication’ (PKD vs. non PKD) 
In analyses performed separately for different age groups and by sex, compared with 
hospital controls, PKD versus non-PKD RRs for serious liver complications were higher in 
women than in men (heterogeneity p<0.001), confirming the observation from the 
accompanying case series reported in the manuscript, found at Appendix 1.3. However, the 
reverse was observed for biliary tract disease (heterogeneity p<0.001; Figure 6-2). RRs for 
serious liver disease were larger among younger people with PKD (trend p<0.001), but the 
reverse was also true for biliary tract disease (trend p<0.001; Figure 6-2A).  
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ESRD only: Rate ratios for ‘biliary tract disease’ and ‘serious liver 
complication’ 
In analyses restricted to people with treated ESRD, PKD versus non-PKD RRs for biliary 
tract disease became similar in both sexes (heterogeneity p=0.22), but RRs for serious liver 
complications remained higher in women than in men (heterogeneity p<0.001; Figure 6-2B). 
There was no difference in RRs for either complication by age in people with treated ESRD 
(Figure 6-2). 
 
6.4.4 Sensitivity analyses 
In sensitivity analyses, results were similar when repeated with the exclusion of secondary 
diagnoses to define disease outcomes (Figure 6-3 & Figure 6-4), or with exclusion of people 
with a serious liver complication (which reduces any over-ascertainment of biliary tract 
disease identified incidentally during any liver investigations, data not shown). 
 
6.4.5 Cause-specific mortality among people with PKD 
Biliary tract or liver disease are an uncommon underlying cause of death among people with 
PKD, except among those that were hospitalised in the cohort for either biliary tract disease 
or serious liver complications, in whom it accounted for 8% of deaths (Figure 6-5). This 
proportion was similar in women and men (9% versus 6%; p=0.06, Figure 6-6).  
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6.5 Discussion 
The disease association study confirmed that hospitalisation for biliary tract disease is more 
common among people with PKD than people without, and that the absolute excess risk was 
larger than for serious liver complications and a range of other better described extrarenal 
manifestations of PKD.  
 
The Halt Progression of Polycystic Kidney Disease Study A (HALT-PKD-A) has 
characterised the biliary tract and liver imaging features of PKD.216 Common bile duct 
dilatation was present in 17% of the cohort, but was the only biliary tract abnormality 
described. These data corroborate earlier observations from a Japanese study of 55 people 
with autosomal dominant PKD, where the prevalence of common bile duct dilatation was 
40%, compared to 7% in controls.207 A higher prevalence of common bile duct dilatation in 
the Japanese study may be accounted for by more advanced PKD, as one-half of the 
Japanese PKD patients had started haemodialysis, whilst all HALT-PKD-A participants had 
an estimated glomerular filtration rate >60 mL/min/1.73m2. No study which had assessed if 
there was an excess risk of clinically significant biliary tract disease associated with PKD. 
The presented results therefore represent the first quantification of the association between 
PKD and serious biliary tract disease.  
 
Another important finding in this disease association study was that the relative size of the 
PKD versus non-PKD RRs for serious liver complications was higher among women than 
men, but the reverse was true for biliary tract disease associations. Other PKD studies, 
including the HALT-PKD-A study, have also found the prevalence of liver cysts is higher in 
women with PKD compared to men.204,216 Oestrogen receptors are expressed in the 
epithelium of liver cysts,196,203,217,218 and female sex, exogenous oestrogen use and 
pregnancy all appear to increase cyst cell proliferation and liver cyst size.196,203,217,218 
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However, liver enlargement in PKD results from both cystic change and increased liver 
parenchymal volume, and men with PKD have been found to have increased height-
adjusted liver parenchymal volume.216 The differing patterns of associations in our subgroup 
analyses by age and sex suggest that cystic change in the liver - which has been reported to 
cause obstructive jaundice219-224 - is not the key cause of biliary tract complications in PKD. 
Instead other mechanisms for disrupted biliary tract epithelial function may exist. Some have 
suggested the bile duct glands can develop cysts,225 and others have raised the possibility of 
a shared biliary phenotype between mutations which cause autosomal recessive and 
autosomal dominant PKD.226-228  
 
Biliary tract disease has featured in the results of recent randomized trials of treatments 
aimed at inhibiting renal cyst cell proliferation and fluid secretion. In a trial of a somatostatin 
analogue, octreotide, the rate of kidney volume increase was slowed compared to 
placebo,229 and post-hoc analyses suggested octreotide may also reduce liver parenchyme 
and cyst expansion.230 However, it also led to increased numbers of non-serious reports of 
gallstones (octreotide 10/40 [25%] versus placebo 0/39 [0%]) and ‘biliary sand’ (7/40 [18%] 
versus 1/39 [3%]). The 2 reported serious cases of acute cholecystitis in this study were both 
among those allocated octreotide.229 These results are consistent with previous reports of 
octreotide associated-gallstones, which is attributed to reduced post-prandial gallbladder 
contractility and biliary stasis (indicated by increased fasting gallbladder volumes).231 
Octreotide exerts its beneficial effects on cysts through inhibition of the secondary 
messenger cyclic adenosine monophosphate in biliary epithelial cells. However, inhibiting 
this pathway with the vasopressin V2-receptor blocker, tolvaptan, significantly reduces the 
rate of increase in total kidney volume compared to placebo without any reported excess of 
upper abdominal pain, gallstones or biliary tract adverse events.232 
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Although not our primary aim, these data represent the largest confirmatory study of the size 
of associations between PKD and a range of previously described extra-renal 
manifestations.203,213 Interestingly, despite a known increased prevalence of incompetent 
mitral and aortic values in PKD,233 after taking account of renal function, serious cardiac 
valve disease was no more common in people with PKD and ESRD than in those with other 
causes of ESRD. This finding may influence how nephrologists counsel PKD patients. 
Testing other hypotheses, no evidence that PKD was associated with increased risk of 
hospitalisation with gastro-esophageal reflux disease, renal stones or aortic aneurysms 
among those with treated ESRD was found (Figure 1 footnote).  
 
This study uses ‘big data’ to test bedside observations made over ~50-years, but there are 
certain limitations. First, since HES does not include laboratory data, differences in renal 
function may confound associations in the PKD versus non-PKD hospital control analyses. 
Analyses stratified by ESRD overcome this limitation, but residual confounding may still 
exist. A second limitation is that distinguishing sources of infection in admissions for sepsis 
is often difficult so rates of infection from particular sources may be underestimates. Lastly, 
PKD definitions were not directly confirmed. Nevertheless, excellent agreement between 
nurse-recorded primary renal diagnosis and PKD recorded in HES data has been shown 
previously, so any misclassification is unlikely to have led to much underestimation in the 
size of RRs.162,212 
  
In summary, the hypothesis that autosomal dominant PKD is associated with clinically 
significant biliary tract disease as well as serious liver complications was tested. Women with 
PKD are at higher relative risk of a liver complication than men, but the reverse was 
observed for the positive association between PKD and biliary tract disease, suggesting liver 
and biliary complications of PKD have distinct disease mechanisms. The absolute excess 
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risks of biliary tract complications in people with PKD are similar to the absolute excess risks 
of some of the better established complications, and so biliary tract disease should be a key 
differential diagnosis in patients with PKD presenting with abdominal pain or sepsis.  
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6.6 Illustrative materials/tables and figures for Chapter 6  
Table 6-1: Baseline characteristics of patients with polycystic kidney disease versus control 
populations at date of entry (all England HES 1998–2012) 
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Figure 6-1: Association between polycystic kidney disease and risk of hospitalisation for 
different diseases in all−England Hospital Episode Statistics 1998−2012 
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Figure 6-2: Association between polycystic kidney disease and risk of hospitalisation for biliary 
tract and serious liver complications by age and sex in all−England Hospital Episode Statistics 
1998−2012 
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Table 6-2: Diagnostic and procedural codes used to define biliary tract disease, 
serious liver complications and extra-renal complications 
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Figure 6-3: Association between polycystic kidney disease and risk of hospitalisation for different disease by diagnostic position in 
all−England Hospital Episode Statistics 1998−2012 (sensitivity analysis) 
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Figure 6-4: Association between polycystic kidney disease and risk of hospitalisation for different diseases by diagnostic position in 
all−England Hospital Episode Statistics 1998−2012 (sensitivity analysis)  
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Figure 6-5: Underlying causes of death in all people with polycystic kidney disease 
by; prior biliary tract or serious liver complication (panel A), or without such 
complications 
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Figure 6-6: Underlying causes of death in all people with polycystic kidney disease 
and prior biliary tract or serious liver complications in; females (panel A), or males 
(panel B) 
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6.7 Bullet points of Chapter 6  
 Autosomal dominant polycystic kidney disease (PKD) is the most common inherited 
renal condition and has recognized extra-renal manifestations. 
 
 The diagnostic coding of PKD is limited to two distinct codes in ICD-10. 
 
 PKD as the primary renal disease, causing ESRD, is easily identifiable from HES. 
 
 Hospitalisation rates were calculated, and compared to a general population for a 
pre-defined group of ‘biliary tract disease’ and ‘serious liver complications’ for both a 
PKD population and general population. 
 
 Rate ratios for patients with PKD were 2.24 times and 4.7 times more likely to have 
hospital admissions with biliary tract disease or serious liver complications than 
controls.  
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Chapter 7  Concluding remarks 
 
Conclusions 
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This thesis was conceived with four aims, which may be useful to have re-stated before the 
concluding remarks. 
 
1) Derive and validate a cohort of end-stage renal disease (ESRD) patients exclusively 
from anonymised, individually-linked prospectively collected hospital inpatients 
datasets 
 
2) Analyse the temporal trends of age, sex and comorbidity adjusted mortality rates in 
the ESRD cohort 
 
3) Concurrently derive a comparative general population to provide an opportunity to 
compare trends between the ESRD and general populations 
 
4) Demonstrate other uses of routinely collected hospital inpatients datasets in renal 
epidemiology
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I aimed to test whether more reliable trends of morbidity and mortality could be performed 
using an ESRD population identified exclusively from routinely collected hospital inpatient 
data. Treatment of ESRD, in the form of maintenance RRT, has developed over the last half 
a century, having begun in the 1960s/1970s under atmosphere of societal and medical 
scepticism. Yet with the perseverance of the early practitioners’, evolving technologies and 
parallel developments in the sphere of organ transplantation, it became obvious that 
maintenance RRT not only saved lives but it also had the capacity to restore patients’ health 
back to a level where they could continue to contribute to society. As the provision of renal 
services grew any historical ‘prioritisation’ of patients selected onto RRT programmes 
dwindled to be irrevocably replaced by older patients with increasingly complex comorbid 
illnesses. To date, no long-term study has had access to the linked mortality and comorbidity 
data of these early recipients of RRT and a cohort of modern day patients. Uniquely, this 
thesis identified and consequently could adjust for the stark changes in patient 
demographics (particularly age and baseline prevalence of comorbid illness) within the 
ESRD cohort, with foreknowledge that comorbidity is a key determinant of mortality. 
Moreover, I was able to compare mortality trends in an ESRD cohort to a 
contemporaneously identified general hospital-control population allowing analyses which 
could suggest whether improvements (or not) were also reflected in the general population; 
to date, the inability to analyse secular changes in the prevalence of comorbidities in a 
general population has hampered any such analysis. Researchers have hitherto, relied on 
national mortality statistics, which do not generally provide comorbid data, making statistical 
adjustments limited to only age and sex. 
 
Using a unique combined resource of ORLS, the oldest source of linked routinely collected 
hospital inpatient admissions [1965-1998] in England, and all-England HES [1998-2011], a 
derivation algorithm was designed to identify maintenance RRT patients (ie patients 
receiving dialytic therapies or a transplant and surviving for >90 days). This provided a 40-
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year regional ESRD cohort from Oxfordshire and a cohort of English patients since the turn 
of the century, with mortality data being obtained via directly linked data from Office of 
National Statistics; providing fact and date of death alongside an underlying cause of death 
(UCD). The anonymised identification of treated ESRD patients was novel and involved a 
series of logical (yet clinically informed) steps to initially identify RRT, before determining 
whether this treatment was given as a maintenance therapy and then restricting the cohort to 
only incident cases. This process was iterative and involved the manual mapping of clinical 
terms (both diagnostic and procedural terms) which were relevant to renal disease and 
major comorbidities and the categorisation of death codes. In all, these codes were mapped 
across four versions of the ICD and three versions of OPCS. 
 
The final cohort provided baseline characteristics of over 40,000 newly treated ESRD 
patients since 1970 and showed the enormous change in terms of their age structure and 
comorbidity profile of incident ESRD patients consistent with the historical context of ESRD 
provision. The descriptive changes are particularly striking especially when analysing the 
magnitude of such changes in ESRD to changes in the comparative general population. This 
highlighted the point that in any proposed assessment of mortality trends there needed to be 
statistical adjustment for comorbid illness for more reliable results to be obtained.  
Historically, data held by renal registries did not have any reliable comorbid variables, only 
inferences obtained from age and occasionally primary renal disease. Uniquely, the ESRD 
and its comparative contemporaneous general populations had their respective baseline 
comorbidity derived from the same datasets and over the same time-period permitting 
analogous standardization techniques. 
 
As the ESRD cohort was anonymously identified, validation of my identification steps was 
performed using a series of indirect and direct techniques. For indirect comparisons, 
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summarized statistics of the counts of ESRD patients and demographic details from the UK-
RR, UK-TR, and OKU were used. For the HES derived portion of the cohort it was also 
possible to validate directly the algorithm using clinically-adjudicated ESRD outcomes from 
prospective randomised controlled trials of patients with renal disease (“3C” and “SHARP”). 
Following this validation work it became apparent that the derived cohorts did indeed provide 
sufficiently reliable identification of treated ESRD patients to allow descriptions of long-term 
changes in mortality rates to be performed. 
 
The results chapter showed that the full extent of mortality declines among RRT patients 
since 1980 is only apparent when changes in comorbidity are taken into account. With such 
an approach it suggested that mortality rates in RRT patient have halved since 1970, faster 
than declines in the mortality in the general population hospital controls. Declines in 
standardized 3-year mortality rates were evident among those who received a kidney 
transplant and those who remained on dialysis suggesting that transplantation has not been 
the only reason for the improvements and that there has been fundamental improvements in 
dialytic care. (See Appendix 1.2 for the peer-reviewed Kidney International journal [Impact 
Factor=8.4] publication of the results. 
 
Having the available resource of all-England HES data allowed another aspect of renal 
epidemiology to be explored: a disease association study of polycystic kidney disease, the 
commonest genetic cause of renal failure. A cohort of PKD patients was identified using 
ICD-10 codes and directly validated against participants in the 3C study. A number of 
outcomes variables including diagnostic and procedural codes for well recognised and 
hypothesis generating disease associations were collected. This demonstrated that 
hospitalisation rates for biliary tract disease and serious liver complications to be 2.2 and 4.7 
times higher in those PKD patients than the general population.  
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Future uses 
While this body of work has focussed principally on mortality trends, it may open 
opportunities to explore the burden of non-fatal outcomes, which often besets these patients. 
However, this would involve considerable new work as working at the episode level of HES 
data, as suppose to using spell-level data (ie summary codes), would bring substantial  
challenges in deciding what are prevalent versus incident clinical events and any such 
analyses would perhaps need to consider competing risk models, which is not necessary in 
all-cause mortality.  
I have designed, validated and studied a new method, which reliably identifies treated ESRD 
which could offer opportunities for participants in randomised controlled trials to be followed 
up in the longer-term which may provide either safety or efficacy signals. Any such direct 
HES linkage could also provide a streamline tool to adjudicate intra-trial clinical events, 
perhaps reducing the need for laborious and often expensive formalised adjudication. Other 
uses of the methods I have described could be used, for example in the UK Biobank Study 
or other prospective British cohort studies, to capture patients who reach ESRD with fresh 
opportunities to study any underlying associations from the exhaustive baseline data which 
particularly UK Biobank holds.  
Another body of work to this, but not one that is not achievable with HES, would be to 
measure patient related outcomes (such as fatigue, itch or quality of life metrics) over time in 
separate studies and combine these data with more traditional outcomes from HES to 
analyse whether the apparent improvements are reflected in patients experiences.  Aligned 
to this, health economics analyses could be performed, suing HES data, which could help in 
ascribing the true burden of ESRD. 
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Summary 
In summary, in this thesis I have demonstrated that routinely collected hospital inpatient data 
can indeed be used to derive a cohort of patients on maintenance RRT in England and 
describe temporal changes in mortality and morbidity, after taking account of the major 
temporal changes in selection of people receiving RRT, and considering the secular 
changes in comorbidity. With this, I have shown that standardized three year-mortality rates 
among patients on RRT have halved since 1970, faster than declines in the mortality in a 
general population hospital controls identified from the same resource. This headline result 
should be cautiously celebrated, because whilst these reductions are manifestly welcomed, 
ESRD patients remain at considerable absolute risk of premature death, both from vascular 
and non-vascular causes. The focus for the nephology community should be to proactively 
identify a range of focussed hypotheses, applicable to broad range of patients with 
advanced CKD, and then to design large-scale randomised clinical trials to test any 
hypotheses in the perpetual aim to narrow this mortality gap. 
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8.1 Information governance toolkit  
Figure 8-1: Information Governance Toolkit from NHS Digital 
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8.2 Ethics approval documentation 
Figure 8-2: Ethics letter of approval  
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8.3 Contributions; by chapter 
My own contributions, fully and explicitly indicated were as follows. 
 
Chapter 1 
To finalise the conception of the study in conjunction with my supervisor. 
I approached the curators of the datasets (MG and then subsequently MJL) to gain 
their approval to use ORLS and HES for this body of work.  
Enduring ethics approval was already in place.  
I drafted, edited and wrote all parts of the chapters. 
 
Chapter 2 
I sourced and converted hard copies of historical diagnostic and procedural manuals 
into usable formats using excel. 
I interrogated these coding manuals and extracted relevant diagnostic and 
procedural codes which could potentially identify an ESRD cohort. 
I mapped across these coding manuals, the clinical codes for all the accompanying 
terms used to identify prior comorbid illness, primary renal disease and categories of 
underlying the causes of death. 
I designed the rules used to identify the ESRD cohort, iteratively tested these rules 
and adapted them into an order to be able to extract the patient cohort used in the 
analyses. 
I reviewed all the clinical extracts of patients identified as potentially having ESRD in 
the ORLS period to determine whether rules for maintenance RRT were satisfied.  
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CH and NS, statistical colleagues, handled cleaned and processed the raw data. CH 
embedded the clinical algorithm into the the derivation programme. 
I drafted, edited and wrote all parts of the chapters. 
 
Chapter 3 
In the baseline characteristics, I reproduced the baseline tables from a cleaned 
dataset provided by CH and reproduced the significance testing for the difference 
across year groups. I created the stratified tables used for various baseline 
characteristics by initial modality of RRT, sex and age. I adapted the conditions and 
procedures used to identify the general population hospital control cohort which was 
extracted from the original ORLS dataset by Raph Goldacre (Research Fellow at 
UHCE) before being given to CH to be used in subsequent analyses. The methods 
used by UHCE have been published previously.  
 
Chapter 4 
I wrote and requested that UK-TR provide me with information on the number of 
kidneys transplant performed in England between 2000-2009, used as the basis for 
the indirect comparison. 
I extracted the relevant UK-RR annual reports and extracted summary statistics on 
the baseline characteristics of incident RRT patients.  
I was able, in my role as Renal Specialist Registar at the Oxford Kidney Unit, to use 
PROTON to extract all incident RRT patients treated by OKU from 1967 to 2008. 
From this, I extracted baseline characteristics and incorporated them into Table 4-3. 
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The direct validation of the HES derived treated ESRD cohort was performed by CH, 
using my algorithm. I performed the direct validation of participants from the 3C 
study, which formed the impetus to Chapter 6. 
 
Chapter 5 
I led, but worked alongside, statistical colleagues (CH and NS) to design the relevant 
mortality analyses, decided on what sensitivity analyses would be appropriate. I 
choose the final tables and figures in the manuscript which I fully drafted, revised and 
later finalized after edits from co-authors before submission. CH ran the Poisson 
regression model and generated the figures that were used in main manuscript. 
 
Chapter 6 
Writing a manuscript in which a disease association study complimented a case 
series of the hepatobiliary complications in polycystic patients treated in the Oxford 
Kidney Unit, occurred in discussion with the paper’s main author PJ, with whom I 
shared an office at CTSU. In conjunction with RH and WH we took forward the 
disease association study. This clinical quartet in addition to NS and CH, designed 
and executed the study which used the derivation algorithm which I had designed for 
my thesis to identify the ESRD population, and the subset of PCKD patients. I 
performed a literature search on the prevalence of conditions which are 
traditionally  associated with PKD and helped co-write the manuscript. 
 
 
The thesis solely contains my own words and any errors I take full responsibility. 
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